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Abstract
Acute care near end-of-life (EOL) is associated with lower quality of life and higher EOL costs, which are
associated with worse quality death. Goals-of-care (GOC) discussions are associated with lower costs.
Racial/ethnic minorities are less likely to have these discussions. It is unknown how costs and healthcare
utilization differ by race/ethnicity following inpatient GOC discussion or how risk factor profiles are
associated with discussion timing. Primary aims included: (1) Exploring associations among EOL
discussions, costs, and proxies for costs (healthcare utilization, place of death) in persons with advanced
cancer near EOL (Chapter 2); (2) Assessing future acute care costs and healthcare utilization among
Whites and African Americans with serious illness who either did or did not have inpatient palliative care
consultation to discuss GOC (“PCC”) (n = 35,154; PCC: n= 1,197; non-PCC: 33,957) (Chapter 3); and (3)
Examining risk factor profiles associated with timing of PCC before death (PCC 0-14 days before death, n
= 612; PCC 15-60 days before death, n = 292; PCC more than 60 days before death, n = 237) among
deceased persons who received PCC (Chapter 4). Secondary analysis included demographic, clinical, and
financial data of patients 18+ admitted to a large, urban, academic medical center July 1, 2014 to October
31, 2016. Patients admitted for childbirth or rehabilitation, patients hospitalized at the end of the study,
and for Chapter 3 patients who died during the admission they first received PCC were excluded. A
systematic review (Chapter 2) found EOL discussions were associated with less acute and intensive care,
greater hospice use, and lower EOL costs among advanced cancer patients. Propensity score matching
(Chapter 3) showed PCC was associated with increased discharge to hospice among African American
and White patients with PCC; and lower 30-day readmissions, fewer future days hospitalized, and lower
future acute care costs (average $8,704 per patient) for Whites with PCC, but not African Americans with
PCC. Multinomial logistic regression and classification and regression tree modeling (Chapter 4) showed
a complex set of variable interactions were associated with PCC timing before death. Results imply need
for investment in PCC across racial groups.
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ABSTRACT
ASSOCIATIONS AMONG END-OF-LIFE DISCUSSIONS, HEALTHCARE UTILIZATION
AND COSTS, AND RACE/ETHNICITY IN PERSONS WITH SERIOUS ILLNESS
Lauren T. Starr, MBE, MS, BA, BSN, RN
Salimah H. Meghani, PhD, MBE, RN, FAAN
Acute care near end-of-life (EOL) is associated with lower quality of life and higher EOL costs,
which are associated with worse quality death. Goals-of-care (GOC) discussions are associated
with lower costs. Racial/ethnic minorities are less likely to have these discussions. It is unknown
how costs and healthcare utilization differ by race/ethnicity following inpatient GOC discussion or
how risk factor profiles are associated with discussion timing. Primary aims included: (1)
Exploring associations among EOL discussions, costs, and proxies for costs (healthcare
utilization, place of death) in persons with advanced cancer near EOL (Chapter 2); (2) Assessing
future acute care costs and healthcare utilization among Whites and African Americans with
serious illness who either did or did not have inpatient palliative care consultation to discuss GOC
(“PCC”) (n = 35,154; PCC: n= 1,197; non-PCC: 33,957) (Chapter 3); and (3) Examining risk factor
profiles associated with timing of PCC before death (PCC 0-14 days before death, n = 612; PCC
15-60 days before death, n = 292; PCC more than 60 days before death, n = 237) among
deceased persons who received PCC (Chapter 4). Secondary analysis included demographic,
clinical, and financial data of patients 18+ admitted to a large, urban, academic medical center
July 1, 2014 to October 31, 2016. Patients admitted for childbirth or rehabilitation, patients
hospitalized at the end of the study, and for Chapter 3 patients who died during the admission
they first received PCC were excluded. A systematic review (Chapter 2) found EOL discussions
were associated with less acute and intensive care, greater hospice use, and lower EOL costs
among advanced cancer patients. Propensity score matching (Chapter 3) showed PCC was
associated with increased discharge to hospice among African American and White patients with
PCC; and lower 30-day readmissions, fewer future days hospitalized, and lower future acute care
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costs (average $8,704 per patient) for Whites with PCC, but not African Americans with PCC.
Multinomial logistic regression and classification and regression tree modeling (Chapter 4)
showed a complex set of variable interactions were associated with PCC timing before death.
Results imply need for investment in PCC across racial groups.
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CHAPTER ONE: INTRODUCTION
Acute care near the end-of-life (EOL) is associated with lower quality of life1 and 80% of
medical spending in the last year of life.2,3 This spending presents significant challenges to health
systems tasked with managing costs while providing quality care, and to patients and families
facing rising out-of-pocket costs. Patient-provider communication about goals-of-care (GOC) or
EOL planning is associated with lower costs and lower rates of high-cost intensive care near EOL
among persons with serious illness,2,4-12 with timing of discussion potentially playing a critical role
in utilization and quality outcomes.12-16 Inpatient conversations occurring 30 days or more before
death are associated with less aggressive and less costly forms of care than conversations
occurring close to death,12,15,16 but little is known about risk factors associated with the timing of
these conversations,17 or how the timing of these conversations is associated with acute care
costs near EOL. Most studies of GOC/EOL communications and utilization or costs focus on
patients with cancer and either do not break out outcomes by race/ethnicity or focus on
predominantly White populations, resulting in a need for more research about these important
conversations among racial/ethnic minority patients with serious illness.
Evidence suggests medical costs are significantly higher for racial/ethnic minorities in the
last six months of life, compared to Whites, and that a significant portion of the higher costs are
due to greater use of intensive procedures such as mechanical ventilation or intubation and care
in the intensive care unit (ICU).18 Unfortunately, racial/ethnic minorities are also less likely than
Whites to have these important care planning conversations.19 Little is known about the
relationship between initial GOC/EOL discussion during hospitalization and acute care costs
following discharge from a hospitalization involving these important conversations (hereafter
called “future acute care costs”) by racial/ethnic group, or how race/ethnicity and the timing of
these conversations are associated with acute care cost outcomes (see Appendix A).20 To our
knowledge, no published research has explored the relationship between inpatient palliative care
consultation (PCC) to discuss GOC (hereafter called “PCC”) during an index admission (defined
1

as the hospital admission during which PCC first occurred in the study period) and future acute
care costs by race/ethnicity, risk factor profiles associated with the timing of these conversations,
or descriptions of EOL acute care costs following discharge from a hospitalization with PCC
(hereafter called “EOL acute care costs”) based on PCC timing.
To fill these critical gaps, the specific aims of this dissertation are (see Table 1.1):
Aim 1: To explore associations among advance care planning, costs, and proxies for
costs (healthcare utilization, place of death) in persons with advanced cancer near EOL using a
systematic review of published literature (January 2012-January 2019) (Chapter 2).
Aim 2a: To assess differences in mean future acute care costs and healthcare utilization
by race/ethnicity among African Americans with PCC, African Americans without PCC, Whites
with PCC, and Whites without PCC (Chapter 3).
Hypothesis 2.1: Mean future acute care costs and utilization will be lower among
persons who received PCC than persons who did not.
Hypothesis 2.2: African Americans who received PCC will have lower mean future acute
care costs and utilization than African Americans who did not have PCC.
Hypothesis 2.3: Whites who received PCC will have lower mean future acute care costs
and utilization than Whites who did not have PCC.
Aim 2b: To describe clinical and cost variables for Asian, Hispanic, and other
racial/ethnic minorities in the dataset.
Aim 3a: To examine risk factor profiles for PCC patients who died during the study period
based on the timing of consultation: PCC 0-14 days before death, PCC 15-60 days before death,
and PCC more than 60 days before death (n = 1,141) (Chapter 4).
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Hypothesis 3.1: African American race, younger age, Medicaid use, primary diagnosis of
condition other than cancer, minor to moderate All-patient refined diagnosis related group (APRDRG) Severity of Illness (physiologic decompensation of a patient, see Appendix A), minor to
moderate APR-DRG Risk of Mortality (likelihood of patient dying, see Appendix A), ICU care
during index admission, ICU care for more than six days during index admission, and Surgery
source of referral to palliative care will be associated with PCC close to death (see Appendix A).
Aim 3b: To describe median EOL acute care costs, discharge to hospice from index
admission, DNR documentation during index admission, and changes in GOC during index
admission among deceased patients who received PCC 0-14 days before death, 15-60 days
before death, and more than 60 days before death (Chapter 4).
This dissertation study fills critical gaps in the literature (1) by using the innovative
methodology of stratified propensity score matching among multiple groups to quantifying cost
savings across hospitalizations associated with PCC in different racial/ethnic populations,7 (2) by
using state-of-the-art classification tree modeling to examine risk factor profiles for the timing of
PCC in inpatient settings where late conversations are most likely to occur,17 and (3) by
describing the EOL acute care costs of deceased patients based on PCC timing. The results of
our study may be used to help systems manage costs when caring for persons with serious
illness, including vulnerable patients near EOL. This research contributes to an emerging body of
literature that explores factors related to racial/ethnic disparities in EOL care and costs.

Background and Significance
The High Cost of End-of-Life Care
High financial costs at EOL continue to burden patients, families, and the systems that
care for them. Growing attention to the cost implications of treatment decisions for patients with
serious illnesses necessitates research into aspects of care that may modify costs and financial
burden, while aligning care with patient preferences.1-3 In the United States, 10% of Medicare
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patients account for almost 60% of Medicare annual spending,4,5 with much of the spending
occurring in the hospital and among persons at EOL.6 According to a 2017 analysis of nine major
countries, the United States spends an average of $80,000 on patients in the last year of life—
more than any other country studied.7 Acute care contributes to 80% of this medical spending in
the last year of life.8,9 This higher spending is influenced by Americans’ high use of intensive care
unit (ICU) and life-prolonging services (e.g., mechanical ventilation, resuscitation, feeding
tubes).8,9 For example, over 40% of adults 65+ who died of cancer in 2010 received ICU care in
the last 180 days of life—a figure significantly higher than the 18% reported in other developed
countries studied.10 In some patient populations, aggressive EOL care has been shown to
contribute to 43% higher costs than non-aggressive EOL care.11 Despite patient preferences for
less aggressive inpatient care near death and uncertainty about the value of intensive care at
EOL, the average number of days patients spent in the ICU during the last six months of life is
trending up in the United States.12 Most importantly, this high utilization of aggressive treatments
near EOL may not be consistent with patient preferences and values near EOL,13,14 a critical
problem.
Intensive, acute care near EOL is more costly than less intensive care, such as
hospice,8,15,16 with higher utilization of intensive care resulting in higher costs. For example, one
study of deceased Americans found the cost of a terminal hospitalization involving care in an ICU
cost an estimated $38,000 compared to $13,000 if ICU care was not involved.17 High costs at
EOL are also associated with perceptions of worse quality of death8 and higher decision
regret18,19 among bereaved families of persons with serious illnesses, providing evidence that
EOL costs have lasting non-financial effects as well. At the same time, health systems are
challenged by the cost of inpatient EOL care, especially care in the ICU. With changing payment
structures and financial penalties for readmissions, hospitals are under increasing pressure to
manage costs during each hospitalization and across visits.5 More research is needed to better
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understand how types of care impact costs across hospitalizations in persons with serious illness
near EOL.
Goals-of-Care Consultations May Reduce Costs and Intensity of Care
The purpose of EOL and care planning conversations is to help clarify patients’
preferences about treatment and care and ensure the care patients receive is consistent with
their expressed preferences.20,21 Patient-provider conversations about goals and end-of-life
include discussion about prognosis, treatment options, and aspects of both living and dying that
clarify patients’ goals, values, priorities, and preferences.22 As intended, these discussions are
associated with patients receiving EOL care consistent with expressed preferences.23,24 These
discussions are also associated with less aggressive treatment5,8,19,25-32 and lower acute care
costs among persons with serious illness.5,8
About seven in ten PCCs include these important GOC discussions.5,33 By promoting
clear communication about prognosis and patient preferences, PCC has been shown to provide
care consistent with patient goals, improve satisfaction, reduce overall and ICU healthcare
utilization, reduce use of laboratory testing and other ancillary services, and significantly lower
hospital costs (9%-25% less) and pharmacy costs compared to usual care in hospital settings.5,2631,34-38

Among persons with advanced cancer, for example, these cost savings are even greater

when a patient has other serious diseases/multiple comorbidities.5,39 In some populations, PCC is
even associated with a doubling of inpatient and outpatient hospice enrollment,40 contributing to
reductions in EOL costs. As May and colleagues conclude in their 2014 meta-review of palliative
care’s effect on costs, inpatient PCC programs provide better care to patients with serious
illnesses and save hospitals money.27 More research is needed to better understand how PCC
involving GOC/EOL discussions influence healthcare costs and utilization across hospitalizations
for persons with serious illness.5
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The 2017 propensity-matched parent study of these data (n = 41,363) found statistically
significant reductions in future acute care utilization and future acute care costs after patients
received PCC.5 Specifically, average future acute care costs were found to be more than $6,000
lower in patients who received PCC following initial hospitalization.5 Patients who received PCC
were less likely to incur “any future acute care cost” during a future hospitalization, had lower 30day readmission rates, fewer average number of days in the hospital post-discharge, and fewer
average number of days in the ICU post-discharge.5
One study that examined relationships between EOL discussions and EOL costs found
direct costs in the last seven days of life to be 36% lower for patients who reported having EOL
discussions about care preferences with their physicians compared to patients who did not have
GOC/EOL conversations.8 This 2009 study estimated costs using national per capita healthcare
data tied to healthcare utilization, and featured data from 2004, which underscores the need for
more current studies of healthcare utilization, actual costs, and EOL discussions among persons
with serious illnesses. This study also analyzed outcomes of patients with cancer, highlighting the
need for more research in persons with other serious illnesses, and similarly did not address the
variable of race/ethnicity.
Finally, self-reported discussion with a physician about EOL care has also been found to
be associated with lower direct costs of care in the last week of life, but authors focused
exclusively on decedents with cancer, used estimated costs based on utilization and not actual
cost data, and failed to report data on the association.1 This study also underscores the need for
actual costs outcomes research on a broader patient population and set of variables. Our study
aims to address this need by providing actual direct cost data (see Appendix A for table of
variables) for White and African American adults with serious illnesses.

6

Advance Care Planning
Advance care planning (ACP) is a process that includes discussing and documenting
patient preferences about GOC for patients who may lose capacity or the ability to communicate
preferences in the future.41 It includes GOC conversations and may include discussion about
EOL, and sometimes but not always occurs during PCC.24,41 Existing studies define ACP
discussions differently,41 with some focused broadly on EOL care conversations32,42-45 or GOC
conversations,46,47 while other studies focus more narrowly on hospice discussions48 or a
combination of advance directives, Physician Orders for Life-Sustaining Treatment (POLST)
orders, or do-not-resuscitate (DNR) or do-not-intubate (DNI) orders49-52 (See Table 1.2 for
definitions of terms). One study, for example, used a broad definition of ACP by studying PCC
and any component of ACP—defined as any GOC discussion, advance directive, POLST order,
or DNR/DNI order.52 Just as little is known how GOC/EOL discussions relate to acute care
utilization and costs near EOL, evidence about associations between ACP, these outcomes, and
race/ethnicity is also limited. One recent study of case-control matched decedents found patients
who had ACP had fewer inpatient admissions and inpatient days before death, and a $9,500
reduction in Medicare costs compared to patients who did not have ACP,53 but gaps in cost
analysis persist. In this dissertation, we systematically review the available literature to identify
and address research gaps related to EOL communication and costs.
Timing of Goals-of-Care Conversations May Influence Costs and Intensity of Care
Although PCC benefits patients, the timing of these conversations also matters. If
GOC/EOL discussions occur too close to death, patients and families may make pressured
decisions leading to care that is not concordant with preferences.20,32,54 In one study of advanced
heart failure patients, PCC during terminal hospital admission was often either absent or very
near death, with a median time of six days between PCC and death and only 24 hours between
orders for comfort care and death.55 One study found the median days between referral to PCC
and death was 10 days for patients with chronic obstructive pulmonary disease, 12 days for
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patients with heart failure, 14 days for patients with severe dementia, and 20 days for patients
with cancer,56 but it is unknown at what point, if at all, GOC were discussed. However, each
additional day from hospital admission to GOC conversation was found to be associated with a
4% increased risk of aggressive interventions and in-hospital death, and 19% greater odds of ICU
admission.57 In many cases, patients may not receive the benefits of comfort care as early as
they might have liked, possibly resulting in greater regret about care decisions.19
Evidence suggests the majority of early PCCs (90 or more days before patient death)
occur in outpatient settings (84%) and the majority of late PCCs (less than 90 days before patient
death) occur in inpatient hospital settings (82%),7 making it important to understand risk factors
associated with the timing of PCC in hospital settings where late conversations are more likely to
occur.58 Earlier PCC is associated with lower rates of inpatient care, ICU care, and emergency
department utilization in the last month of life; and lower inpatient and outpatient costs in the last
six months of life compared to persons receiving late palliative care less than 90 days before
death.58,59 Earlier PCC is also associated with greater family satisfaction with care, as well.60
Family members of veterans whose first PCC occurred 91-180 days before death, for example,
were more likely to rate their loved one’s care as excellent compared to families of veterans
whose PCC occurred 0-7 days before death (adjusted odds ratio = 1.37).60 In this study, PCCs
that took place more than one month before death were associated with higher ratings of
emotional and spiritual support, and respectful care and communication.60
In the literature, “early” GOC discussions are defined inconsistently.32,43,57,61,62 Some
studies define “early” as occurring more than 30 days before patient death.32,43 One study defined
“early” as a GOC conversation occurring in the first month following diagnosis.42 In contrast,
another study generalized late timing to be when a patient had lost decisional capacity following
hospital admission (requiring surrogate involvement).62 In this case, the author implied late timing
is actually too late. Despite differences in definition, it is important to understand outcomes
associated with the timing of early and late inpatient GOC discussions.

8

Inpatient GOC discussions occurring 30 or more days before death are associated with
less intensive healthcare utilization near EOL and greater quality of life than conversations
occurring less than 30 days before death.32,61 For example, Mack et al. found evidence that
patients with advanced cancer who had EOL discussions more than 30 days before death were
less likely to receive aggressive EOL care, acute care in the last 30 days of life, and
chemotherapy in the last seven days of life; and were more likely to receive hospice care.32
Ahuluwalia et al. found EOL care planning discussion in the first month following cancer diagnosis
was associated with a lower likelihood of receiving acute care at EOL among veterans with
advanced cancer.42 Although evidence on GOC timing in cancer populations is growing, evidence
is limited among patients with other serious illnesses. Our study aims to meet that need by
assessing a broad population of persons with serious illness.
In addition, little is known about risk factors and risk factor profiles associated with the
timing of GOC conversations in inpatient settings. To our knowledge, no known studies have
assessed risk factors or the interaction of risk factors associated with time between PCC and
death, or whether race/ethnicity is associated with the timing of inpatient PCC. Our study aims to
address this gap by identifying risk factor profiles of patients based on the timing of consultation
before death (PCC 0-14 days before death, PCC 15-60 days before death, and PCC more than
60 days before death). By exploring the relationship between the timing of PCC and EOL acute
care costs, our study also aims to contribute to an emerging body of literature about the timing of
inpatient communications and costs near EOL in patients with serious illness.
Racial/Ethnic Disparities in Goals-of-Care Discussions and End-of-Life Costs
Unfortunately, racial/ethnic minorities with serious illness in the United States are less
likely than White persons with the same illnesses to have these important EOL discussions with
healthcare providers and non-providers, such as family members.63-68 As one recent study
concluded, most racial and ethnic minorities with a serious illness have not talked with anyone
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about their goals, values, or care preferences—a difference that may result in lower quality
care.63 This difference is unnecessary given that most racial minorities think doctors should
discuss EOL care issues with patients [82% of African American adults, 83% of Hispanic adults,
and 82% adults self-reporting as “Other” (compared to 87% of White adults)].63
Although research suggests health literacy, rather than race, predicts EOL
preferences69,70 and that communication-based interventions can influence these preferences,69,71
African Americans are more likely than Whites to receive life-prolonging care in the last few days
of life72 and aggressive care at the end-of-life,68,73,74 and are less likely to complete advance
directives68,72,75-77 or receive hospice care.73,75 Compared to Whites, racial/ethnic minorities
experience less ACP63,78,79 and receive more intensive EOL care.63,78,80-84
Higher End-of-Life Costs among Racial/Ethnic Minorities
This higher use of intensive care contributes to greater costs for minorities near EOL.
One large study (n = 158,780) of Medicare data found that in the last six months of life, medical
costs were 32% higher for African Americans and 57% higher for Hispanics compared to Whites;
and that about 40% of the higher costs for Non-Whites were due to greater use of intensive
procedures (e.g., gastrostomies) and ICU hospitalization.80 (Differences in age, sex, cause of
death, morbidity burden, hospice use, and other variables accounted for the other differences in
higher EOL costs for minority patients.80) African Americans and Hispanics were more likely to die
in hospitals compared to Whites,80 also contributing to differences in costs. Across
races/ethnicities, expenditure dramatically increased in the last month of life, with Hispanics
receiving the most costly care of any racial/ethnic group studied ($13,900 compared to Whites,
whose expenditure averaged $8,900 in the last month of life).80 These racial/ethnic disparities in
ACP, EOL care, and EOL costs are concerning, and have prompted the National Academy of
Medicine to call for more research on the subject.24
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Innovation
The study is innovative in a number of ways. First, it fills gaps in the literature relevant to
the care of persons with serious illnesses. Second, stratified propensity score matching is a
robust, innovative method for exploring PCC, race/ethnicity, and cost outcomes. Similarly,
classification tree modeling is an effective, novel way to identify associations between risk factor
profiles (the interaction of risk factor variables) and the timing of PCC. Finally, study findings may
further underscore the need for timely GOC and EOL discussions (hereafter called “EOL
discussions”) for patients with serious illness. Clinicians may use the results of our study to
identify persons with risk factors for having EOL conversations close to death, then initiate those
conversations earlier to help reduce disparities and enable EOL care consistent with preferences.
Goals-of-Care/End-of-Life Communications, Utilization, and Costs
Little is known about the relationship between EOL discussions and acute care utilization
and costs across hospitalizations among racial/ethnic groups with serious illnesses.61 The parent
study of this dissertation research found future acute care costs to be significantly higher among
persons with serious illnesses who did not receive PCC, compared to similar patients who had
received PCC;5 and that consultations involving GOC discussions may decrease future
healthcare utilization and costs beyond initial hospitalization.5 While most available research on
EOL conversations and EOL costs focuses on healthcare utilization, not actual costs (see
Appendix A),61 or predominantly on the cancer population, no published research analyzes EOL
communications, acute care utilization and costs, and race/ethnicity.61 In fact, most available
research on racial/ethnic disparities in EOL discussions focuses on advance directive
completion,63,85 documents that do not always include preferences for EOL care (see Table 1.2
for description of terms) and alone may not facilitate care consistent with patient goals.63,86 This
dissertation research will explore race/ethnicity beyond the limited scope of advance directives by
focusing on GOC discussions, which are more likely to result in EOL care concordant with patient
values, goals, and wishes.24

11

Timing of Goals-of-Care and End-of-Life Discussions
Evidence about demographic, clinical, and financial risk factors associated with the timing
of GOC discussions among adults with serious illness prior to death is very limited61 (see Table
1.1, Appendix A). Although a small number of studies have assessed associations between
healthcare utilization and the timing of EOL discussions,32,42,43,57,62 they have generally focused
on decedents with cancer and have not analyzed race/ethnicity or cost outcomes. It is unknown
what variables are associated with the timing of consultations for EOL care planning. Because
GOC and EOL discussions near death are associated with more aggressive interventions, ICU
care, and death in the hospital,32,42,43,57,61,62 it is important that clinicians be aware of factors
associated with later EOL conversations to reduce any disparities in EOL communication and
care. End-of-life acute care costs associated with the timing of such discussions are also
unknown. And because high medical costs at EOL are associated with worse quality death
among persons with serious illness,8 it is ethically imperative that risk factor profiles associated
with the timing of these discussions be explored.

Parent Study Dataset for Secondary Analyses
The parent study of this dissertation research (n = 41,363 patients) was conducted at a
776-bed, urban, academic medical center in the Northeast region.5 The medical center is located
in a racially, ethnically, and socioeconomically diverse city and service area. African Americans
represent the largest racial or ethnic group (46%) in the medical center’s service area
population—Whites represent 36%, Asians 9%, and Hispanics 6%.87 The majority (84%) of
residents in the medical center’s service area speak English at home, with translation services
available for the 4% who speak Spanish at home and the 7% who speak an Asian language.87
Less than half (49%) of residents age 25+ in the service area graduated from high school,87
possibly influencing health literacy. In addition, a majority of families (53%) in the medical center’s
service area live in poverty, suggesting diversity in the dataset’s socioeconomic representation.87
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Finally, across the medical center’s service area, one in four adults 60+ are in fair or poor
health.87
The purpose of the parent study was to compare future acute care costs across
hospitalizations following PCC between patients who had PCC (n = 1,853) and a propensitymatched cohort of patients who did not (n = 39,510). The study found PCC was associated with
reductions in intensive care and other acute care utilization, and a mean cost-savings of over
$6,000 per patient.5
Study data include admissions of patients age 18 and older who were admitted to the
medical center between July 1, 2014 and October 31, 2016. To assess a population of patients
with serious illness, patients were excluded if they had been admitted for childbirth or
rehabilitation. Patients who died during index admission (the admission during which the first
PCC occurred within the study period, see Appendix A) or whose discharge information was
unknown (i.e., patients still hospitalized at the end of the study period) were excluded. The
medical center’s palliative care registry was then used to identify patients who received PCC
specifically to discuss GOC, according to records indicating the reason for each PCC. Patients
who exclusively received PCC for reasons other than GOC (e.g., pain management, spiritual
distress, transition planning) were excluded to enable cleaner assessment of associations
between GOC discussions, utilization, and costs. The medical center’s cost accounting system
(McKesson Health Solutions, King of Prussia, PA) was then used to track acute care utilization
and direct costs (see Appendix A) forward after the index admission through the end of the study
period (“future acute care costs”).5 According to the parent study, direct costs represent the best
estimate of the actual cost of providing hospital services including nursing labor, other allied
health professional labor, pharmaceuticals, supplies, procedures, and testing.5 Utilization and
costs incurred during the index admission were excluded.
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The medical center’s palliative care team, which primarily operates as a consultation
service, includes physicians, advance practice nurses, registered nurses, social workers, a
pharmacist, and a chaplain.5 Managed by a nurse coordinator, the palliative care registry includes
demographic and clinical information. The parent dataset ties these data to the utilization and
financial data available from the cost accounting system.

Chapter Aims and Rationale
The aims of this three article for publication dissertation research are to: (Aim 1) Explore
associations among ACP, costs, and proxies for costs (healthcare utilization, place of death) in
persons with advanced cancer near EOL (Chapter 2); (Aim 2) (a) Assess future acute care costs
and healthcare utilization among Whites and African Americans with serious illness who either do
or do not have PCC (Chapter 3) and (b) describe PCC patients across racial/ethnic groups using
cost and utilization variables, including discharge to hospice, DNR documentation, and changes
in GOC; and (Aim 3) (a) Examine risk factor profiles associated with the timing of PCC before
death (0-14 days before death, 15-60 days before death, more than 60 days before death) among
deceased persons with serious illness, and (b) Describe median EOL acute care costs, discharge
to hospice, DNR documentation, and changes in GOC based on PCC timing (Chapter 4).
Chapter 2
Aim. Chapter 2 presents a systematic review of published literature (January 2012-January 2019)
describing associations between ACP/EOL discussions in persons with advanced cancer and
financial costs and proxies for cost, such as healthcare utilization and place of death, near EOL.
We chose to focus the review on persons with advanced cancer because half of patients with
advanced cancer receive aggressive treatment within the last month of life.32 Evidence suggests
aggressive EOL care among persons with advanced cancer contributes to 43% higher costs than
cancer care managed non-aggressively at EOL.11 Given that cancer is one of the most expensive
conditions to treat,88 it made sense to focus on this important population. In addition, most
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research on GOC/EOL discussions explores associations in the cancer population, limiting our
opportunity to review studies of associations between ACP and costs in a broader population of
persons with serious illness.
Rationale. The systematic review identified only three studies with cost outcomes, two of which
were based on the same dataset. The review did not find any studies that assessed EOL
communications and costs in the context of race/ethnicity. Finally, the review identified six studies
related to the timing of ACP/GOC conversations, but none of the studies examined factors
associated with the timing of GOC or EOL conversations—associations we will explore in this
dissertation. Although consistent with the published literature, our Chapter 2 (systematic review)
focuses on persons with advanced cancer, we will apply our findings to a broader population of
persons with serious illnesses in Chapters 3 and 4.
Chapter 3
Aim. Chapter 3 describes a secondary analysis of a retrospective cohort study conducted at a
large, urban, academic medical center in the Northeast region (n = 41,363). The goal is to
understand if there is a difference in mean future acute care costs and healthcare utilization
among the following subgroups of persons with serious illness: African Americans with PCC,
African Americans without PCC, Whites with PCC, and Whites without PCC. Asian, Hispanic, and
other racial/ethnic minorities in the dataset will also be described; as will DNR documentation
during index admission and, for PCC patients, changes in GOC during index admission.
Rationale. Compared to Whites, racial/ethnic minorities experience less ACP/GOC
planning,63,78,79 receive more intensive EOL care,63,78,80-84 and incur higher medical costs in the
last six months of life.80 High medical costs at EOL are associated with worse quality death.8,89
Although PCC is associated with significantly lower hospital costs and utilization of acute
care,5,27,29,34-38 no published research explores associations between race/ethnicity and costs or
utilization in the context of PCC. The parent study did not assess costs or utilization by
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race/ethnicity, so it is unknown how race/ethnicity influences future acute care costs and
utilization following PCC.
Chapter 4
Aim. Chapter 4 describes a secondary analysis of deceased patients who received PCC at a
large, urban, academic medical center in the Northeast region (n = 1,141), supplemented by new
data (Medicaid status and days between PCC and death) pulled from electronic medical records.
The goals of this study are to: (a) examine risk factor profiles for PCC patients who died during
the study period based on the timing of consultation: PCC 0-14 days before death, PCC 15-60
days before death, and PCC more than 60 days before death; and (b) describe median EOL
acute care costs, discharge to hospice, DNR documentation, and changes in GOC by PCC
timing.
Rationale. Goals-of-care conversations occurring more than 30 days before death are associated
with less intensive healthcare utilization near EOL and greater quality of life32,61 and use of
hospice,32 supporting the idea that time enables patients and families to make informed decisions
possibly more consistent with preferences for less intensive care near EOL. Evidence suggests
many patients who have GOC discussions with their providers have these conversations close to
death,32,42,43,62,90 typically in inpatient settings following a change in health resulting in
hospitalization.58 Racial/ethnic minorities are less likely to receive GOC discussions,63,78,79 but
among those who do have these conversations with providers it is unknown how close to death
the conversations occur. In fact, despite the well-established relationship between GOC
discussion timing and healthcare utilization and costs, little is known about patient and clinical risk
factors associated with the timing of PCC conversations before death. Understanding risk factor
profiles and EOL costs associated with the timing of discussions may contribute to developing
clinical decision tools and encourage clinicians to have timely GOC discussions with patients.
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End-of-life (EOL),
goals-of-care (GOC),
or advance care
planning (ACP)
discussion (e.g.,
advance directives,
physician orders for
life-sustaining
treatment
documentation)

1. Palliative care
consultation for GOC
(“PCC”) (yes, no)

Aim 1

Aim 2

2. Self-reported
race/ethnicity (White,
African American)

Independent
variable(s)

Aims

3. Number of future
hospital days following

2. Future acute care costs
following discharge from
index admission (U.S.
dollars)

1. Any future acute care
cost following discharge
from index admission (yes,
no)

Financial costs (dollars) or
healthcare utilization (e.g.,
hospital days, ICU days,
intensive or acute
procedures, emergency
department visits, use of
hospice, et al.) or place of
death near the end-of-life

Dependent variable (s)

Table 1.1 Key Variables and Analytic Plan for Main Aims
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6. APR-DRG Risk of Mortality at time
of discharge

5. APR-DRG Severity of Illness at
time of discharge

4. Primary diagnosis

3. Medicaid status

2. Gender

1. Age

Demographic and clinical variables in
the literature (e.g., age, gender,
primary diagnosis).

Covariates

Tables

Two stratified propensity
score models (one for
African Americans with and
without PCC; one for
Whites with and without
PCC) were created using
sociodemographic, clinical,
and financial variables to
account for potential
inherent differences
between the race-based

Systematic review of
literature (January 2012 to
January 2019)

Analytical plan
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Aim 3

3. Race/ethnicity

2. Gender

1. Age
1. “PCC close to death”:
PCC 0-14 days before
death

Timing of PCC before
death

7. Patient discharge to
hospice from index
admission (yes, no).

6. 30-day readmissions
following discharge from
index admission (yes, no)

3. Race/ethnicity

2. Gender

1. Age

The variable “Change in GOC” and
documentation of DNR orders are
also described. Asians, Hispanics,
and other racial/ethnic minorities not
matched by propensity scoring are
described.

……

11. Direct cost of index admission
(impact per $1000, for every increase
of $1,000 in direct costs, the estimate
shows the expected increase in
getting PCC.

10. Whether a patient was seen by
Oncology during index admission

9. Admitted to medical center within
prior 30 days

8. ICU care more than six days
during index admission (yes, no)

4. Number of future ICU
days following discharge
from index admission
5. Any ICU care following
discharge from index
admission (yes, no)

7. ICU care during index admission
(yes, no)

discharge from index
admission

To inform development of
a classification and
regression tree (CART)
model, an adjusted
multinomial logistic
regression model was

Subsequent analysis
focused on the two highest
tiers of propensity scores
for each model.
Significance tests for
continuous variables were
analyzed using a pooled t
test and percentage
variables were analyzed
using a Cochran–Mantel–
Haenszel test. Statistical
significance was taken at
the 0.05 level.

groups with and without
PCC.
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3. “Early PCC”: PCC more
than 60 days before death

5. Primary diagnosis

6. Source of referral to
palliative care

12. Prior acute care
admission within 30
days of index
admission.

11. Whether a patient
was visited by an
Oncology team during
the index admission
(yes, no)

10. ICU care more than
six days during index
admission (yes, no)

9. ICU care during
index admission (yes,
no)

8. APR-DRG Risk of
Mortality

7. APR-DRG Severity
of Illness

2. “Moderately-timed
PCC”: PCC 15-60 days
before death

4. Medicaid status

The following variables were used to
describe the sample:
1. Change in GOC during PCC
2. Discharge to hospice from index
admission or any future admission
3. EOL acute care costs (following
discharge from hospitalization with
PCC to point of death in health
system).

12. Prior acute care admission within
30 days of index admission.

11. Whether a patient was visited by
an Oncology team during the index
admission (yes, no)

10. ICU care more than six days
during index admission (yes, no)

9. ICU during index admission (y/n)

8. APR-DRG Risk of Mortality

7. APR-DRG Severity of Illness

6. Source of referral to palliative care

5. Primary diagnosis

4. Medicaid status

created to identify
variables associated with
PCC timing before death.
A CART model was then
created to identify risk
factor profiles (interaction
of risk factors) of patients
likely to receive early PCC,
moderately-timed PCC,
and PCC close to death.

Definition
The process of discussing EOL care, clarifying values and goals, and documenting preferences through
written documents and medical orders. The process can start at any time and occur over time, and
becomes more focused as a patient’s health declines. The discussions ideally include a patient’s health
care agent (the person who can make medical decisions for the patient should he or she lose decisional
capacity) and the patient’s primary clinician and care team members. The conversations are ideally
recorded and updated. Finally, the conversations should allow for flexible decision making in light of the
patient’s current medical condition. 1
Refers to different patient-oriented documents, including living wills and durable power of attorney for
healthcare documents to name a healthcare agent, that patients can complete at any time, in any state of
health. 1
This advance directive document is a written or video-recorded statement about the types of medical care a
person wants or does not want under specific conditions (e.g., terminal illness) should the person no longer
be able to communicate their desires. 1
This advance directive document allows a person to identify the name of their preferred healthcare agent,
the person they want to make medical decisions for them should they lose the capacity to make decisions. 1
Documents seriously ill patients create with their health professionals (usually a physician, but in some
states a nurse practitioner or physician assistant), signed by the health professional as a doctor’s order that
other health professionals (including emergency personnel) are required to follow. 1
Medical order to not resuscitate a patient. This order is written in a healthcare facility but does not cross
care settings and may not be honored in the community. An “out-of-hospital DNR” is a do-not-resuscitate
medical order that is intended to ensure a patient will not be resuscitated against his or her wishes when
the patient is outside a healthcare facility setting (e.g., hospital or nursing home). 1

Term

Advance care planning

Advance directive

Living will

Durable power of attorney
for health care

Medical orders

Do-not-resuscitate (DNR)

Table 1.2 Definitions of End-of-Life Communication Terms (adapted from The National Academy of Medicine’s Dying in America Report1)
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Medical order to not intubate a patient. This order is written in a healthcare facility, but does not cross care
settings and may not be honored in the community. 1
Medical order to not hospitalize a patient. This order is written in a healthcare facility, but does not cross
care settings and may not be honored in the community. 1
Medical orders signed by a physician that cross care settings and are honored in the community in an
emergency. These orders span a range of topics that may emerge when caring for a person near EOL. Use
of POLST differs by state, but is becoming more popular. 1

Do-not-intubate (DNI)

Do-not-hospitalize

Physician Order for LifeSustaining Treatment
(POLST)
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CHAPTER TWO: ASSOCIATIONS AMONG END-OF-LIFE DISCUSSIONS,
HEALTHCARE UTILIZATION, AND COSTS IN PERSONS WITH ADVANCED
CANCER: A SYSTEMATIC REVIEW
Published: American Journal of Hospice and Palliative Medicine (May 9, 2019)

Abstract
Background: Aggressive end-of-life (EOL) care is associated with lower quality of life and
greater regret about treatment decisions. Higher EOL costs are also associated with lower quality
EOL care. Advance care planning and goals-of-care conversations (“EOL discussions”) may
influence EOL health-care utilization and costs among persons with cancer.
Objective: To describe associations among EOL discussions, health-care utilization and place of
death, and costs in persons with advanced cancer and explore variation in study measures.
Methods: A systematic review was conducted using PubMed, Embase, and CINAHL. Twenty
quantitative studies published between January 2012 and January 2019 were included.
Results: End-of-life discussions are associated with lower health-care costs in the last 30 days of
life (median US$1048 vs US$23482; P < .001); lower likelihood of acute care at EOL (odds ratio
[(OR] ranging 0.43-0.69); lower likelihood of intensive care at EOL (ORs ranging 0.26-0.68); lower
odds of chemotherapy near death (ORs 0.41, 0.57); lower odds of emergency department use
and shorter length of hospital stay; greater use of hospice (ORs ranging 1.79 to 6.88); and
greater likelihood of death outside the hospital. Earlier EOL discussions (30. days before death)
are more strongly associated with less aggressive care outcomes than conversations occurring
near death.
Conclusions: End-of-life discussions are associated with less aggressive, less costly EOL care.
Clinicians should initiate these discussions with patients having cancer earlier to better align care.
with preferences.
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Background and Significance
Aggressive, life-sustaining end-of-life (EOL) care is associated with lower quality of life,1
family perceptions of lower quality of care,2,3 and greater regret about treatment decisions.4 It is
also more costly.5-7 In one study, cancer patients who received aggressive EOL care incurred
43% higher costs than patients who received non-aggressive care.8 High costs near EOL, which
are a proxy for more acute care, are associated with worse quality of death6 and may contribute
to patients’ financial toxicity, the financial burden and stress caused by cancer that is associated
with myriad negative clinical and quality outcomes.9-13 High costs also create hardship for
families, one-third of whom report spending all or most of their savings on costs related to their
loved one’s terminal cancer care,14 and for health systems tasked with managing costs while
providing high-quality care.15 Most importantly, costly aggressive care may not always reflect
patient preferences.4 To better align care with preferences, the National Academy Medicine and
American Society of Clinical Oncology recommend patients and providers have goals-of-care
(GOC) conversations16 and that palliative care, which typically involves such discussions,15 be
integrated into standard oncology care.17 These conversations may include discussions about
patient values, prognosis, treatment options, aspects of living and dying, or specific interventions
a patient may want if certain future conditions occur—all of which may occur in advance care
planning (ACP).18 Interventions that include communication about ACP and care preferences
have been found to improve concordance between care preferences and actual care delivered.19
Given that the costs of cancer care may vary by diagnosis, stage of disease, and
treatment options;20 and that cancer disproportionately burdens racial minorities, who are often
diagnosed at later stages when treatment may be very expensive,20,21 it is important to
understand how care planning conversations are associated with healthcare utilization and costs
among persons with advance-stage cancer, when utilization and costs may increase.20 Evidence
suggests patient-provider discussions about EOL preferences are associated with less
aggressive treatment near death6,22,23 and that interventions involving GOC discussions may
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reduce costs.24,25 Cancer is the second leading cause of mortality in the United States and
globally,26,27 and one of the most expensive diseases to treat,28 in part due to rapid (often
expensive) advances in cancer science that are adopted as standard of care. Although reviews of
ACP and costs among older adults exist,29,30 variables and patient populations vary, limiting
conclusions and warranting separate analysis among patients with cancer. The purpose of this
review is to explore associations among ACP/GOC/EOL discussions, hereafter called “EOL
discussions,” healthcare utilization, and costs among persons with advanced cancer (Stage III+)
or persons who died of cancer. This review will also assess consistency and variation in how
studies define EOL discussions and measure healthcare utilization outcomes.

Methods
Literature search strategy. Authors used PubMed, Embase, and CINAHL databases to
find studies conducted in the United States published from January 1, 2012 to January 8, 2019
that explored relationships between EOL discussions and financial costs, healthcare utilization, or
place of death in adults with advanced cancer (see Table 1 for search terms). Because
healthcare payment schemes differ by country, resulting in different costs and ways to measure
costs, studies outside the United States were excluded. Qualitative studies, studies of children or
adolescents, and studies presented at meetings or as abstracts were excluded. To enable
comparability of costs and utilization near EOL, studies of patients with primarily early-stage
cancer were excluded unless they focused on EOL care. The authors screened titles in search
results and selected abstracts for review. Data extracted from each study were organized in a
table of evidence summarizing key characteristics and study quality (Table 2). The review
followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
recommendations.31 Two authors independently rated the quality of evidence using the Oxford
Centre for Evidence-based Medicine grading guide.32
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Results
Literature search. Systematic searches resulted in 2,911 unduplicated articles. Twentythree additional articles were identified through references and search engine recommendations
(Figure 1). After identifying relevant titles in each database and importing those listings into
EndNote software, 236 unduplicated abstracts were reviewed. Based on review criteria, 20
studies were included.
Description of studies. Included studies were conducted with populations
predominantly composed of patients with Stage III or IV cancer, or patients who recently died
from cancer. Cancer types included breast,33 hematological,34,35 gynecological,1,36,37 lung or GI,38
and any type.23,39-50 Sample sizes ranged from 84 to 2,752 participants, with a median of 226
participants per study. Two studies featured fewer than 100 participants.36,40 All studies were
conducted in the United States. Settings varied and included for-profit, not-for-profit, and
government institutions. Some hospital-based studies incorporated data from outpatient care. The
studies’ comparator was an EOL discussion, defined as any conversation about EOL goals or
treatment preferences with a healthcare provider or trained facilitator, documented in medical
records or self-reported by patients or surrogates, or described as ACP, which sometimes
includes advance directives (AD), physician orders for life-sustaining treatment (POLST), or donot-resuscitate (DNR) or do-not-intubate (DNI) orders that suggest discussion about preferences.
Because ADs, POLSTs, and DNR documentation may be associated with preference for
treatment limitations,41,51 results of studies that exclusively or predominantly assessed ADs,
POLSTs, or DNR were differentiated. Three studies examined EOL costs using either EOL
discussion or a proxy such as AD as comparator.41,42,50 No studies examined the impact of out-ofpocket costs on patients. Eighteen studies assessed relationships between EOL discussions and
healthcare utilization near death1,23,33,35-38,40,43-50,52 and six studies assessed place of death.1,3335,37,44

In addition, six studies incorporated elements of time in their assessment of EOL

discussions, generally referring to these discussions as early (31+ days before death) or late
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(within 30 days of death), with later conversations typically occurring in inpatient
settings.1,23,39,47,49
Quality of Studies. To assess study quality, two authors (L.T.S. and K.L.C.)
independently used the Oxford Centre for Evidence-based Medicine Levels of Evidence grading
guide.32 Independent ratings were then compared. Disagreements on ratings (10% of studies)
were resolved by further analyzing study methodology. One study was a retrospective analysis of
a randomized clinical trial (RCT);50 one study was non-randomized, intervention-based;45 and 18
studies were observational.1,23,33,35-38,40-44,46-49,52,53 Strengths of the studies included clearly-stated
objectives and inclusion criteria, sample sizes adequate for meeting objectives, and well-defined
outcomes and variables (Table 2). Study limitations included prevalence of retrospective cohort
design; variation among independent variable measurement, with some studies assessing EOL
discussions based on self-report and others based on medical chart review; diversity in outcomes
measured; and small sample size for two studies,36,40 limiting power and analysis (Table 2). Six
studies received lower ratings because they did not account for confounders.1,37,40,44,47,49
Summary of Findings.
EOL discussion associated with lower EOL costs. Only three studies (two from the same
dataset) measured costs,41,42,50 but one of these studies was a high-quality RCT.50 In their RCT,
Patel and colleagues found patients with advanced cancer who received a six-month program to
discuss and document EOL preferences with a trained lay health worker, and who later died
(n=120), had lower total healthcare costs within 30 days of death (median [interquartile range],
$1,048 [$331-$8,522] vs. $23,482 [$9,708-$55,648]; p < .001) than patients in the control group
who died.50 Fifteen months after randomization, total healthcare costs among the entire study
population were lower in the intervention group, but the difference was not statistically significant
(median [interquartile range], $86,025 [$63,255-$133,256] vs. $111,958 [$75,803-$171,025]; p =
.08).50
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The two studies by Garrido and colleagues41,42 are limited in their applicability due to how
authors defined and used EOL communications as variables. In their 2015 study, the authors
assessed costs in the last week of life in terms of preferences for heroic treatment or no heroic
treatment, as documented in ADs.41 As expected, costs were lower among patients who reported
a preference for no heroic measures at EOL (adjusted mean incremental effect = - $3,082, p =
0.03) compared to patients who preferred heroic measures.41 Because AD completion was
associated with a difference in EOL care preferences, the authors’ results may be biased toward
lower costs, limiting comparison to the RCT by Patel and colleagues. The other study by Garrido
and colleagues claimed a self-reported EOL discussion with a doctor about EOL care preferences
was significantly associated with costs in the last week of life (p = 0.001), but failed to provide
cost data, limiting comparison.42
EOL discussion associated with less acute care near EOL. Despite variations in
discussion comparators, we found each study in the review identified some, if not many,
significant associations between EOL discussion and either lower costs near EOL,41,42,50 lower
utilization of high cost care such as acute or intensive care,1,36-40,43,46,47,50 or reduced use or
duration of hospital services.1,36,38,45,47,49,50 Studies of EOL or GOC discussions not involving ADs
or POLST found associations between these discussions and a lower likelihood of having acute
care in the last 30 days of life [Odds Ratios (OR) ranging 0.43 to 0.69)23,39,45,50 and a lower
likelihood of receiving ICU care in the last 30 days of life (ORs 0.26 and 0.68),45,46 with
insignificant results suggesting trends toward lower utilization. Patients who complete ADs may
be more likely to prefer less intensive EOL care,41 but Cappell and colleagues (n=422) found
similar odds: patients with an AD were similarly less likely to receive ICU care within 30 days of
death (25% vs. 40%, OR 0.49, p = 0.001) than patients without ADs.35
Studies did not consistently measure readmission rates, emergency department visits, or
length of stay, although those that did often found associations with reduced rates.36,45,47,50 For
example, Rocque and colleagues (n = 2,752) found patients who started or completed an ACP
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discussion about care goals and preferences with a lay facilitator trained in the Respecting
Choices method had lower hospitalization rates within 30 days of death (46% vs. 56%, p = 0.02)
and that patients with ACP discussions had lower Emergency Department (ED) visit rates within
14 days of death (33% vs. 42%, p = 0.04).45 In their RCT, Patel and colleagues found patients
who received a structured ACP program involving GOC or care preference discussion before
death were also less likely to visit the ED (5% vs. 45%, p < 0.001) or be hospitalized (5% vs.
43%, p < 0.001) in the last 30 days of life compared to the control group (n = 120 total deceased
patients), and had fewer mean ED visits (p < 0.001) and fewer mean admissions (p < 0.001) in
the last 30 days of life.50 Hoerger and colleagues (n = 125 deceased patients) similarly found that
palliative care visits to discuss treatment decisions were associated with a lower odds of
hospitalization within the last 60 days of life (OR 0.62, p = .005).38 In total, four studies found
evidence of reduced hospital length of stay (LOS), as well.36,47,49,50
The six studies that assessed place of death found associations between EOL discussion
and death outside a hospital, but generally used mixed definitions of ACP as the comparator.1,3335,37,44

Eckhert and colleagues (n = 163), who broadly defined an EOL discussion as an outpatient

GOC discussion, AD, POLST, or DNR/DNI more than 30 days before death, found patients with
ACP were more likely to die in hospice than the ICU (p = 0.001) or in a non-ICU acute care
setting (p = 0.004).34 Conceptualizing EOL discussion to also include ACP, GOC, and discussion
proxies such as POLSTs and ADs, Zakhour and colleagues (n = 136) found patients who had a
discussion inpatient had much higher odds of dying in the hospital than patients who had a
discussion outpatient (34% vs. 0%, OR 20.5, 95% CI, 1.19 to 352.6, p = 0.04), providing context
to possible relationships between discussion location and place of death.37 In this study, 70% of
patients had a GOC discussion, suggesting the findings may compare to studies with GOC as a
comparator.37 Studies that assessed place of death among patients who had ADs or POLST
found similar results. For example, Cappell and colleagues found patients with ADs were less
likely to die in the ICU and more likely to die at home (p = 0.003).35 Pedraza and colleagues (n =

37

2,159) found the odds of dying outside the hospital were more than two times greater for patients
with POLSTs than patients with ADs (OR 2.3, p < 0.001).54
Of the 11 studies that assessed hospice use, nine studies found significant associations
with EOL discussions (ORs ranging 1.79 to 6.88).23,33,34,37,38,40,44,48 Findings were strongest among
studies that defined discussions based on EOL, GOC, and treatment preference
conversations.23,33,38,40,48 Among patients who died during the RCT (n = 120), for example, Patel
and colleagues found an GOC intervention was associated with higher rates of hospice use (48%
vs. 77%, p = 0.002; OR 3.51, 95% CI 1.6-7.69, p = 0.002).50 Mack and colleagues (n = 1,231)
also found patients who had EOL discussions were much more likely to receive hospice care (OR
6.88, 95% CI 4.36-10.8, p<0.001),23 as did Gramling and colleagues (n = 231), who found
patients engaged in a length-of-life discussion were more likely to enroll in hospice by six-month
follow-up (OR = 2.16; 95% CI 1.25–3.73).48 The two studies that defined EOL discussions based
on a mix of GOC, ADs, and POLST use also found significant results.34,37 Zakhour and
colleagues, for example, found patients who had a conversation involving GOC, AD, or POLST
31+ days before death were more likely to have higher rates of hospice (p = 0.001) and more
days in hospice (p < 0.001).37 Adding context to these findings, Pedraza and colleagues found
patients with POLST were more likely than patients with ADs to enroll in hospice (OR 2.69, 95%
CI 2.25 to 3.22, p < 0.0001).44 Two other studies that measured hospice use did not find
significant results.39,45
Associations between EOL discussion and chemotherapy use near EOL were mixed. For
example, Mack and colleagues (n = 1,231) found patients who had EOL discussions were less
likely to have chemotherapy in the last 14 days of life (OR 0.41, p < 0.001)23 and Hoerger and
colleagues (n = 171) found palliative care visits that addressed treatment decisions were
associated with lower odds of a patient receiving new chemotherapy within 60 days of death (OR
0.57, 95% CI 0.35 to 0.90, p =0.02).38 However, Ahluwalia and colleagues (n = 665), who defined
EOL discussion as any documented care planning discussion in the first month following cancer
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diagnosis among veterans, did not find an association between discussion and chemotherapy
near death (OR: 0.79, p = 0.35).39 With or without an EOL discussion, Garrido and colleagues
found baseline chemotherapy (median 3.5 months before death) was significantly associated with
higher costs of care in the last week of life.42 Studies of AD or POLST use did not assess late
chemotherapy as an outcome.35,44
Earlier EOL discussion associated with stronger outcomes. Finally, the six studies that
explored associations between EOL communications and care-related outcomes in the context of
time identified significant associations.1,23,37,39,47,49 Of the studies that exclusively looked at EOL
discussions not AD or POLST documentation, earlier conversations (defined as occurring 30-31
days or more before death, typically in inpatient settings) were found to be associated with lower
likelihood of receiving any aggressive care in the last 30 days or life (ORs ranged 0.10 to
0.34),1,23 lower likelihood of receiving acute care in the last 30 days of life (ORs ranged 0.03 to
0.67),1,23,39 lower likelihood of ICU care in the last 30 days of life (ORs ranged 0.19 to 0.33),1,23
and greater likelihood of enrollment in hospice care (OR 2.8, 95% CI 2.06 to 3.75, p< 0.001).23
Some studies did not find significant associations between the timing of EOL discussions and
hospice care or did not measure hospice enrollment overall but did measure time between
hospice enrollment and death. Lopez-Acevedo and colleagues, for example, found early EOL
discussions were associated with significantly more days of hospice care before death (median
length of enrollment 53 days vs. 11 days, p < 0.001) and a lower likelihood of late enrollment in
hospice within three days of death (OR 0.16, p = 0.02).1 Zakhour and colleagues, whose sample
predominantly engaged in GOC discussions but also may have completed ADs or POLST, found
patients who had late EOL discussions were eight times as likely to either enroll in hospice within
three days of death or not enroll at all (OR 8.0, 95% CI 3.3-19.2, p < 0.0001) than those who had
an early conversation.37 Earlier conversations were also associated with a much greater
likelihood of patients dying outside the hospital (OR 8.9, p = 0.0001) compared to late
conversations.1
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Variation in conceptualization of EOL discussions. We found wide variation in how
studies defined EOL discussions. Most studies based EOL discussions on documentation in the
medical record or patient/surrogate reports of an EOL conversation with a healthcare provider;
and others defined ACP in terms of documentation of medical orders such as DNR/DNI, POLST,
AD, or living will. Some studies conceptualized EOL communication as a mix of terms. Eckert and
colleagues, for example, defined ACP as documentation of an outpatient GOC conversation, AD
or POLST, and/or DNR/DNI code status.34 Professional health providers led most discussions,
though two studies featured professionally-trained lay healthcare workers, reflecting trends to
train both lay workers and a growing body of primary palliative care providers.45,50 The wide
variation in how clinicians and researchers define EOL discussions makes comparison difficult.
Variation in healthcare utilization outcomes. We also found wide variation in EOL
healthcare utilization outcomes measured. These measures serve as proxies for costs, but also
represent variance in how clinicians conceptualize aggressive care and overuse of healthcare
services near EOL. For example, Loggers and colleagues defined intensive EOL care as
resuscitation and/or ventilation in the last week of life followed by death in the ICU or hospice,43
whereas Ahluwalia and colleagues defined an intensive intervention as any of the following
occurring in the last 30 days of life: an ICU admission, new hemodialysis, placement of a gastric
tube, new mechanical ventilation, or death despite attempts at cardiopulmonary resuscitation
(CPR).39 Furthermore, Mack and colleagues measured ICU care in the last 30 days or life, but
also grouped measures into a category called “aggressive care” that included any ICU care or
acute care in the last 30 days of life, or chemotherapy in the last 14 days of life.23 Similar
variations in conceptualizing or grouping measures were common across studies, making clean
comparisons difficult. These findings suggest a lack of standardization in what may represent
unnecessary care near EOL.
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Discussion
This systematic review evaluated the relationship between EOL discussions about care
planning and EOL costs, healthcare utilization, and place of death in persons with advanced
cancer. The 20 included studies provide evidence that an EOL discussion is associated with less
costly and less aggressive or intensive forms of care near EOL, and greater use of hospice
services; and that relationships are even stronger when conversations occur 30 days or more
before death. Findings were similar for studies that assessed proxies for EOL discussion such as
ADs, POLST, and DNR orders. The implications of these findings are significant.
First, it appears patient-provider EOL discussions influence patients’ decisions to receive
less aggressive, less costly care at EOL, possibly due to a patient’s increased knowledge and
understanding of their illness and care options. Because less aggressive, less costly EOL care is
associated with numerous quality outcomes,1-4,55 EOL discussions about care preferences may
help improve the EOL experience for patients and families.3 To improve the EOL experience,
clinicians should routinely have these conversations with cancer patients—and in a timely matter,
not just in the weeks or days before death. For patients with cancer who are hospitalized, it is
critical that clinicians initiate these discussions early in the hospital stay.
Although none of the studies assessed EOL costs or healthcare utilization by race, some
studies did find evidence that racial minorities were less likely than Whites to have these
important EOL discussions with their healthcare providers,23,40 a finding that is consistent with the
literature.56-58 For example, Mack and colleagues found that compared to White patients, African
American patients (OR 0.37, 95% CI 0.19 to 0.73) and Hispanic patients (OR 0.29, 95% CI 0.12
to 0.73) were less likely to experience EOL discussions (p = 0.005).23 Clinicians should initiate
EOL discussions with all their patients, especially racial and ethnic minorities who may be less
likely to have these conversations.
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As part of EOL care planning, clinicians may also consider discussing patients’ financial
wellbeing and the estimated costs of treatment options—not to make clinical decisions based on
costs, but to acknowledge the financial burden cancer care has on patients and families and
support informed decision-making. A majority of cancer patients report some desire to discuss
treatment-related out-of-pocket costs with their care team, but less than 20% of patients actually
discuss costs with their doctors.59 In the study by Apostol and colleagues, the need patients
reported providers most poorly met in GOC conversations was the need for more economic and
insurance information related to cancer,40 further supporting the idea that such conversations
matter. The high cost of cancer care is associated with decreased quality of life and increased
risk of mortality and morbidity,9-11 making it a clinical and ethical concern.
End-of-life discussions also influence hospital and payer costs. One recent study found
palliative care consultations for GOC/EOL were associated with a decrease in future acute care
utilization, reducing future costs by more than $6,000 per patient.15 Although EOL discussions
should never be used to deny necessary care, hospitals and payers may benefit from patients
choosing less costly forms of care when consistent with patient goals. Finally, this review
highlights the need for more research about EOL communication and costs, the timing of
discussions, and racial/ethnic disparities across such measures. Standardization of outcome
measurement and greater consistency in definition of outcomes is recommended.

Limitations
This review has several limitations. First, only one study tested causal relationships
through an RCT.50 This study was also the only study to assess associations among EOL
discussions for GOC and costs;50 the other two cost studies compared AD utilization or did not
adequately provide cost data.41,42 Third, studies did not account for the same utilization variables,
consistently define the variables, or collect data on variables the same way. Studies that used
self-report to measure EOL conversations could not account for recall bias, while studies using
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medical records could not account for undocumented conversations. Fourth, variation in
healthcare utilization variables limits study comparison. Finally, studies captured results in
different cancer populations and healthcare systems that have varying levels of efficiency, rates
of intensive care at EOL, training in EOL communications, and resources.39 These differences
may limit generalizability of results. Despite these limitations, this review provides clinical insights
that may help improve EOL care for persons with cancer and justify investment in EOL
communication interventions.

Ethical Considerations
This review provides preliminary evidence that EOL discussions may reduce costs and
utilization of aggressive EOL care. Reducing costs should not be a driving reason for engaging
patients in EOL discussions.60 Instead, clinicians and payers should consider EOL discussions an
intervention that uniquely increases patient autonomy, improves quality of care and quality of
death, and saves resources at the same time.25 When communication is improved, better quality
results and lower costs tend to follow, mutually benefitting patients and systems and further
strengthening the case for EOL discussions.

Conclusions
End-of-life discussions are associated with lower EOL costs, less acute and aggressive
care, less time spent hospitalized, greater use of hospice, and greater odds of dying outside the
hospital—all outcomes associated with greater quality of life and quality of care. Separately, ADs
and POLST documentation are similarly associated with reductions in intensive care at EOL.
Earlier discussions about care goals give patients with advanced cancer more time to make
informed decisions and result in higher quality EOL care that happens to be less costly. Clinicians
should initiate EOL discussions with patients earlier to support patient-centered care and enable
informed decision-making. More standardized research is needed to better understand
relationships between these important discussions, healthcare utilization, and costs.
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Illustrations and Tables
Figure 2.1 PRISMA flow diagram showing systematic review screening and inclusion process,
adapted from Moher and colleagues 1

1.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for

systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8:336-41.
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Table 2.1 Systematic Review search strategy in PubMed, Embase, and CINAHL
Cancer terms

"Neoplasms"[mesh] OR cancer OR oncolog*

EOL terms

"end of life" OR end-of-life OR "terminal care"[mesh] OR end-stage OR
advanced OR "stage III" OR "stage iv" OR terminal*

Communication
terms

communicat* OR discuss* OR conversation* OR "advanc* care plan*"
OR "advanc* directive*" OR "goals of care" OR polst OR "physician
order for life sustaining treatment”

Financial terms

financ* OR "loss of income" OR "productivity loss" OR "economic
burden*" OR "aggressive treatment" OR "aggressive care" OR
"intensive care" OR ICU* OR "length of stay" OR "emergency room*"
OR "emergency department" OR readmission* OR re-admission* OR
readmi* OR hospice* OR cost* OR debt* OR bankrupt* OR "out of
pocket" OR out-of-pocket OR "Cost of Illness"[Mesh] OR "personal
cost*" OR "financial toxicity" OR expense* OR "financial burden”

Excluded terms

pediatric* OR paediatric* OR child* OR infan* OR neonat* OR newborn*
OR adolescen* OR Britain OR Japan OR Uganda OR Korea OR Italy
OR Ireland OR Australia[MeSH Terms]

Publication
dates

January 2012- January 9, 2019
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Retrospective
cohort
study

Pilot
cohort
study

Ahluwalia
et al.,
2015 1

Apostol
et al.,
2015 2

86
hospitalized
cancer
patients at
risk for

665
veterans
with stage
IV
colorectal,
lung, or
pancreatic
cancer.

Participant
/ Setting

GOC
meeting vs.
no GOC:

46.8% had
care planning
discussion
within the
first month of
diagnosis.

97.1% male,
74.7% white,
mean age
66.4 years at
time of
diagnosis.

Patient
Attributes

Patients with
GOC meeting
(reported by
physician as
having occurred

Documentation
of a care
planning
discussion in
the first month
following
diagnosis
compared to no
documentation
of discussion.

Intervention/
Comparator

- Receipt of critical
care
- Readmission to
hospital within 30
days

- Intensity of EOL
care defined as
acute care at EOL

EOL Costs /
Treatment
Components
Measured

Less likely to receive critical care
(use of continuous veno-venous
hemofiltration dialysis and/or
ventilation) (0% vs. 22%, p
=0.003); more likely to be

Lower likelihood to receive acute
care at EOL (OR: 0.67l; p =
0.025), but not associated with
less intensive interventions (OR:
0.74, p = 0.28), late
chemotherapy (OR: 0.79, p =
0.35), or hospice use (OR: 0.75,
p = 0.09).

Results

4

2b

2

Study
quality

EOL is end-of-life; ACP is advanced care planning; GOC is goals-of-care (conversation); AD is advance directive; POLST is physician order for
life sustaining treatment; POST is physician order for scope of treatment; DNR is do not resuscitate; DNI is do not intubate; CPR is
cardiopulmonary resuscitation; CI is confidence interval; SD is standard deviation.
2
The quality of each study was assessed following the Oxford Centre for Evidence-based Medicine quality rating scheme.

1

Study
Design

Study

Table 2.2 Table of Evidence for Studies Included in Systematic Review1
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Retrospective
cohort
study

Retrospective
cohort
study

Cappell
et al.,
20183

Doll et
al., 20134

47

84 gyn/onc
patients
near EOL
discharged
to hospice
care after
inpatient
hospitalization

422 patients
who died
after
allogeneic
hematopoiet
ic cell
transplant
(HCT)
2008-2015.

critical care
in an
academic
medical
center.

Hospice
discussion
group (HD, n
= 15) vs. Nohospice
discussion
group (NHD,
n = 69).
Median age,
63 years.

42% female,
56% White.
Patients with
ADs were
older (p <
.0001) and
more likely to
be White (p =
.0007).

Mean age 54
vs. 60 (p =
0.03); white
56% vs. 78%
(p = 0.05);
male 67% vs.
50%; solid
tumor 59%
vs. 71%.

Exposure to
hospice
discussion
during the last
outpatient
clinical
encounter prior
to hospital
admission.

Documentation
and timing of
AD (pre-HCT,
during HCT
(day of HCT to
day 30), or
post-HCT)

recently or
during the study
hospitalization)
compared to
patients
without.

- Use of palliative
care consultations
during
hospitalization

- Length of hospital
stay

-ICU days
-Use of mechanical
ventilation
-Location of death

- DNR/DNI order
- Discharge to
hospice
-Death during index
hospitalization
- Death within 30
days (including in
hospital).
Patients without AD were more
likely to have ICU admission after
HCT (52% vs. 41%, P = .03),
within 30 days of death (40%
versus 25%, P = .001), and
within 2 weeks preceding death
(36% versus 21%, P = .001);
more likely to undergo
mechanical ventilation (37%
versus 21%, P = .0007); more
likely to die in hospital and less
likely to die on hospice.
Decreased length of stay (3 days
vs. 7 days, p = 0.008) and
increased use of palliative care
consultations during hospital stay
(93.3% vs. 65.2%, p = 0.03). No
significant difference in invasive
procedures 4 weeks before
hospitalization or chemotherapy
8 weeks before hospitalization.

discharged to hospice (48% vs.
30%, p = 0.04). No statistical
difference in readmissions, death
during index hospitalization, or
death within 30 days.

2b

2b

Singlecenter
retrospective cohort
study

Prospective cohort
study with
patient
data and
postmortem
caregiver
interviews,
20022008.

Prospective cohort
study with
postmortem
caregiver
interviews,
20022008.

Eckhert
et al.,
2017 5

Garrido
et al.,
2015 6

Garrido
et al.,
2016 7
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311 patients
with
advanced
cancer who
died 20022008.

336
deceased
patients
with
advanced
cancer and
their
caregivers

163 patients
treated with
HCT for a
hematologic
malignancy
who died
2012-2015

Mean age,
59 years;
55% male;
61% white,
21% black,
17%
nonwhite
Hispanic

Mean age,
58.3 years;
54.5% male;
62.2% white,
19.6% black,
16.7%
Hispanic.

53% male,
67% white;
34% multiple
myeloma,
27% acute
myeloid
leukemia,
12% nonHodgkin
lymphoma.

EOL discussion
with a physician
reported by
patient during
baseline
interview

ADs (based on
preference for
heroic or nonheroic EOL
care)

Documentation
of ACP: GOC
outpatient, AD,
POLST, and/or
a code status of
DNR/DNI > 30
days prior to
death.

Costs of care
estimated using
reports of services
(excluding
chemotherapy) and
place of death;
based on average
hospital
expenditures,
Medicare payment

Estimated costs of
care received in the
week before death
based on average
hospital
expenditures,
Medicare payment
rates, and
published
estimates not
actual costs.

- Place of death:
ICU, non-ICU acute
care setting,
hospice.

EOL discussion significantly
associated with lower costs in
last week of life in unadjusted
generalized linear models
(p=0.001), however cost data
was not reported for this variable.

ADs were associated with lower
estimated costs in last week of
life in adjusted models of patients
who reported a preference for no
heroic measures at EOL
(adjusted mean incremental
effect = - $3082, standard error =
$1395, p = 0.03) compared to
patients who wanted heroic
measures.

More likely to die in hospice than
in ICU (p = 0.001) or non-ICU
acute care setting (p = 0.004).

2b

2b

2b

Multisite
cohort
study

Prospective cohort
study
(secondary
analysis of
randomize
d control
trial data)

Multisite,
prospective, cohort
study

Gramling
et al.,
20188

Hoerger
et al.,
20189

Loggers
et al.,
201310
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292 selfreported
Latino (n =
58) and
White (n =
234)
patients
with Stage
IV cancer

231 patients
with
metastatic
cancer
171 patients
diagnosed
within 8
weeks with
advanced
lung or GI
cancer who
received
early
palliative
care

Mean age,
54.6 vs. 60.3
years (p =
0.01)

Hispanic vs.
White
populations:

50% female;
13% African
American,
8% Latino.
Mean age of
sample was
65.44 years.
88.9% of
patients were
white.

Self-reported
EOL discussion
with doctor
about wishes
for care if
patient were
dying, by
ethnicity (White
and Latino)

Monthly
palliative care
consultation
involving
advance care
planning.

Discussion of
length of life

Intensive EOL care,
defined as
resuscitation and/or
ventilation followed
by death in an ICU.

-Location of death

-Receipt of hospice
care

-Healthcare
utilization:
chemotherapy,
hospitalization,
emergency
department visits
during the 60 days
preceding death

-Hospice
enrollment

rates, and
published
estimates.

No White or Hispanic patient who
reported having EOL discussion
at baseline received intensive
EOL care. No difference in
intensive EOL care among Latino
and White patients with EOL
discussion (p = 0.11).

Increased likelihood of
enrollment in hospice by 6-month
follow-up (OR = 2.16; 95% CI =
1.25–3.73).
Visits focused on treatment
decisions associated with lower
odds of new chemotherapy (OR,
0.57; p = .02) and hospital
admission (OR, 0.62; P = .005)
60 days before death. Higher
proportion of visits focused on
ACP associated with higher odds
of hospice (OR, 1.79; P = .03).

2b

2b

2b

Retrospective cohort
study

Prospective cohort
study

LopezAcevedo
et al.,
201311

Mack et
al.,
201212
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1,231
patients
with stage
IV lung or
colorectal
cancer in
the Cancer
Care
Outcomes

220 women
who died of
advanced
ovarian,
fallopian
tube, or
primary
peritoneal
cancer
diagnosed
between
1999 and
2008, and
treated by a
gynecologic
oncologist.

76% nonHispanic
white, 12%
non-Hispanic
black, 5%
Hispanic, 4%
Asian; 61%

62% male;

Mean age,
61.2 years;
76%
Caucasian,
21% African
American;
87% ovarian
cancer, 13%
primary
peritoneal
cancer; 52%
hospitalized
in the last
month; 62%
had invasive
procedures in
the last 6
months of
life, 35% had
invasive
procedures in
the last
month of life.

a) Patient or
surrogate report
of a discussion
with the
physician about

EOL
discussions,
identified via:

Documented
EOL discussion
with healthcare
provider ≥ 30
days before
death vs. < 30
days before
death, defined
as discussion
with patient
during which
DNR status/
resuscitation,
comfort care
(i.e., transition
from extending
life to focusing
on improving
EOL symptoms
and
experience), or
hospice care
was mentioned.
- Chemotherapy in
last 14 days of life
- Acute care in last
30 days of life
- ICU care in last 30
days of life
- Aggressive. EOL
care (any of
above)

Chemotherapy in
the last 14 days of
life, >1
hospitalization in
the last 30 days of
life, >1 ER visit in
the last 30 days of
life, ICU admission
in the last 30 days
of life, dying in an
acute care setting,
admission to
hospice ≤ 3 days

Patients with EOL discussions
less likely to have chemotherapy
in the last 14 days of life (OR
0.41, p < 0.001), acute care in
the last 30 days of life (OR 0.43,
p < 0.001), or any aggressive
care in last 30 days of life (OR
0.40, p < 0.001); more likely to
have hospice care (OR 6.88, p <

chemotherapy in last 14 days of
life (p = 0.003); >1 hospitalization
in last 30 days of life (p <0.001);
ICU in last 30 days of life (3% vs.
16%, p = 0.005); dying in acute
care setting (p = 0.01); hospice
initiated ≤ 3 days before death (p
= 0.02), or any EOL quality
measure (listed here) (p <0.001);
lower likelihood of hospitalization
in last month of life (p < 0.001)
and in-hospital death (p < 0.001);
fewer invasive procedures in last
month of life (p < 0.001); and
longer hospice enrollment (53 vs.
11 days, p < 0.001).

EOL discussion ≥ 30 days before
death associated with lower
incidence of:

2b

4

Retrospective cohort
study

Retrospective cohort
study

Marcia et
al.,
201813

O’Connor
et al.,
2015 14
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182 patients
who died of
metastatic
breast
cancer and
eligible for
hospice

203 patients
with stage
IV cancer
referred to
acute care
surgical
service
2009-2016

Research
and
Surveillance
Consortium
who died
during the
15-month
study period
but survived
at least 1
month.

Hospice vs.
Nonhospice
differences:
≤ high school
education,
14% in
hospice

Mean age
55. 51%
female, 12%
White, 43%
Hispanic,
28% Black.
27% colon
cancer.

married/living
as married;
14% age 2154, 25% age
55-64, 34%
age 65-74,
27% 75+;
18% college
degree or
greater; 82%
lung cancer,
18%
colorectal
cancer.

Documentation
of an advance
directive
discussion with
oncology team

Documentation
and timing of
AD

b) Medical
record
documentation
of a discussion
about advance
care planning
or venue for
dying.

resuscitation or
hospice care;

- Medication use

- Date of last
chemotherapy

- Hospice utilization

-Length of hospital
stay
-ICU length of stay

- Hospice care
- Hospice in the last
3 days of life, in
last 7 days of life

Patients who completed AD
(including DNR status) postadmission had longer hospital
lengths of stay (P < 0.001) and
ICU lengths of stay (P< 0.001)
compared to patients who
continued full-code status
throughout hospitalization and
patients with a DNR onadmission.
Patients admitted to hospice
more likely to have AD
discussion documented (p <
0.001) and discussion of
palliative care (p<0.001) than
patients who died without
hospice. Place of death was

0.001). No association found
between EOL discussion and
ICU care in last 30 days of life (p
= 0.55). Patients with EOL
discussion > 30 days before
death less likely to receive
aggressive EOL care (p < 0.001),
acute care in last 30 days of life
(p < 0.001), chemotherapy in last
14 days of life (p =0.003), and
hospice 7 days before death (p <
0.001); more likely to have
hospice (p < 0.001). ICU care in
last 30 days of life insignificant (p
= 0.16).

2b

4

Patel et
al.,
201815

52

Randomized clinical
trial
(retrospective
analysis of
randomize
-ed quality
improvement
study)

213
veterans
with Stage
III or IV or
recurrent
cancer
planning to
receive care
2013 2015.

1999 to
2010.

Mean age 69
years; 99%
male. 78%
non-Hispanic
White, 5%
Black, 3%
Asian/Pacific
Islander, 2%
Hispanic.

group vs.
31% in nonhospice
group, p =
0.02.
Documentation
of GOC/EOL
preferences by
oncology
clinician within
6 months of
randomization.
Intervention: 6month
structured
program where
lay health
worker assisted
patients with
ACP, including
GOC, care
preferences,
choosing a
surrogate
decision maker,
discussing AD,
encouraging
GOC
discussion with
providers.

-Health care use:
chemotherapy,
surgery, and radiotherapy use, VA
and non-VA
emergency
department use,
hospitalizations,
inpatient and
outpatient palliative
care visits, and
hospice service use
-Total health care
costs were
measured a) 6
months prior to
randomization, b) 6
months after
randomization and
c) 15 months after
randomization

- Place of death.

Patients in intervention group
who died had fewer ED visits (P
< .001) and fewer
hospitalizations (P < .001), were
more likely to receive hospice
care (P = .002), and had lower
health care costs within 30 days
of death (median [interquartile
range], $1048 [$331-$8522] vs
$23 482 [$9708-$55 648]; P <
.001) than patients in the control
group who died. Patients in
intervention group more likely to
have used hospice within 6 and
15 months of randomization (P =
.006; P = .009, respectively).

associated with hospice
utilization (p < 0.001).

1b

Retrospective cohort
study

Convergent,
parallel
mixed
method
design to
evaluate
implementation of
navigatorled ACP
across 12
cancer
centers

Multisite,
prospective cohort
study with
chart

Pedraza
et al.,
2017 16

Rocque
et al.,
2017 17

Sharma
et al.,
2015 18
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353
terminally ill
patients
with
metastatic

2,752
deceased
patients
with cancer;
437 patients
completed
or were in
the process
of
completing
the lay
Patient
Care
Connect
Program
(PCCP).

2,159 West
Virginians
with ADs
and/or
POLST who
died of
cancer
2011-2016.

Mean age 58
years; 54%
male; 64%
white, 19%
black, 16%

Group that
completed or
started the
PCCP
program:
56% male,
79.9% white,
51.7% high
acuity.

Lung (28%),
colorectal
(9%),
pancreatic
(6%), breast
(6%),
prostate
(3%), other
(48%)
cancers.

of EOL
discussion with

Self-reported
recollection

Completion or
involvement in
program with
ACP
discussions vs.
no involvement
in program/
discussion.

Use of POLST
vs AD

- ICU care in the
last week of life

-Hospitalization
within 14 days and
30 days of death

- ICU visit within 14
days and 30 days
of death

- ER visit within 14
days and 30 days
of death

Out-of-hospital
death (OHD) and
hospice admission

Patients who had ICU care at
EOL less likely to report EOL
discussion with doctor (19% vs.
38%, p = 0.02) than patients who
did not receive EOL ICU care.

Patients who started or
completed ACP discussion with a
navigator had lower
hospitalization rates within 30
days of death (46% vs. 56%, p =
0.02), but not within last 14 days
of life (36% vs. 44%, p = 0.09).
PCCP patients had lower ER
rates within 14 days of death
(33% vs. 42%, p = 0.04).

OHD 85.7% for patients with
POLST, 72.0% for ADs (p <
.001); hospice admission 49.9%
for POLST, 27.0% for ADs (p <
.001).
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Retrospective cohort
study

review and
interviews
of
caregivers
to identify
ICU stay in
the last
week of
life.

invasive
gynecologic
malignancie
s 20102012

136 patients
who died of

cancer
interviewed
before
death, and
their
caregivers,
from six
comprehens
ive cancer
centers.
Median age
at death, 70
years; 79%
White, 11%
African
American;
91%
advanced
stage (III/IV);
71%
documented
EOL
discussion;
52%
documented
AD at death.
81% had
EOL
discussion in
inpatient
setting.

Hispanic;
23% lung
cancer, 34%
GI cancer,
12% breast
cancer, 32%
other cancer.

death

EOL discussion
(GOC for EOL,
hospice or
palliative care,
code status) or
completion of
AD or POLST
(hereafter
called “EOL
discussion”)
>30 days
before

doctor (wishes
about care
patient would
like to receive
when dying); by
gender.

- Non-compliant
with ≥1 National
Quality Forum
(NQF)

- No hospice or ≤3
days hospice care

- Chemotherapy
last 14 days of life

- Death in hospital

- ICU admission
last 30 days of life

- ED visit last 30
days of life

- Hospital
admission last 30
days of life

Compared to patients with
inpatient EOL discussion,
patients with first discussion
outpatient less likely to die in
hospital (0% vs. 34%, p = 0.001)
or have ICU care in last 30 days
of life (p = 0.06).

Compared to patients who had
late or no EOL discussion before
death, patients with earlier
discussions less likely to have
inpatient admission (p = 0.001) in
last 30 days of life; more likely to
have hospice (p=0.001) and
more days in hospice (p < 0.001),
less likely to be non-compliant
with ≥1 National Quality Forum
(NQF) overutilization measures
(12% vs. 38%, p = 0.005)

Men with EOL discussion less
likely to have ICU care at EOL
than men without EOL discussion
(odds ratio, 0.26; p = 0.04); no
difference in EOL ICU for women
based on EOL discussion (p =
0.4).

4
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Retrospective cohort
study

115 adult
patients
with
advanced
cancer who
were
documented
to have
decisional
capacity
upon
admission
and died in
the hospital.

52% age >
65 years;
59% male;
cancer type
37% lung,
30% bone
marrow, 7%
esophagus,
6%
pancreatic,
5% liver, 5%
colon, 10%
other

Patients who
participated in
EOL discussion
vs. patients
who lost
decisional
capacity after
admission and
had surrogate
participate in
EOL discussion
- Chemotherapy
- Artificial nutrition
or hydration
- Antibiotics
- CPR
- ICU treatment
(admission or
transfer)
- Length of
hospitalization

-Ventilation support

Utilization during
terminal admission:

overutilization
measures
Patients who had EOL
conversations themselves,
compared to patients with
surrogates, were less likely to
receive ventilator support (23.2%
vs. 56.5%, p < 0.01); artificial
nutrition or hydration (25% vs.
45.7%, p = 0.03); chemotherapy
(5.4% vs. 39.1%, p < 0.01);
antibiotics (78.6% vs. 97.8%, p <
0.01); ICU treatment (23.2% vs.
56.5%, p < 0.01); had shorter
length of hospitalization (mean
15.8 days vs. 10.3 days, p =
0.03).
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CHAPTER THREE: PALLIATIVE CARE CONSULTATION FOR GOALS-OF-CARE
AND FUTURE HEALTHCARE UTILIZATION AND COSTS AMONG AFRICAN
AMERICAN AND WHITE PATIENTS: A PROPENSITY-MATCHED STUDY
Abstract
Background: End-of-life (EOL) medical costs are higher for racial/ethnic minorities than Whites
in the United States. Palliative care consultation to discuss goals-of-care (hereafter “PCC”) is
associated with lower use of intensive care and cost-savings. Little is known about how PCCassociated cost and utilization outcomes differ among African Americans and Whites.
Objective: To compare future acute care costs and healthcare utilization (30-day readmissions,
future hospital days, future ICU admission and number of ICU days, and discharge to hospice)
between African Americans who had inpatient PCC (n = 383) and a propensity-matched cohort of
African Americans who did not (n = 10,777) and between Whites who had PCC (n = 814) and a
propensity-matched cohort of Whites who did not (n = 23,180) in an academic medical center.
Methods: In this secondary analysis of a retrospective cohort study, stratified propensity score
modeling was applied using sociodemographic, clinical, and financial variables to account for
potential inherent differences between the race-based groups with and without PCC.
Results: There was no statistically significant difference between African Americans with or
without PCC in accumulated mean future acute care costs ($11,651 vs. $15,050, P = 0.09), 30day readmissions (P = 0.58), future hospital days (P = 0.34) future ICU admission (P = 0.25) or
number ICU days (P = 0.30). However, there was a significant difference between Whites with
PCC compared to Whites without PCC in in accumulated mean future acute care costs ($8,095
vs. $16,799, P < 0.001), 30-day readmissions (10.2% vs. 16.7%, P < 0.0001), future days spent
hospitalized (3.7 vs. 6.3 days, P < 0.0001). PCC resulted in significantly greater discharge to
hospice from index hospitalization for both African Americans and Whites (African Americans with
PCC and without PCC, respectively, 36.5% vs. 2.4%, P < 0.0001; Whites with PCC and without
PCC, respectively, 42.7% vs. 3.0%, P < 0.0001).
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Conclusions: Our findings suggest PCC appears to decrease future acute care utilization and
costs in White patients and, directionally but not significantly, in African Americans. Research is
needed to explain why acute care utilization and cost disparities persist among African Americans
despite PCC. These consultations are effective at dramatically increasing hospice use among
African American and White patients.
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Introduction
Despite growing evidence that patient-provider discussions about goals-of-care (GOC)
and end-of-life issues (EOL) are associated with patients receiving EOL care concordant with
preferences1,2 and less aggressive treatment3-13 perceived to be higher quality,12,14-16 African
Americans and other racial/ethnic minorities in the United States are less likely than Whites to
have such conversations with their healthcare providers.17-22 This disparity suggests an unmet
need that may result in lower quality care.17,23 Because race does not determine EOL
preferences24,25 and communication-based interventions can affect such preferences,24,26 it is
important to understand relationships between GOC discussions and the EOL care African
Americans and other racial minorities receive.27
Communication disparities and differences in the effectiveness of EOL discussions22 may
help explain why minority patients are more likely than White patients to prefer and receive
intensive EOL care17,23,28-34 and less likely to receive hospice care.35,36 These differences in
healthcare utilization contribute to acute care spending disparities near EOL. One large study of
Medicare data found that in the last six months of life, medical costs were 32% higher for African
Americans and 57% higher for Hispanics compared to Whites; and that about 40% of the higher
costs for racial/ethnic minorities was due to greater use of intensive procedures (e.g., mechanical
ventilation, gastrostomies) and intensive care unit (ICU) hospitalization.28 African Americans and
Hispanics are also more likely to die in hospitals compared to Whites,28 adding to differences in
costs. Across races/ethnicities, expenditure is dramatically higher in the last month of life, with
African Americans and Hispanics receiving the most aggressive and costly care.28 These
disparities in EOL costs persist across studies, even after controlling for individual and
geographic factors.37 Unfortunately, high medical costs at EOL are associated with worse quality
death, underscoring the ethical need to understand EOL cost disparities among racial/ethnic
groups and interventions, such as palliative care consultation, that mitigate those disparities.12,38
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Palliative care consultations may involve discussion of GOC, pain and symptom
management, psychosocial or spiritual distress, transition planning, or EOL issues. Inpatient
palliative care consultations that specifically address GOC (hereafter called “PCC”), however,
have been found to be associated with reductions in future acute care utilization, hospital
readmissions, hospital days, and ICU use; and an average savings of over $6,000 in acute care
costs following discharge from a hospitalization with PCC.6 Some studies suggest cost reductions
associated with GOC discussions, such as those occurring in PCC, are driven by lower utilization
of inpatient care.12,39,40 The benefit of PCC for patients and health systems appears to be mutual:
patients who have these conversations seem to experience a higher quality dying experience
more consistent with their preferences and health systems incur lower costs as a result.12 In
addition, early evidence of urban academic medical centers suggests race/ethnicity is not a factor
in which patients receive PCC,6,41-43 making it an intervention that may help overcome
racial/ethnic disparities in EOL communication and care.
However, it is unknown how PCC is associated with acute care utilization and costs
across racial groups, particularly among African Americans. The purpose of this secondary
analysis is to compare future acute care costs and healthcare utilization (30-day readmissions,
future hospital days, future ICU admission and number of ICU days, and discharge to hospice)
between African Americans with serious illness who had PCC and a propensity-matched cohort
of African Americans who did not, and between Whites with serious illness who had PCC and a
propensity-matched cohort of Whites who did not. In addition, patients self-reporting as Hispanic,
Asian, and “Other” racial/ethnic minorities will be described using demographic, cost, and
utilization variables. The presence of a do-not-resuscitate (DNR) order during index admission
and, among PCC patients, whether GOC changed during index admission will also be described.
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Methods
Study Design
This secondary analysis included pre-existing clinical, administrative, and cost data from
a retrospective cohort study that found PCC was associated with lower costs and lower use of
acute care, but did not explore outcomes by race.6 Supplementary Medicaid data was pulled
from electronic medical records. Our sample included 35,154 self-identified African American and
White patients 18 years or older admitted to a 776-bed urban, academic medical center in the
Northeast region between July 1, 2014 and October 31, 2016 who were admitted for conditions
other than childbirth or rehabilitation, were not hospitalized at the end of the study period, and did
not die during index hospitalization (defined as the hospitalization during which the first PCC
occurred). The hospital’s palliative care registry, which includes demographic and clinical
information such as the reason for consultation, was used to identify all patients who received a
consultation with palliative care during the study period. Only consultations involving discussion of
GOC were included (i.e., consultations to discuss pain management, but not GOC, were
excluded). Our sample included 11,158 African Americans (PCC = 383; No PCC = 10,777) and
23,994 Whites (PCC = 814; No PCC = 23,180) (Table 3.1).
Future acute care utilization and accumulated direct costs (Appendix A) were tracked
forward after discharge from the index hospital admission through the end of the study period
using the medical center’s cost accounting system (McKesson Health Solutions, King of Prussia,
PA).6 (Utilization and costs incurred during the index admission were not included in analysis, but
are described in Table 3.1.) Direct costs represent the best estimate of the actual cost of
providing hospital services including nursing labor, other allied health professional labor,
pharmaceuticals, supplies, procedures, and testing (Appendix A).6
Setting
According to research by the medical center, the center serves a diverse area composed
of 46% African Americans, 36% Whites, 9% Asians, and 6% Hispanics44 and receives transfer
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patients and referrals from surrounding suburban areas. Over half (53%) of families in the
medical center’s main service area live in poverty and one in four adults 60+ are in fair or poor
health,44 contributing to the population’s diversity and need for quality care. The medical center’s
palliative care team is well-established and predominantly works as a consultation service.6
Physicians, advance practice nurses, registered nurses, social workers, a pharmacist, and a
chaplain make up the team. ICU teams request one-third of all consultations with palliative care.6
Procedures
The institutional review board of the University of Pennsylvania approved this secondary
analysis study. The study followed University of Pennsylvania procedures for ensuring patient
data privacy and security. To ensure Health Insurance Portability and Accountability Act (HIPAA)
compliancy and participant privacy, all HIPAA-identifiers were removed prior to data transfer.
Penn Medicine transferred de-identified data through Secure Share, an internet-based application
for secure file exchange. Data was saved to a secure, encrypted folder on the University of
Pennsylvania School of Nursing’s network drive that exists behind firewall protection. Accessing
the folder and the network drive requires two-step authentication. The network drive that
contained the data is routinely monitored for system and security breaches. Only study
investigators and university statisticians had access to the data.
Power Analysis
Based on the parent study’s finding of $8,831 in future acute care costs among patients
with PCC and $15,654 for patients without PCC, and variance of 10% (standard deviation
unreported),6 a sample of 771 Non-White patients who received PCC and a cohort of 15,780
Non-White patients who did not receive PCC achieves 91% power to detect a clinically
meaningful difference of at least $2,000 in mean future acute care costs with a significance level
(alpha) of 0.01 using a two-sided two-sample unequal variance t-test.30,31,33 (The majority of NonWhite patients in the dataset were African American.6) A $2,000 difference is a conservative

68

estimate given the parent study’s finding of $6,000 cost-savings among the entire study
population6 and suggests adequate power in this study.
Measures
Independent variable. The primary independent variable is PCC as recorded in the
palliative care registry according to patient self-identified racial group (African American, White).
All hospital admissions during the study period were placed into one of four groups: (1) African
Americans who had PCC, (2) African Americans who did not have PCC, (3) Whites who had
PCC, and (4) Whites who did not have PCC (Appendix A). Although propensity score-matched
analysis of other racial/ethnic groups is desirable, sample sizes for other racial and ethnic groups
(Hispanics, Asians, American Indian/Alaskan Natives, Native Hawaiian/Pacific Islanders) were
too small for independent group analysis. These patient populations are described using available
clinical and cost variables (Tables 7-10, Appendix A).
Outcomes
Future Acute Care Costs. The primary outcome is future acute care costs, defined as
accumulated mean acute care costs from all hospitalizations after the index hospitalization during
the study period (Appendix A). We measured “future acute care costs” in two ways: (1) if a
patient had any direct future acute care costs following discharge from index admission (yes, no)
and (2) total direct future acute care costs a patient had during the study period following
discharge from index admission, measured in U.S. dollars. Direct costs include hospital services
such as physician and nursing labor, allied health professional labor, pharmaceuticals, supplies,
procedures, testing, and emergency department (ED) visits that resulted in hospitalization. Direct
costs provide the best estimate of actual costs, as they exclude indirect or fixed costs (i.e.,
overhead costs such as the cost of utilities) that cannot be reduced by avoiding future
hospitalizations 6. The medical center’s cost accounting system, McKesson Health Solutions
(King of Prussia, PA), provided acute care costs data based on charges coded during each
hospital encounter throughout the study period. Healthcare costs outside the health system, such
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as emergency room visits at local hospitals unaffiliated with the medical center, were not
available and therefore not included, and have been identified as a limitation.
Future Healthcare Utilization. Secondary outcomes include (1) the number of future
hospital days (in the health system) following discharge from the index hospital admission, (2) the
number of future ICU days (in the health system) following discharge from the index hospital
admission, (3) any ICU care following discharge from the index hospital admission (yes, no), (4)
30-day readmissions (in the health system) following discharge from index admission, and (5)
patient discharge to hospice from index admission (yes, no) (Appendix A).
Covariates
Covariates include demographic variables such as age, gender, and Medicaid status
(yes, no); acute care utilization 30 days before index hospitalization (yes, no); acute care costs
accumulated during the index admission to represent acute care utilization (defined as the impact
of $1,000; for every increase of $1000 in direct costs, the estimate shows the expected increase
in getting a palliative care consult); and the following clinical variables (1) primary diagnosis at the
time of index hospitalization discharge [based on diagnosis-related group (DRG)], (2) All Patient
Refined (APR)-DRG Severity of Illness at the time of index admission discharge, (3) APR-DRG
Risk of Mortality at the time of index admission discharge, (4) if the patient had any ICU care
during the index admission (yes, no), (5) if the patient had ICU care greater than six days during
the index admission (yes, no), and (6) whether the patient had Oncology services during the
index admission (Appendix A).6
APR-DRG Severity of Illness and Risk of Mortality. APR-DRG Severity of Illness, which
indicates the extent of physiologic decomposition or organ system loss of function in a patient,
and APR-DRG Risk of Mortality, which indicates the likelihood a patient will die in the hospital,
feature four subcategories (minor, moderate, major, extreme) that are assigned to a patient at
discharge by an algorithm in the hospital’s medical record software based on the diagnoses and
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procedures coded for billing during the hospitalization.6,45 Developed by 3M (St. Paul, MN) to
enable hospitals to analyze patient risk and possible resource use, APR-DRG Severity of Illness
and Risk of Mortality scores take into account a patient’s comorbidities and the interaction of
those illnesses, disease staging, and the kind of procedures and resources required by a patient
during hospitalization.46 High Severity of Illness and Risk of Mortality are characterized by
multiple serious diseases and the interaction among those diseases. Severity of Illness appears
to be associated with the risks of morbidity and mortality,47 making it a proxy for considering
comorbidity severity. Our study is unable to account for the number of comorbidities each patient
has due to limitations in the dataset but uses Severity of Illness and Risk of Mortality to
meaningfully express how sick a patient is at the time of index hospitalization.
Secondary Aims
Patients who self-identified as Asian, Hispanic, and “Other” race/ethnicity were not
included in this propensity score-matched study. However, the parent dataset6 included an
additional 4,733 patients 18 years and older who self-reported to be a race/ethnicity other than
African American or White who met our study criteria. These patients were also discharged from
an inpatient hospitalization at the academic medical center and excluded patients who had been
admitted for childbirth or rehabilitation, patients who died during index admission, and patients
still hospitalized at the end of the study period.
For the secondary descriptive aim, which did not include propensity score matching to
account for differences in patients with and without PCC, the sample included 961 Asians (PCC =
48; No PCC = 913); 851 Hispanics (PCC = 22; No PCC = 829); and 1,134 patients with “Other”
race/ethnicity (PCC = 39; No PCC = 1,095). Healthcare utilization and costs of these patients are
described in Tables 3.7-3.10. In addition, the presence of a DNR order during index admission
(Table 3.6) and whether a patient changed GOC during PCC are described for African.
Americans, Whites, Asians, Hispanics, and other racial/ethnic minority patients (Table 3.1,
Tables 3.7-3.10).
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Statistical Methods
Descriptive statistics were generated to characterize all variables and describe the
sample (Table 3.1). Continuous variables were described using means and standard deviations
following analysis with a Student’s t test. Categorical variables were described as frequencies
and percentages using a Chi-squared (χ2) test. For the PCC groups, whether or not the patient
changed GOC preferences is also included.
A systematic process to balance the four PCC-race groups (African Americans with and
without PCC, Whites with and without PCC) was followed (Tables 3.2 and 3.3). We created two
stratified propensity score matching models: one in the African American sample and then,
separately, one in the White sample to account for possible inherent differences and nonrandom
assignment of variables in the PCC and Non-PCC groups within each racial group. Before
propensity scoring, patients in the PCC and Non-PCC groups for each race had different baseline
characteristics (Table 3.1). For this reason, we employed a two-step matching process to make
the PCC and Non-PCC groups similar for each race. First, we used logistic regression analysis
with relevant variables available in the dataset to identify factors associated with the likelihood of
an individual receiving PCC (Table 3.2). These variables included demographic data such as
gender, age at time of index admission, and Medicaid status; and clinical and utilization data
including primary diagnosis, APR-DRG risk of morality and severity of illness at the time of index
admission discharge, ICU care during index admission (yes, no), ICU care greater than six days
during index admission to indicate high acuity during the hospitalization, index admission acute
care costs to represent acute care utilization; and prior inpatient hospitalizations in the health
system during the 30 days before index admission.
The results from the final logistic model for African Americans and the results of the final
logistic model for Whites are presented in Table 3.2. In both models, both the Akaike Information
Criterion (AIC) and the Schwarz Criterion (SC) values became substantially lower when the
covariates were included, showing much of the variation was explained by the predictors. As a
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result, the model of African American PCC and Non-PCC patients had a C statistic of 0.907,
indicating adequate model fit. The model of White PCC and Non-PCC patients had a C statistic of
0.901, also indicating adequate model fit.
Individual-level propensity scores were then created for each patient in the sample using
output from the logistic regression models, by racial group. These individual propensity scores
were then ranked and stratified into propensity tiers, from highest to lowest, to identify which
patients were most likely to have received PCC (Table 3.3). Patients in the highest tiers were
most likely to have received PCC. For each racial group’s model, the patients in the PCC and
Non-PCC groups were similar in terms of their propensity scores (Table 3.3), which enabled
direct comparison of PCC patients to Non-PCC patients within tiers, within each racial group
(Tables 3.4 and 3.5). To understand outcomes among patients with the highest likelihood of
receiving PCC per racial group, subsequent analysis focused on the two highest tiers of
propensity scores for each model. Lower propensity tiers were excluded because very few
patients with a low propensity score actually received PCC. Significance tests for continuous
variables were analyzed using a pooled t test and percentage variables were analyzed using a
Cochran–Mantel–Haenszel test. Statistical significance was taken at the 0.05 level.
Missing Data
Although clinicians try to obtain and document complete data on every patient, missing
clinical and administrative data is inevitable due to human error, oversight, or time constraints.48
The parent study handled missing data by examining the underlying mechanism for missing
data—missing completely at random (MCAR), nonignorable or not missing at random (NMAR)—
prior to adjusting to minimize bias from missing data.48-50 Most missing data was found to be
MCAR (e.g., clinicians may have found data collection burdensome). For this reason, completecase only analyses for data missing completely at random was used to analyze missingness.
Although the number of patients with missing data was small (<5%) and missing data was
considered MCAR, the parent study opted to exclude 0.4% of patients due to missing data.
73

Primary hypotheses were then tested on the remaining dataset. There was no missing data for
our study, so additional analyses were not necessary.

Results
The sample for this study included 35,154 patients who were discharged from an
inpatient hospitalization at an academic medical center in the Northeast region (Table 3.1). The
sample included 1,197 patients who received PCC prior to discharge and 33,957 patients who did
not. Specifically, the sample was composed of 11,160 African American patients (PCC = 383,
Non-PCC = 10,777) and 23,994 White patients (PCC = 814, Non-PCC = 23,180).
At baseline, before propensity score matching, African Americans in the PCC group were
significantly different from African Americans in the Non-PCC group (Table 3.1). Compared to
African Americans who did not receive PCC, African Americans who received PCC were more
likely to be older; less likely to have Medicaid; more likely to have cancer, a cardiovascular
disorder or heart failure, a respiratory disorder, an infectious disease or sepsis and less likely to
have an endocrine disorder, GI disorder, gynecologic or urologic disorder, neurologic disorder, or
“other” condition; more likely to have major or severe severity of illness; more likely to have major
or severe risk of mortality; more likely to have been hospitalized in the 30 days prior to index
admission; more likely to have had ICU care during the index admission; more likely to have had
ICU care for greater than six days during the index admission; more likely to have been seen by
Oncology providers during the index admission. These differences are reflected in PCC patients’
average utilization and costs during index admission. Compared to African Americans without
PCC at baseline, African Americans with PCC had longer length of stay, more days in the ICU,
and more than twice the average direct costs accrued during index admission, suggesting sicker
African American patients received PCC.
At baseline, before propensity score matching, White patients in the PCC group were
also significantly different from White patients in the Non-PCC group (Table 3.1). Compared to
Whites who didn’t receive PCC, Whites who received PCC were older; more likely to have
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cancer, an infectious disease or sepsis, or a respiratory disorder and less likely to have a
cardiovascular disorder or heart failure, endocrine disorder, GI disorder, gynecologic or urologic
disorder, neurologic disorder, or “other” condition; more likely to have major or severe severity of
illness; more likely to have major or severe risk of mortality; more likely to have been hospitalized
in the 30 days prior to index hospitalization; more likely to have received ICU care during index
admission; more likely to have received ICU care for more than six days during index admission;
more likely to have been seen by Oncology providers during index admission; and more likely to
have a DNR documented during the index admission. Like African Americans, these differences
are reflected in PCC patients’ average utilization and costs during index admission. Compared to
Whites without PCC at baseline, Whites with PCC had longer length of stay, more days in the
ICU, and twice the average direct costs accrued during index admission, also suggesting sicker
White patients received PCC.
After the African American PCC and Non-PCC groups were propensity score matched on
available variables (Table 3.2), the group of African Americans who received PCC and the group
of African Americans who did not became similar (Table 3.3), such that the only difference between
the groups was whether or not a patient had PCC. The groups of Whites who had PCC and Whites
who did not have PCC also became similar after propensity score matching (Table 3.3). By
matching variables within racial groups such that PCC is the only difference between groups within
races, we were able to identify differences in outcomes associated with PCC.
Cost Outcomes
Any future acute care cost. Compared to African American patients who received PCC,
African American patients who did not receive PCC were significantly more likely to incur “any
future acute care cost” across the two highest propensity tiers when blended (31.9% vs. 37.7%, P
= 0.047), but not when tiers were assessed separately (highest tier, 33.7% vs. 38%, P = 0.26;
second highest tier, 29.5% vs. 37.3%, P = 0.08) (Table 3.4). White patients who received PCC
were also significantly less likely than White patients who did not receive PCC to incur “any future
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acute care cost” across the two highest propensity tiers when blended (25.9% vs. 35.5%, P <
0.0001) and when top tiers were assessed separately (highest propensity tier, 26.9% vs. 33.9%, P
= 0.008; second highest propensity tier, 24.5% vs. 37.2%, P < 0.0001) (Table 3.5).
Total future acute care costs. Although average accumulated future acute care costs were
lower across propensity tiers among African Americans with PCC compared to those without PCC
(highest tier, $11,452 vs. $15,867, P = 0.055; second highest tier, $11,925 vs. $14,256, P = 0.53;
blended top two tiers, $11,651 vs. $15,050, P = 0.09), the differences were not statistically
significant (Table 3.4). Data support a trend toward an average difference in future acute care costs
of $4,415 between PCC and Non-PCC African American groups in the highest propensity tier, but
the difference was not statistically significant (P = 0.055). However, average future acute care costs
were significantly lower among Whites who had PCC across tiers (highest tier, $8,302 vs. $14,995,
P < 0.0001; second highest tier, $7,813 vs. $18,558, P < 0.001) and when the top two tiers were
blended ($8,095 vs. $16,799, P < 0.001) (Table 3.5). In effect, PCC among Whites is associated
with an average difference in future acute care costs of $6,693 (highest tier) to $10,745 (second
highest tier) per person ($8,704 difference in blended top tiers). A large effect-size difference is
represented among White patients with PCC.
Healthcare Utilization Outcomes
Increase in hospice utilization among African Americans and Whites. African American
patients with PCC were more likely to be discharged to hospice from index admission than African
Americans without PCC (highest tier, 30.3% vs. 2.6%, P <0.0001; second highest tier, 45% vs.
2.3%, P < 0.0001; blended top tiers, 36.5% vs. 2.4%, P < 0.0001) (Table 3.4). White patients with
PCC were also more likely than White patients without PCC to be discharged to hospice from index
admission (highest tier, 41.1% vs. 3.3%, P <0.0001; second highest tier, 44.8% vs. 2.8%, P <
0.0001; blended top tiers, 42.7% vs. 3.0%, P < 0.0001) (Table 3.5).
30-day readmissions. Significant differences among African Americans with and without
PCC were not evident in 30-day readmission rates (highest tier, 15.7% vs. 16.3%, P = 0.84; second
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highest tier, 17.8% vs. 14.6%, P = 0.31; blended top tiers, 16.6% vs. 15.4%, P = 0.58), but were
evident among Whites with PCC compared to Whites without PCC (highest tier, 11.4% vs. 15.8%,
P = 0.03; second highest tier, 8.6% vs. 17.6%, P = 0.0002; blended top two tiers, 10.2% vs. 16.7%,
P < 0.0001).
Future days in hospital post-discharge. Significant differences in the number of future
hospitalized days were not found among African Americans with and without PCC (highest tier, 5.8
vs. 6.7 days, P = 0.18; second highest tier, 5.5 vs. 6.0 days, P = 0.74; blended top two tiers, 5.5
vs. 6.4 days, P = 0.34), but were found among Whites with PCC compared to Whites without PCC
(highest tier, 3.6 vs. 5.7 days, P = 0.04; second highest tier, 3.9 vs. 7.0 days, P = 0.0006; blended
top two tiers, 3.7 vs. 6.3 days, P < 0.0001).
Future admission to ICU. African Americans with PCC were no less likely than African
Americans without PCC to be admitted to the ICU following index hospital discharge (highest tier,
17.4% vs. 15.8%, P = 0.58; second highest tier, 15.5% vs. 12.6%, P = 0.34; blended top two tiers,
16.6% vs. 14.2%, P = 0.25). Results were similar for Whites, among whom there were no significant
differences in future ICU admission by PCC or Non-PCC group (highest tier, 12% vs. 13.9%, P =
0.33; second highest tier, 13.2% vs. 14.9%, P = 0.46; blended top two tiers, 12.5% vs. 14.4%, P =
0.20).
Future days in ICU post-discharge. Significant differences in the number of future ICU days
were also not found among African Americans with PCC compared to those without (highest tier,
1.3 vs. 1.2 days, P = 0.81; second highest tier, 1.3 vs. 0.80 days, P = 0.28; blended top two tiers,
1.3 vs. 0.99 days, P = 0.3). Among Whites with and without PCC, significant differences in the
number of future ICU days were only evident in the highest propensity group (0.6 vs. 0.9 days, P =
0.042; second highest tier, 1.0 vs. 1.6, P = 0.85; blended top two tiers, 0.8 vs. 1.0 days, P = 0.15).
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Results of Secondary Aims
Presence of a DNR order during index admission. Table 3.6 describes differences in
DNR documentation among the propensity-matched cohorts of African Americans and Whites
with and without PCC. Although DNR documentation could not be assessed as an outcome
because the timing of DNR documentation during index admission may have occurred before,
during, or after PCC, associations with increased DNR documentation among PCC groups was
also significant. Across tiers, African Americans with PCC were almost 9 times more likely to
have a DNR than African Americans without PCC (blended top two tiers, 46% vs. 5%, P <
0.0001). Similarly, Whites with PCC were 8.5 times more likely to have a DNR than Whites
without PCC across tiers (blended top two tiers, 54% vs. 6%, P < 0.0001) (Table 3.6).
Description of Asian patients with and without PCC. Table 3.7 describes Asian patients
who had PCC (n = 48) and Asian patients who did not have PCC (n = 961) prior to discharge
from index admission. Propensity score matching was not used on these groups to make them
similar, so data is best understood as descriptive. However, some differences among groups was
still apparent. For example, Asians with PCC had significantly greater mean number of hospital
days, ICU days, and direct acute care costs incurred during index hospital admission than Asians
without PCC (P < 0.0001). Almost six out of ten Asian PCC patients (58%) changed their GOC,
likely contributing to the significantly higher hospice use at time of index discharge among Asian
PCC patients (33.3% vs. 0.8%, P < 0.0001) and DNR documentation (35.4% vs. 2.4%, P <
0.0001) compared to Asians without PCC.
Description of Hispanic patients with and without PCC. Propensity-score matching was
also not applied to Hispanic patients in our sample. Table 3.8 describes Hispanic patients who
had PCC (n = 22) and Hispanic patients who did not have PCC (n = 829) prior to discharge from
index admission. Hispanics with PCC also had greater mean number of hospital days and ICU
days (P < 0.0001), and direct acute care costs (P = 0.0005) incurred during index hospital
admission than Hispanics without PCC. Similar to Asians, about six out of ten Hispanic PCC
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patients (59.1%) changed their goals-of-care during PCC. Hispanic PCC patients were also more
likely to be discharged to hospice (31.8% vs. 0.4%, P <0.0001) and have a DNR documented
during index admission (31.8% vs. 0.97%, P < 0.0001) compared to Hispanics without PCC.
Description of Other racial/ethnic minority patients. Table 3.9 describes patients with
“Other” race/ethnicity (self-reported as “Other” race/ethnicity, American Indian or Alaska Native,
or Native Hawaiian or Pacific Islander) who had PCC (n = 39) and did not have PCC (n = 1,095).
These patients were also not matched using propensity scoring. Like all other patients in the
sample, other racial/ethnic minority PCC patients had index admissions with higher mean number
of days hospitalized (P <0.0001), higher mean number of days spent in the ICU (P < 0.0001), and
higher mean direct acute care costs (P = 0.0002), indicating the greater acuity among PCC
patients. Almost seven out of ten other racial/ethnic minority PCC patients changed their goals-ofcare during PCC. These PCC patients were also more likely to be discharged to hospice from
index admission compared to Non-PCC patients (28.2% vs. 1.6%, P < 0.0001) and have a DNR
(46.2% vs. 3.5%, P < 0.0001).
Descriptive comparison of PCC patients across racial/ethnic groups. Table 3.10 explores
differences among PCC patients across racial/ethnic groups. Again, these racial groups were not
matched on available variables. Patients with “unknown” race/ethnicity include those who did not
self-report their race/ethnicity. While there was no difference in mean index admission costs (P =
0.17), there was a statistically significant difference in median acute care costs accrued during
the index admission (P = 0.04), with African American and Hispanic PCC patients spending the
most, or most heavily using acute care services, consistent with other literature.28 Asian PCC
patients accumulated the lowest median costs during index admission (median $14,739; IQR
$24,510), but one of the highest mean costs ($46,739, SD $81,216), suggesting very high
utilization among some Asian patients. Future acute care costs appear to differ by race, with any
future cost (P = 0.004), mean future acute care costs (P = 0.047), and median future acute care
costs (P = 0.02) all showing statistically significant differences. Thirty-day readmission rates also
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significantly varied by race (mean 13.3% yes, P = 0.006), with African American and Hispanic
PCC patients demonstrating the highest readmission rates (18.3%, 18.2% respectively) and
White and Unknown race/ethnicity PCC groups demonstrating the lowest rates (11.6%, 4.8%
respectively). Significant differences were also observed in the number of future hospital days
(sample mean 4.5 days, P = 0.005; sample median 0.0 days, P = 0.01) across racial/ethnic
groups, with African Americans (mean 6.6 days) and “Other” race/ethnicity (mean 6.9 days) PCC
patients spending the most time hospitalized after discharge from index admission. Asian (mean
3.1 days), White (3.9 days), and Unknown race/ethnicity (2.0 days) PCC patients spent the
fewest days hospitalized following discharge (P = 0.005).
Although DNR documentation significantly varied by race/ethnicity (sample mean 49%, P
= 0.03), with White (51.2%) and Unknown race/ethnicity (56%) PCC patients documenting
resuscitation wishes most prevalently, and Hispanic (32%) and Asian (35%) PCC patients
documenting such preferences least commonly, the most interesting finding is that the proportion
of PCC patient who were discharged to hospice did not significantly differ across racial/ethnic
groups (P = 0.16). Racial/ethnic disparities in discharge to hospice did not differ by racial group
among patients who received PCC. The majority of PCC patients (65%) changed their GOC
during PCC, which might explain high hospice use across racial groups. Whether a patient
changed GOC during PCC also did not significantly differ by PCC racial group (P = 0.14).

Discussion
This propensity-matched study found PCC is associated with statistically significant
differences in 30-day readmissions, number of future days spent hospitalized, and accumulated
mean future acute care costs (resulting in an average reduction of $8,704 per patient) in White
patients, but no statistically significant differences in accumulated costs or acute care utilization in
African Americans with PCC. It is unclear why these outcomes declined for White patients with
PCC, but not African Americans with PCC. The higher proportion of White patients discharged to
hospice from index admission (43% vs. 37%) may help explain some of these differences, as
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hospice-eligible African American PCC patients not enrolled in hospice may have had greater or
more frequent acute care utilization near EOL.51,52 One recent study found that the effect of
inpatient PCC on 30-day readmissions in oncology was largely driven by hospice enrollment,
suggesting hospice may help explain some of our findings.53 However, more research is needed
to better understand why, when all available variables were held constant, PCC was associated
with different cost and utilization outcomes among African American and White patients.
Differences in outcomes between African American and White PCC groups may be
explained by variables not measured in our study. Socioeconomic variables such as income and
education, which have been found to help explain differences in ACP in African Americans,54 were
not available in the dataset and may have contributed. Compared to Whites, African Americans
endure significant systematic disadvantages resulting in disproportionate and poor economic
resources to higher unemployment and lower incomes, which impact health, health literacy, and
access to quality care.54,55 Patients with lower levels of education have been found to have lower
levels of health literacy,54,56 which can influence how a patient understands, recalls, and applies
information exchanged during PCC or other healthcare encounters.56,57 Patients with lower health
literacy have an increased risk of hospital admission,58,59 use an inefficient mix of healthcare
services,60 and have higher healthcare costs,60 all associations that may help explain why PCC
among African Americans was not associated with acute care utilization and cost reductions.
Specifically, socioeconomic disadvantages may have contributed to avoidable use of the
emergency department (ED). According to the literature, low socioeconomic status is
independently associated with increased use of the ED, regardless of the visit or medical condition
urgency.61 Patients described as “working poor”62 who do not qualify for Medicaid, patients without
access to timely care in the community,63 and patients with low health literacy who do not know
how to navigate health resources64 may visit the ED for possibly preventable care and subsequently
be hospitalized.64 Our study included the cost of ED visits that resulted in hospitalization, but
excluded ED visits that did not involve inpatient care. It is therefore possible that patients who
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visited the ED following discharge from an admission with PCC and were hospitalized for care that
may have otherwise been treated in an outpatient setting also contributed to differences in future
acute care cost totals among race-based PCC groups. Similarly, PCC patients without caregiver
assistance may have increased ED use and hospitalization following discharge from index
admission resulting in greater future costs,65,66 although evidence is mixed on the role of informal
caregivers and acute care costs.66
Religiosity, defined as strong religious beliefs, was not measured in the study but may have
also contributed to outcome differences. Evidence suggests religiosity is associated with
preferences for more treatment and life prolongation near EOL,67 while religious coping is
associated with receipt of intensive life-prolonging medical care near death.68 African Americans’
higher religiosity,69 greater religious participation,70 and greater reliance on support from church
communities70-72 are well-documented and may help explain why some utilization and cost
outcomes did not differ among African American PCC and Non-PCC groups. African Americans’
faith influences how they perceive hospice and EOL treatments73 and greater deference to
perceptions of God’s will in healthcare decision-making is associated with stronger preferences for
life-prolonging treatment,74 possibly influencing our results. Although palliative care attends to the
spiritual needs of patients, it is unknown if PCC reduces future acute care utilization in religious
patients who do not enroll in hospice. And while African Americans’ trust in their physicians may
not be a significant factor in ACP involvement or preference for EOL treatments,54 their greater
dependence on church and community information when making healthcare decisions (compared
to Whites who report primarily relying on healthcare providers)71 may help explain why many PCC
outcomes differed for Whites but not African Americans.
Race was not a factor in which patients received PCC in this medical center,6 but study
results for African Americans may be partially explained by possible disparities in concordance
between care preferences expressed during PCC and actual care received during subsequent
hospitalizations. One urban, academic study found that despite similar rates of EOL discussions
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among African American and White cancer patients, African American patients tended to receive
life-prolonging measures at EOL even when they had DNR orders or stated a preference for
symptom-oriented care.22 The study found EOL discussions helped White patients receive less lifeprolonging EOL care, but that African American patients did not experience the same benefits.22
More research is needed to better understand why these differences exist and how clinicians can
help prevent them to reduce racial disparities in the care of persons with serious illness.
Intensive care unit utilization did not statistically differ between PCC/Non-PCC groups for
either racial group when tiers were blended, suggesting some ICU care may be unavoidable.75
Given nationwide increases in ICU use in the last 30 days of life among patients with serious
illnesses76 and one study’s finding that 7% of ICU days are perceived as “futile,”77 and therefore
modifiable by PCC, it is possible that (despite matching for characteristics at the time of index
admission) differences in the necessity and futility of future ICU use may have differed among PCCrace groups, also possibly contributing to cost findings among African Americans.78
Although acute care utilization and costs did not decline for African Americans with PCC,
PCC was associated with a 15-fold increase in discharge to hospice among African American
patients and a 14-fold increase among White patients. This is a remarkable finding given known
racial/ethnic disparities in hospice use.51,54,79,80 These figures do not include hospice use among
patients who may have learned of hospice during PCC, then enrolled in hospice weeks or months
after discharge from index admission. In theory, future hospice use may be even greater among
PCC patients. These increases in hospice use suggest patients who received PCC and were
discharged to hospice may have benefited from improved quality of life and symptom
management, reduced suffering, and for those who later died, possibly better quality of death.81
PCC’s demonstrated ability to reduce racial disparities in hospice utilization make it an
intervention worth expanding in populations with known differences in EOL care quality.
Although the majority of African American PCC patients (60.1%) and White PCC patients
(67.7%) changed their goals-of-care during index admission during or following PCC, there was a
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significant difference among the PCC groups (P = 0.01), suggesting unmeasured factors may
influence PCC outcomes (Table 3.1). Even so, these high proportions suggest patient-provider
PCC communication may have enabled patients make care decisions and may explain increases
in hospice use across races and in DNR documentation (Table 3.6). Given that PCC has been
shown to increase DNR documentation across racial groups, it is likely PCC in this study
contributed to the increase in DNR orders.82 Although DNR orders do not always ensure patients
receive care concordant with their expressed preferences, DNRs are associated with higher quality
of life near death83 and reduced use of medical interventions near death,84 which may suggest
lower costs, possibly influencing our study results.
Finally, the comparison of outcomes across racial/ethnic groups of PCC patients highlights
some important findings worth future investigation. Given racial disparities in hospice use,35,36 it is
remarkable that significant differences in discharge to hospice were not found across PCC
racial/ethnic groups. Significant differences were also not found across PCC race/ethnicity groups
for changes in GOC, suggesting PCC is effective in enabling patients to communicate care
preferences and supporting decisions to enroll in hospice across race/ethnicity groups. Palliative
care consultations may therefore be an intervention that helps reduce racial/ethnic disparities in
the care of persons with serious illness. Significant differences in future acute care costs and
utilization, notably the number of days hospitalized, did exist across PCC race/ethnicity groups,
implying the need for more research to better understand if and how PCC differs across
racial/ethnic groups, and whether other unmeasured factors influence findings.

Limitations
This study has several limitations. First, as is the case with all propensity-score studies,
our models cannot account for unmeasured or unknown confounding variables.6,85 We were
unable to control for comorbidities, income, insurance status, education level, health literacy,
religious beliefs, or duration of survival because these variables were not available in the dataset;
dates of patient deaths outside the health system were unavailable. Unmeasured variables may
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be distributed differently in patients who received PCC and those who did not (e.g., patients in
one group may have died sooner than patients in another after discharge).6
In addition, diagnostic analysis of propensity score matching was not available, limiting
understanding of how closely propensity tier groups matched on each of the ten specific
variables. As with all propensity score matching studies with smaller samples, such as the PCC
group in this study, it is difficult to perfectly match patients across a large number of variables.
When comparing the two groups of patients (those who had PCC and those who did not)
using propensity scores, the groups should have similar propensities for having had a consult. As
is standard, these propensities are determined through logistic regression models. In this study,
there were separate models for Caucasian patients and for African-American patients, but the
methodological approach and variables used were similar. Each propensity model featured as its
dependent variable whether or not an individual had a palliative care consult (yes or no) and ten
predictor variables (gender, age, disease severity, primary diagnosis, Medicaid status, direct cost
of index admission, visitation by Oncology team, ICU admission, ICU admission for more than 6
days, and 30-day prior admission). Although patients in propensity-score matched PCC and NonPCC groups may look different when it comes to some of the matching variables, what is
important is that the groups have similar propensities for having PCC. We used a tiered
approach, where we cut the data into six evenly-sized groups (based on propensity scores) but
eliminated the lowest four propensity groups because those groups did not have enough patients
with high propensity for PCC. The two highest propensity score tiers, which were used to assess
outcomes, matched very well—both tiers have essentially identical minimums and maximums and
similar mean propensities, indicating the groups can be compared. The similarity of these specific
values increases confidence in the analysis.
Second, our analysis only examined acute care direct costs and healthcare utilization
incurred within the health system after index hospitalization discharge.6 Our analysis did not
include costs incurred between hospitalizations or outside the health system (e.g., outpatient
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care, skilled nursing care, homecare) or ED visits that did not result in hospitalization. The health
system is the largest acute care provider in the Northeast, so few patients were likely admitted to
hospitals outside the system, but even so we were unable to track costs of patients who were
readmitted to local hospitals outside the hospital system.6 Demographic and socioeconomic
variables such as health literacy, religiosity, and marital status and clinical variables such as
number of comorbidities, number of ED visits, and specific types of intensive interventions were
unavailable in the dataset and therefore could not be analyzed. In addition, the variable 30-day
readmissions only applies to patients still alive 30 days after discharge from index admission,
which is not the entire sample population, as deaths among persons with serious illness occurred
during the study period. Despite these limitations, study results may be used to show possible
cost and utilization outcomes associated with PCC beyond the initial hospitalization among
African Americans and among Whites in a sample matched, within racial group, on known
covariates.5,6,8
Finally, our study examined a single academic medical center with high acuity and a wellestablished palliative care team and may not represent all hospitals caring for patients with
serious illnesses. In the parent study at this medical center, race was not found to be a factor in
whether or not patients received PCC.6 However, the researchers did not investigate whether
future acute care cost and utilization outcomes differed by race/ethnicity when PCC access is
similar. Our study used robust measurement strategies to fill this gap. Depending on resources,
training, culture, and patient population, PCC may also affect patients differently in other
systems.6 More research is needed to understand the influence of PCC on costs and healthcare
utilization for specific racial/ethnic subgroups (e.g., Hispanics, Asians), which this analysis will be
unable to address given smaller sample sizes for certain racial/ethnic populations. By studying
the variable of race/ethnicity, our study provides more insight into future cost and healthcare
utilization outcomes for African American patients who have or do not have PCC, and for White
patients who have or do not have PCC while hospitalized. By comparing these outcomes among
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propensity-matched White and African American patients with similar access to PCC, we were
able to better understand associations between PCC and race/ethnicity on outcomes.

Ethical Considerations
Assessing acute care utilization and costs among different races raises ethical
considerations. First, analyzing costs in the context of patient care may be perceived as a step
toward rationing necessary healthcare among vulnerable persons. Although health systems
benefit from reducing costs, saving money should never be the primary reason for engaging
patients in PCC or making any clinical decisions.86 Clinical decisions should be made with patient
goals in mind and intentions to provide patients high quality of care, quality of life, and quality of
death—outcomes associated with EOL discussions11,81 and PCC.87,88 Costs represent the kinds
of care patients receive, with high EOL costs associated with worse quality of death.12 Lower
acute care costs represent less acute care utilization, which implies better quality of life for
patients.12 Palliative care consultation offers patients, clinicians, and payers the opportunity to
uniquely increase patient autonomy, improve quality of care and quality of death, and reduce
resource use.89 Better communication about patient goals, values, prognosis, and treatment
options benefits patients and tends to result in lower future acute care costs and admissions,
benefiting patients and health systems alike. These mutual benefits clinically, financially, and
ethically justify investment in PCC programs that aim to improve care for patients with serious
illness.
Second, the goal of any racial disparities research in healthcare is to reduce disparities
and improve care and quality for disadvantaged racial minorities. The results of our study suggest
there are unmeasured factors influencing future acute care utilization and costs among African
Americans who received PCC. More research is needed to better understand which modifiable
variables influence the effectiveness of PCC among African Americans and the concordance of
care preferences and future actual care provided in both community and acute care settings.
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The results of our study have implications for patients, clinicians, healthcare systems,
payers, and policy makers in the United States and beyond. As healthcare systems seek to
provide evidence-based, patient-centered, cost-effective quality care to racially diverse patient
populations with serious illness, including those near EOL, PCC appears to be an intervention
that reduces costs and saves resources overall while improving quality outcomes such as
hospice use across races and additional outcomes among White patients.

Conclusion
This is the first known study to quantify PCC cost savings across hospitalizations by race.
These cost-savings and reductions in acute care use among Whites and, directionally yet not
significantly, among African Americans justify the development of PCC programs that help
patients better understand their illness, prognosis, and care options; and support patients’
decisions to experience quality hospice care near EOL. Research is needed to explain why acute
care utilization and cost disparities persist among African Americans despite PCC, and how
clinicians can help overcome these disparities to provide high quality care for racial/ethnic
minorities with serious illness.
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Gender

Age (years)

Female

Male

>75

71-75

66-70

61-65

56-60

51-55

46-50

40-45

18-39

Table 3.1 Description of Study Population
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Total
N=
35,154
5,739
(16%)
2,419
(7%)
2,642
(8%)
3,614
(10%)
4,338
(12%)
4,320
(12%)
4,223
(12%)
3,199
(9%)
4,660
(13%)
17,286
(49%)
17,868
(51%)

African
Americans
Non-PCC
N = 10,777
2385
(22.1%)
980
(9.1%)
953
(8.8%)
1215
(11.3%)
1330
(12.3%)
1165
(10.8%)
955
(8.9%)
668
(6.2%)
1126
(10.5%)
4543
(42.2%)
6234
(57.8%)

Tables

African
Americans
with PCC
N = 383
19
(5.0%)
4
(1.0%)
21
(5.5%)
45
(11.8%)
55
(14.4%)
53
(13.8%)
51
(13.3%)
41
(10.7%)
94
(24.5%)
172
(44.9%)
211
(55.1%)
.2836

<.0001

P
value

Whites
with PCC
N = 814
55
(6.8%)
30
(3.7%)
29
(3.6%)
60
(7.4%)
99
(12.2%)
115
(14.1%)
124
(15.2%)
104
(12.8%)
198
(24.3%)
423
(52.0%)
391
(48.0%)

Whites
Non-PCC
N =23,180
3280
(14.2%)
1405
(6.1%)
1639
(7.1%)
2294
(9.9%)
2854
(12.3%)
2987
(12.9%)
3093
(13.3%)
2386
(10.3%)
3242
(14.0%)
12148
(52.4%)
11032
(47.6%)

0.80

<.0001

P
value

APR-DRG
Severity of Illness

Primary
Diagnosis

Medicaid
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Major

Moderate

Minor

Other

Respiratory disorder

Gynecologic
or urologic disorder
Infectious disease
and Sepsis
Neurologic disorder

GI disorder

Cardiovascular disorder /
Heart Failure
Endocrine disorder

Cancer

No

Yes

1,394
(4.0%)
5,462
(15.5%)
8,044
(22.9%)
13,876
(39.5%)
9,912
(28.2%)

Total
N=
35,154
4,819
(14%)
30,335
(86%)
6,955
(19.8%)
6,430
(18.3%)
1,942
(5.5%)
4,120
(11.7%)
2,393
(6.8%)
2,950
(8.4%)
3,508
(10%)
493
(4.6%)
1881
(17.5%)
2343
(21.7%)
4446
(41.3%)
3140
(29.1%)

African
Americans
Non-PCC
N = 10,777
3454
(32.0%)
7323
(68.0%)
1063
(9.9%)
1774
(16.5%)
902
(8.4%)
1147
(10.6%)
1086
(10.1%)
1227
(11.4%)
1204
(11.2%)
23
(6.0%)
33
(8.6%)
6
(1.6%)
36
(9.4%)
167
(43.6%)

African
Americans
with PCC
N = 383
83
(21.7%)
300
(78.3%)
103
(26.9%)
76
(19.8%)
8
(2.1%)
29
(7.6%)
17
(4.4%)
63
(16.5%)
31
(8.1%)

<.0001

<.0001

<.0001

P
value

59
(7.3%)
48
(5.9%)
15
(1.8%)
78
(9.6%)
335
(41.2%)

N = 814
39
(4.8%)
775
(95.2%)
317
(38.9%)
136
(16.7%)
18
(2.2%)
72
(8.9%)
23
(2.8%)
95
(11.7%)
46
(5.7%)

N =23,180
1243
(5.4%)
21937
(94.6%)
5472
(23.6%)
4444
(19.2%)
1014
(4.4%)
2872
(12.4%)
1267
(5.5%)
1565
(6.8%)
2227
(9.6%)
819
(3.5%)
3500
(15.1%)
5680
(24.5%)
9316
(40.2%)
6270
(27.1%)

Whites
with PCC

Whites
Non-PCC

<.0001

<.0001

0.48

P
value

Visited by
Oncology service
during index
admission (1st or
2nd service)

ICU care > 6
days during index
admission

Acute care
hospitalization 30
days prior to
index
hospitalization
ICU care during
index admission

APR-DRG
Risk of Mortality
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11,448
(32.6%)
23,706
(67.4%)
2,637
(7.5%)
32,517
(92.5%)
2,984
(8.5%)
32,170
(91.5%)

Yes

No

Yes

No

Yes

No

34,501
(98.1%)

No

Yes

Severe

Major

Moderate

Minor

Severe

Total
N=
35,154
3,322
(9.4%)
15,914
(45.3%)
10,112
(28.8%)
6,637
(18.9%)
2,491
(7.1%)
653
(1.9%)

10321
(95.8%)

2792
(25.9%)
7985
(74.1%)
624
(5.8%)
10153
(94.2%)
456
(4.2%)

10650
(98.8%)

African
Americans
Non-PCC
N = 10,777
848
(7.9%)
5142
(47.7%)
3072
(28.5%)
1940
(18.0%)
623
(5.8%)
127
(1.2%)

306
(79.9%)

197
(51.4%)
186
(48.6%)
104
(27.2%)
279
(72.8%)
77
(20.1%)

303
(79.1%)

African
Americans
with PCC
N = 383
174
(45.4%)
11
(2.9%)
50
(13.1%)
179
(46.7%)
143
(37.3%)
80
(20.9%)

<.0001

<.0001

<.0001

<.0001

<.0001

P
value

20992
(90.6%)

8025
(34.6%)
15155
(65.4%)
1683
(7.3%)
21497
(92.7%)
2188
(9.4%)

551
(67.7%)

434
(53.3%)
380
(46.7%)
226
(27.8%)
588
(72.2%)
263
(32.3%)

608
(74.7%)

N = 814
386
(47.4%)
20
(2.5%)
136
(16.7%)
341
(41.9%)
317
(38.9%)
206
(25.3%)

N =23,180
1914
(8.3%)
10741
(46.3%)
6854
(29.6%)
4177
(18.0%)
1408
(6.1%)
240
(1.0%)
22940
(999.0%)

Whites
with PCC

Whites
Non-PCC

<.0001

<.0001

<.0001

<.0001

<.0001

P
value

African
Americans
with PCC
N = 383
172
(44.9%)
211
(55.1%)
17.05
(19.5)
10.0
(6.0-20.0)
6.03
(12.70)
1.0
(0-6.0)
$35982
($49024)
$18,578
($10,811$38,119)
60.1%

African
Americans
Non-PCC
N = 10,777
242
(2.2%)
10535
(97.8%)
5.96
(7.63)
4.0
(2.0-7.0)
1.18
(4.26)
0
(0-0)
$15665
($22667)
$9,723
($5,898$15,641)
n/a
-

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

P
value

6.36
(13.78)
1.0
(0-7.0)
$40126
($59607)
$20,017
($10,455$41,445)
67.7%

N = 814
417
(51.2%)
397
(48.8%)
16.53
(19.06)
10.0
(6.0-20.0)

N =23,180
594
(2.6%)
22586
(97.4%)
6.29
(7.67)
4.0
(2.0-7.0)
1.45
(4.00)
0
(0-1.0)
$19583
($25209)
$12,114
($7,639$21,373)
n/a

Whites
with PCC

Whites
Non-PCC

0.01

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

<.0001

P
value

Significance tests for the percentage variables involved a Chi-squared test; significance tests for parametric continuous variables involved a t test;
significance tests for non-parametric continuous variables involved a Kruskal-Wallis non-parametric test of ranks.

Changed goals-of-care during PCC index admission
(% yes)

Median direct acute care costs during index admission
(IQR)

Mean direct acute care costs during index admission (SD)

Median number of ICU days during index admission (IQR)

Total
N=
35,154
DNR documented Yes
1,425
during index
(4.1%)
admission
No
33,729
(95.9%)
Mean number of days hospitalized during index admission
(SD)
Median number of days hospitalized during index
admission (IQR)
Mean number of ICU days during index admission (SD)
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APR-DRG
Risk of Mortality

Primary Diagnosis

Medicaid*

Gender

Parameter
Intercept
Age (years)
56-65
66-75
>75
Male
Female
Yes
No
Cancer
Cardiovascular disorder
and Heart Failure
Endocrine disorder
GI disorder
Gynecologic
or urologic disorder
Infectious disease and
Sepsis
Neurologic disorder
Respiratory disorder
Other
Minor
Moderate
Major
Severe

18-39
40-55
0.113
0.126
0.0593
0.082
0.137
0.334
0.203
0.247
0.151
0.193
0.282
0.186
0.239
0.141
0.111
-

0.222
0.077
0
-0.0548
0
0.114
0
0
-0.100
-0.449
-0.011
-0.193
-0.070
-0.370
0.282
-0.130
-2.129
-0.602
0.988
0

0.056
0.199
0.484
<.0001
<.0001
<.0001
-

0.641

0.18
0.956
0.436

0.467

0.164

0.0497
0.544
0.356

African American patients
Estimate
SE
P value
-2.0415
0.1688
<.0001
-0.858
0.212
<.0001
-0.189
0.128
0.139

Table 3.2 Logistic Regression Analysis of Likelihood of Receiving Palliative Care Consult
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-0.254
0.615
-0.288
-2.371
-0.423
1.013
0

0.016

0.082
0.066
-0.260

0.154
0.148
0.153
0.176
0.094
0.080
-

0.120

0.235
0.130
0.215

White patients
SE
0.1351
0.133
0.094
-0.148
0.094
0.119
0.077
-0.013
0.078
0
-0.1562
0.0407
0
0.141
0.095
0
0
-0.492
0.102
Estimate
-1.8617
-0.315

0.099
<.0001
0.059
<.0001
<.0001
<.0001
-

0.891

0.727
0.612
0.2259

<.0001

0.139

0.123
0.872
0.0001

P value
<.0001
0.018
0.113
0.1133

2.92*10-3

1.52*10-3
.0535

African American patients
0.138
0.066
0.036
0
0.232
0.090
0.01
0
0.284
0.088
0.001
0
1.435
0.097
<.0001
0
1.72*10-3

0.149
0
0.265
0
0.266
0
1.589
0
9.55*10-4

White patients
0.043
0.056
0.051
0.064
-

Abbreviation: SE, standard error
* For every increase of $1000 in direct costs, the estimate shows the expected increase in getting a palliative care consult.

ICU during index
Yes
admission
No
ICU > 6 days during Yes
index admission
No
Seen by Oncology
Yes
in index admission
No
Admitted to
Yes
hospital 30 days
No
prior
Direct Cost of index admission
(impact per $1,000) *
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0.072

<.0001

<.0001

<.0001

0.0005

1

Palliative care consult to discuss goals-of-care

Propensity Scores Ranked Highest to Lowest, African American patients
Patients with Palliative Care Consult,1 n = 383
Patients without Palliative Care Consult,1 n = 10,777
Tier
Propensity Score Mean
n
Min, Max
Propensity Score Mean
n
Min, Max
Highest
0.303
178
0.202
0.481
0.276
1,667
0.202 0.498
2nd Highest
0.134
129
0.078
0.201
0.114
1,717
0.073 0.202
0.061
18
0.042
0.073
0.058
1,827
0.04 0.073
Middle
0.024
10
0.015
0.033
0.021
1,836
0.014 0.040
0.010
1
0.01
0.01
0.012
1,844
0.009 0.014
Lowest
0
0.006
1,845
0.004 0.009
Propensity Scores Ranked Highest to Lowest, White patients
Patients with Palliative Care Consult,1 n = 814
Patients without Palliative Care Consult,1 n = 23,180
Tier
Propensity Score Mean
n
Min, Max
Propensity Score Mean
n
Min, Max
Highest
0.331
350
0.212 0.498
0.298
3,604
0.212 0.498
2nd Highest
0.153
257
0.097 0.212
0.141
3,698
0.096 0.212
0.061
55
0.062 0.096
0.080
3,900
0.061 0.096
Middle
0.039
19
0.015 0.061
0.028
3,935
0.014 0.061
0.013
1
0.0126 0.0126
0.012
3,954
0.011 0.014
Lowest
0.010
2
0.0099 0.0105
0.009
3,952
0.006 0.011

Table 3.3 Propensity Scores Ranked from Highest to Lowest Tiers, by Race
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38.0%
37.3%
37.7%
$15,867 ($45,316)
$14,256 ($36,670)
$15,050 ($41,158)
16.3%
14.6%
15.4%
6.72 (17.2)
6.00 (13.99)
6.35 (15.66)
15.8%
12.6%
14.2%
1.18 (7.03)
0.80 (3.25)
0.99 (5.45)
2.6%
2.3%
2.4%

15.7%
17.8%
16.6%
5.47 (10.86)
5.45 (18.84)
5.46 (14.72)
17.4%
15.5%
16.6%
1.27 (4.17)
1.29 (5.14)
1.28 (4.60)
30.3%
45.0%
36.5%

Non-PCC
n = 1,667
n = 1,717
n = 3,384

33.7%
29.5%
31.9%
$11,452 ($26,684)
$11,925 ($40,709)
$11,651 ($33,244)

PCC
n = 178
n = 129
n = 307

0.84
0.31
0.58
0.18
0.74
0.34
0.58
0.34
0.25
0.81
0.28
0.30
<.0001
<.0001
<.0001

0.26
0.08
0.047
0.055
0.53
0.09

P
value b

Sample sizes are consistent within each column (across all outcome variables).b Significance tests for the percentage variables involved a
Cochran-Mantel-Haenszel test; significance tests for the continuous variables involved a pooled t test. SD is standard deviation

a

Did patient have any future acute care costs?
(% yes)

Highest propensity group
Second highest propensity group
Top Two Tiers Blended
Highest propensity group
Mean accumulated future acute care costs (SD)
Second highest propensity group
Top Two Tiers Blended
Secondary Outcomes: Future healthcare utilization
Highest propensity group
Was the patient admitted within 30 days? (% yes)
Second highest propensity group
Top Two Tiers Blended
Highest propensity group
Mean number of days in hospital post-discharge
Second highest propensity group
(SD)
Top Two Tiers Blended
Highest propensity group
Was the patient admitted to ICU post-discharge
Second highest propensity group
(% yes)
Top Two Tiers Blended
Highest propensity group
Mean number of ICU days post-discharge (SD)
Second highest propensity group
Top Two Tiers Blended
Highest propensity group
Discharge to hospice from index admission
Second highest propensity group
(% yes)
Top Two Tiers Blended

Primary Outcomes: Future costs

African American patients

Propensity Group
Highest Tier (n)a
Second Highest Tier (n)a
Top Two Tiers Blended (n)a

Table 3.4 Future Costs, Healthcare Utilization, and Discharge to Hospice After Propensity Score Matching, African American patients.
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PCC
n = 350
n = 257
n = 607

Non-PCC
n = 3,604
n = 3,698
n = 7,302

P
valueb

Did patient have any future acute care costs? (%
yes)

Highest propensity group
24.5%
33.9%
0.008
Second highest propensity group
24.5%
37.2%
<0.0001
Top Two Tiers Blended
25.9%
35.5%
<0.0001
Highest propensity group
$8,302 ($11,237)
$14,995 ($16,347) <0.0001
Mean accumulated future acute care costs (SD)
Second highest propensity group
$7,813 ($25,617)
$18,558 ($47,998) <0.0001
Top Two Tiers Blended
$8,095 ($26,947)
$16,799 ($44,898) <0.0001
Secondary Outcomes: Future acute care utilization
Highest propensity group
11.4%
15.8%
0.032
Was the patient admitted within 30 days?
Second highest propensity group
8.6%
17.6%
0.0002
(% yes)
Top Two Tiers Blended
10.2%
16.7%
<0.0001
Highest propensity group
3.56 (10.88)
5.66 (14.16)
0.0009
Mean number of days in hospital post-discharge
Second highest propensity group
3.86 (13.61)
6.97 (16.90)
0.0006
(SD)
Top Two Tiers Blended
3.69 (12.11)
6.32 (15.62)
<0.0001
Highest propensity group
12.0%
13.9%
0.331
Was the patient admitted to ICU post-discharge
Second highest propensity group
13.2%
14.9%
0.459
(% yes)
Top Two Tiers Blended
12.5%
14.4%
0.202
Highest propensity group
0.61 (2.33)
0.90 (4.25)
0.042
Mean number of ICU days post-discharge (SD)
Second highest propensity group
1.00 (4.18)
1.06 (4.79)
0.849
Top Two Tiers Blended
0.78 (3.25)
0.98 (4.53)
0.154
Highest propensity group
41.1%
3.3%
<0.0001
Discharge to hospice from index admission
Second highest propensity group
44.8%
2.8%
<0.0001
(% yes)
Top Two Tiers Blended
42.7%
3.0%
<0.0001
a
Sample sizes are consistent within each column (across all outcome variables). b Significance tests for the percentage variables involved a
Cochran-Mantel-Haenszel test; significance tests for the continuous variables involved a pooled t test.

Primary Outcomes: Future costs

White patients

Propensity Group
Highest Tier (n)a
Second Highest Tier (n)a
Top Two Tiers Blended (n)a

Table 3.5 Future Costs, Acute Care Utilization, and Discharge to Hospice After Propensity Score Matching, White patients.
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b

a

African
American
with PCC
n = 178
n = 129
n = 307
42.7%
49.6%
45.6%

African
American
Non-PCC
n = 1,667
n = 1,717
n = 3,384
5.6%
4.7%
5.2%

Sample sizes are consistent within each column (across all outcome variables).
Significance tests for the percentage variables involved a Cochran-Mantel-Haenszel test.

DNR documented during
index admission (% yes)

Highest Tier (n)a
Second Highest Tier (n)a
Top Two Tiers Blended (n)a
Highest propensity group
Second highest propensity group
Top Two Tiers Blended

Propensity Group

<.0001
<.0001
<.0001

P
valueb
n = 350
n = 257
n = 607
50.3%
58.4%
53.7%

White
with PCC

Table 3.6 DNR Documentation among African Americans and Whites with or without Palliative Care Consultation
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n = 3,604
n = 3,698
n = 7,302
7.5%
5.1%
6.3%

White
Non-PCC

<.0001
<.0001
<.0001

P
valueb

Asians
with PCC
N = 48
18.0 (24.9)
7.0 (13.0)
10.2 (20.6)
1.5 (8.5)
$46,766
($81,216)
$14,739
($24,510)
27.1%
$6,893 ($16,778)
$0 ($0-$1,560)
14.6%
14.6%
3.08 (8.0)
0.0 (0-2)
0.77 (2.1)
0.0 (0.0)
33.3%
35.4%
58.3%

Asians
without PCC
N = 913
6.3 (8.4)
4.0 (5.0)
1.2 (3.8)
0.0 (1.0)
$18,875
($26,570)
$10,805
($12,190)
25.3%
$9,874 ($33,927)
$0 ($0-$2,755)
8.7%
11.1%
3.8 (12.5)
0.0 (0-1)
0.70 (4.3)
0.0 (0.0)
0.8%
1.5%
-

6.88 (10.2)
4.0 (5.0)
1.6 (6.2)
0.0 (1.0)
$20,268
($32,102)
$10,969
($12,628)
25.4%
$9,725 ($33,282)
$0 ($0-$2,049)
9.0%
11.2%
3.8 (12.3)
0.0 (0-1)
0.67 (4.2)
0.0 (0.0)
2.4%
3.2%
-

Asians Total
N = 961

0.78
0.55
0.86
0.16
0.45
0.70
0.84
0.87
0.16
<0.0001
<0.0001
-

.002

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

P
value

Percentage variables analyzed using a Chi-squared test. Continuous parametric variables were analyzed using a Two-sample t test with equal
variances. Continuous non-parametric variables were analyzed using a Mann–Whitney U-test.

Future: Any future acute care costs post-discharge (% yes)
Future: Mean total direct acute care costs post-discharge (SD)
Future: Median total direct acute care costs post-discharge (IQR)
Future: Any ICU days post-discharge (% yes)
Future: Readmitted within 30 days (% yes)
Future: Mean number hospital days following index admission (SD)
Future: Median number hospital days following index admission (IQR)
Future: Mean number ICU days following index admission (SD)
Future: Median number ICU days following index admission (IQR)
Discharged to hospice from index admission (% yes)
DNR documented during index admission (% yes)
Changed goals-of-care during palliative care consult (% yes)

Index admission: Median direct acute care costs (IQR)

Index admission: Mean number of days hospitalized (SD)
Index admission: Median number of days hospitalized (IQR)
Index admission: Mean number of ICU days (SD)
Index admission: Median number of ICU days (IQR)
Index admission: Mean direct acute care costs (SD)

Outcomes
(Sample not propensity-score matched)

Table 3.7 Description of Asians (alive at the time of discharge from index admission) with and without PCC
* Groups were not propensity-score matched.
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Hispanics
with PCC
N = 22
17.8 (17.6)
9.0 (17.0)
5.22 (10.1)
0.0 (0-7.0)
$38,739
($45,258)
$18,907
($33,937)
36.4%
$7,800
($14,007)
$0 (14,257)
13.6%
18.2%
4.05 (6.3)
0.0 (0-9.0)
1.05 (3.2)
0.0 (0.0)
31.8%
31.8%
59.1%

Hispanics
without PCC
N = 829
5.85 (7.1)
4.0 (4.0)
1.2 (3.3)
0.0 (0-1.0)
$18,332
($26,403)
$10,635
($12,207)
25.6%
$11,435
($42,366)
$0 ($3,762)
9.7%
11.6%
4.18 (13.5)
0.0 (0-1.0)
0.80 (5.1)
0.0 (0.0)
0.4%
0.97%
-

Hispanics
Total
N = 851
6.16 (7.8)
4.0 (5.0)
1.2 (3.7)
0.0 (0-1.0)
$18,859
($27,207)
$10,801
($12,702)
25.9%
$11,341
($41,876)
$0 ($3779)
9.8%
11.8%
4.18 (13.4)
0.0 (0-1.0)
0.81 (5.1)
0.0 (0.0)
1.2%
1.8%

0.32
0.53
0.34
0.96
0.13
0.82
0.48
<0.0001
<0.0001
-

0.69

0.25

0.002

0.0005

<0.0001
<0.0001
<0.0001
0.03

P
value

Percentage variables analyzed using a Chi-squared test. Continuous parametric variables were analyzed using a Two-sample t test with equal
variances. Continuous non-parametric variables were analyzed using a Mann–Whitney U-test.

Future: Median total direct acute care costs post-discharge (IQR)
Future: Any ICU days post-discharge (% yes)
Future: Readmitted within 30 days (% yes)
Future: Mean number hospital days following index admission (SD)
Future: Median number hospital days following index admission (IQR)
Future: Mean number ICU days following index admission (SD)
Future: Median number ICU days following index admission (IQR)
Discharged to hospice from index admission (% yes)
DNR documented during index admission (% yes)
Changed goals-of-care during palliative care consult (% yes)

Future: Any future acute care costs post-discharge (% yes)
Future: Mean total direct acute care costs post-discharge (SD)

Index admission: Median direct acute care costs (IQR)

Index admission: Mean number of days hospitalized (SD)
Index admission: Median number of days hospitalized (IQR)
Index admission: Mean number of ICU days (SD)
Index admission: Median number of ICU days (IQR)
Index admission: Mean direct acute care costs (SD)

Outcomes
(Sample not propensity-score matched)

Table 3.8 Description of Hispanics (alive at the time of discharge from index admission) with and without PCC
* Groups were not propensity-score matched.
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“Other”
Race/Ethnicity
with PCC
N = 39
20.5 (33.7)
10.0 (16.0)
6.9 (12.3)
2.0 (10.0)
$43,376
($57,448)
$20,540
($38,849)
30.8%
$14,693
($30,331)
$0 ($0-$13,980)
15.4%
15.4%
6.9 (13.4)
0.0 (7.0)
1.0 (3.5)
0.0 (0.0)
28.2%
46.2%
69.2%

“Other”
Race/Ethnicity
without PCC
N = 1,095
7.2 (9.7)
4.0 (6.0)
1.9 (5.9)
0.0 (1.0)
$21,258
($35,946)
$11,382
($15,450)
23.3%
$7,227
($26,848)
$0 ($0)
7.3%
12.1%
2.7 (9.3)
0.0
0.65 (5.5)
0.0 (0.0)
1.6%
3.5%
-

“Other”
Race/Ethnicit
y Total
N = 1,134
7.7 (11.6)
5.0 (6.0)
2.0 (6.3)
0.0 (2.0)
$22,019
($37,075)
$11,508
($15,950)
23.5%
$7,483
($26,995)
$0 ($0)
7.6%
12.2%
2.9 (9.5)
0.0 (0.0)
0.66 (5.5)
0.0 (0.0)
2.5%
4.9%
-

0.13
0.06
0.53
0.007
0.10
0.67
0.06
<0.0001
<0.0001
-

0.28
0.09

0.0003

<0.0001
<0.0001
<0.0001
<0.0001
0.0002

P
value

Percentage variables analyzed using a Chi-squared test. Continuous parametric variables were analyzed using a Two-sample t test with equal
variances. Continuous non-parametric variables were analyzed using a Mann–Whitney U-test.

Future: Median total direct acute care costs post-discharge (IQR)
Future: Any ICU days post-discharge (% yes)
Future: Readmitted within 30 days (% yes)
Future: Mean number of hospital days following index admission (SD)
Future: Median number of hospital days following index admission (IQR)
Future: Mean number of ICU days following index admission (SD)
Future: Median number of ICU days following index admission (IQR)
Discharged to hospice from index admission (% yes)
DNR documented during index admission (% yes)
Goals-of-care changed during palliative care consult (% yes)

Future: Any future acute care costs post-discharge (% yes)
Future: Mean total direct acute care costs post-discharge (SD)

Index admission: Median direct acute care costs (IQR)

Index admission: Mean number of days hospitalized (SD)
Index admission: Median number of days hospitalized (IQR)
Index admission: Mean number of ICU days (SD)
Index admission: Median number of ICU days (IQR)
Index admission: Mean direct acute care costs (SD)

Outcomes
(Sample not propensity-score matched)

Table 3.9. Description of “Other” race/ethnicity patients (alive at the time of discharge from index admission) with and without PCC
* Groups were not propensity-score matched. This sample includes patients who self-reported as American Indian or Alaska Native, Native
Hawaiian or Other Pacific Islander, or “Other” race/ethnicity.
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Index admission: Mean number of days
hospitalized (SD)**
Index admission: Median number of
days hospitalized (IQR)***
Index admission: Mean number of ICU
days (SD)**
Index admission: Median number of ICU
days (IQR)***
Index admission: Mean direct acute
care costs (SD)**
Index admission: Median direct acute
care costs (IQR)***
Future: Any future acute care costs postdischarge (% yes)*
Future: Total mean direct acute care
costs post-discharge (SD)**
Future: Median total direct acute care
costs post-discharge (IQR)***
Future: Readmitted within 30 days
(% yes)*
Future: Mean total number of hospital
days following index admission (SD)**
Future: Median total number of hospital
days following index admission (IQR)***
Future: Any ICU days post-discharge (%
yes)*

N = 48
18.0
(24.9)
7.0
(13.0)
10.2
(20.6)
1.5
(8.5)
$46,766
($81,216)
$14,739
($24,510)
27.1%
$6,893
($16,778)
$0.00
($1,560)
14.6%
3.1
(8.0)
0.0
(2.0)
14.6%

N= 1,390
17.1
(19.9)
10.0
(15.0)
6.7
(13.9)
1.0
(8.0)
$40,140
($58,073)
$19,713
($31,212)
28.2%
$9,616
($28,720)
$0.00
($2,005)
13.3%
4.5
(13.3)
0.0
(1.0)
13.9%

18.0%

6.6
(16.8)
0.0
(6.0)

18.3%

$13,162
($34,129)
$0.00
(11,144)

34.7%

N = 383
17.0
(19.5)
10.0
(14.0)
6.0
(12.7)
1.0
(6.0)
$35,982
($49,024)
$35,982
($18,578)

13.6%

4.1
(6.3)
0.0
(9.0)

18.2%

$7,800
($14,007)
$0.00
($14,257)

36.4%

N = 22
17.8
(17.6)
9.0
(17.0)
5.2
(10.1)
0.0
(7.0)
$38,739
($45,258)
$28,907
($33,937)

12.7%

3.9
(12.0)
0.0
(1.0)

11.6%

$8,384
($27,223)
$0.00
($855)

26.2%

N= 814
16.5
(19.0)
10.0
(14.0)
6.4
(13.8)
1.0
(7.0)
$40,125
($59,607)
$20,017
($30,991)

15.4%

6.9
(13.4)
0.0
(7.0)

15.4%

$14,694
($30,331)
$0.00
($13,978)

30.8%

N = 39
20.5
(33.7)
10.0
(16.0)
6.9
(12.3)
2.0
(10.0)
$43,376
($57,448)
$20,540
($38,849)

6.0%

2.0
(9.7)
0.0
(0.0)

4.8%

$5,052
($21,047)
$0.00
($0.00)

15.5%

N = 84
19.8
(18.3)
14.5
(18.5)
10.6
(16.2)
3.0
(15.0)
$54,307
($67,052)
$27,311
($53,322)

Table 3.10 Comparison of groups receiving palliative care consultation (PCC) for goals-of-care/end-of-life by race/ethnicity
All PCC
Asians
African
Hispanics
Whites
“Other”
Unknown
PCC Comparison by Race
Patients
with
Americans with PCC
with
Ethnicity
Ethnicity
PCC
with PCC
PCC
w/ PCC
with PCC
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0.051

0.01

0.005

0.006

0.02

0.047

0.004

0.04

0.17

0.11

0.04

0.19

0.62

P
value

Asians
with
PCC
N = 48
0.77
(2.1)
0.0
(0)
33.3%
35.4%
58.3%

All PCC
Patients
N= 1,390
1.0
(4.2)
0.0
(0)
39.1%
48.8%
65.0%

60.1%

44.9%

N = 383
1.50
(5.8)
0.0
(0)
35.5%

African
Americans
with PCC

IQR: Inter quartile range.
*Percentage variables analyzed using a Chi-squared test.
**Parametric continuous variables were analyzed using one-way ANOVA.
***The Kruskal-Wallis test was used for non-parametric continuous data.

Future: Mean total number of ICU days
following index admission (SD)**
Future: Median number of total ICU days
following index admission (IQR)***
Discharged to hospice from index
admission (% yes) *
DNR documented during index admission
(% yes) *
Goals-of-care changed during palliative
care consult (% yes) *

PCC Comparison by Race
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59.1%

31.8%

N = 22
1.05
(3.2)
0.0
(0)
41.2%

Hispanics
with PCC

67.7%

51.2%

N= 814
0.82
(3.5)
0.0
(0)
28.2%

Whites
with
PCC

69.2%

46.2%

N = 39
1.03
(3.5)
0.0
(0)
28.2%

“Other”
Ethnicity
w/ PCC

65.5%

56.0%

N = 84
0.59
(3.2)
0.0
(0)
45.2%

Unknown
Ethnicity
with PCC

0.14

0.03

0.16

0.54

0.22

P
value
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CHAPTER FOUR: RISK FACTOR PROFILES ASSOCIATED WITH PALLIATIVE
CARE CONSULTATIONS BEFORE DEATH
Abstract
Background: Previous studies show benefits of having early palliative care consultations (PCC)
to discuss goals-of-care (GOC) with seriously ill patients. To help clinicians identify patients atrisk for late PCC, it is important to understand risk factor profiles associated with the timing of
these conversations in hospital settings where late conversations are more likely to occur.
Objective: To identify risk factor profiles associated with the timing of inpatient PCC before death
(0-14 days before death, 15-60 days before death, > 60 days before death) using available
clinical, demographic, and administrative variables.
Design: Secondary analysis of an observational, retrospective cohort study involving
supplementary de-identified patient data.
Sample and Setting: This study was conducted using preexisting clinical and administrative data
from a large, urban, academic medical center in the Northeast region. Supplementary data
(Medicaid status and days between PCC and death) was extracted from electronic medical
records and matched to unique patient identifiers. The sample included 1,141 patients age 18+
who were admitted to the medical center, had PCC, and died between July 1, 2014 to October
31, 2016 (PCC 0-14 days before death, n = 612; PCC 15-60 days before death, n = 292; PCC >
60 days before death, n = 237). Patients who were admitted for childbirth or rehabilitation, and
patients whose date of death was unknown were excluded.
Measurements and Analysis: Adjusted multinomial logistic regression was used to identify
variables associated with the timing of PCC. Variables included age, gender, race/ethnicity,
Medicaid status, primary diagnosis, source of referral to palliative care, APR-DRG Severity of
Illness (physiological decomposition), APR-DRG Risk of Mortality (likelihood patient will
die), intensive care unit (ICU) use during index admission, ICU use greater than six days during
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index admission, visitation by Oncology services during index admission, and source of referral to
palliative care. Regression results were used to develop a Classification and Regression Tree
(CART) model to identify risk factor profiles based on complex variable interactions associated
with the timing of PCC before death.
Results: Over half (54%) of patients received PCC “close to death” (0-14 days before death),
26% received “moderately-timed” PCC (15-60 days before death) and 21% received “early” PCC
(>60 days before death). The median PCC was 13 days before death. No evidence of
multicollinearity was found among variables. Adjusted multinomial logistic regression identified no
variables with significant differences across the three PCC timing groups overall. However,
compared to patients over age 75, patients aged 56-60 were almost twice as likely to have
consults close to death relative to early (OR = 1.94, 95% Confidence Interval 1.09, 3.47; P=0.03),
with no significant difference for moderately-timed PCC relative to early. Compared to referrals
from Oncology specialists, patients referred to PCC by General Medicine/Hospitalists were twice
as likely to have consults close to death relative to early (OR = 2.02, 95% Confidence Interval
1.16, 3.53; P = 0.01), with no significant difference for moderately-timed PCC relative to early.
The CART model was effective at identifying which patients received PCC 0-14 days before
death (88.2% sensitivity), but not which patients received PCC 15-60 days before death (27.4%)
or PCC > 60 days before death (1.7%). The model was effective at identifying which patients did
not receive early or moderately-timed PCC (specificity 99.1% and 82.1%, respectively). Patients
with extreme illness severity who were in the ICU and were Hispanic or “Other” racial/ethnic
minority were more likely to receive PCC close to death (85%); age under 46 or older than 75
further increased this probability (98%). On the other hand, patients with non-extreme illness
severity who were not in the ICU were least likely to receive PCC close to death (24%). ICU
patients with extreme illness severity were more likely to receive PCC close to death (64%), but
50% of ICU patients with less than extreme severity of illness also received PCC within 14 days
of death.
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Conclusion: In this secondary analysis, a majority of patients with serious illness (e.g., cancer,
cardiovascular disease, etc.) received PCC close to death. A complex set of variable interactions
were associated with the timing of PCC. A systematic process for engaging patients with PCC
earlier in the care continuum, and especially in the ICU regardless of illness severity, is needed.
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Introduction
As medicine and technology advance and providers are able to alter the normal dying
process with life-extending treatments, patients with serious illness and their families are
increasingly tasked with making difficult decisions about end-of-life (EOL) care.1 Although less
aggressive EOL care is often preferred2-4 and is associated with family perceptions of higher
quality care and lower regret,5,6 hospitals’ default mechanism to maintain life often results in
patients receiving intensive, sometimes unnecessary, care near death.7 Evidence suggests a
majority of patients receive intensive care unit (ICU) treatment within six months of dying8 and up
to 38% of patients receive non-beneficial treatments near EOL, which may alter quality of life.7
Patient-provider discussions about goals-of-care (GOC) and EOL, including
conversations that occur during palliative care consultations (PCC), enable providers to
understand patient values and needs, help patients make informed decisions about their care
experience before dying,9 and are associated with patients receiving the kind of care they prefer
at EOL.10-12 Patients who have PCC are almost seven times more likely to document advance
care planning wishes than patients who do not have PCC,13 which may further help achieve care
concordant with preferences.11,14 These conversations are also associated with less aggressive
treatments and lower use of intensive care, 9,11,15-18 lower 30-day readmission rates and
hospitalizations overall,9,16,17,19 fewer in-hospital deaths and greater utilization of hospice, 10,15-18,20
and higher quality EOL care.18,21 Perhaps as a result of supporting patients who choose less
aggressive care near EOL, these discussions are also associated with lower EOL costs,16,22-27
which evidence suggests is associated with better quality of death.17 When patients have these
important discussions and receive the EOL care they prefer, lower costs often follow, benefiting
patients and health systems alike.28
Palliative care consultations offer many communication and clinical benefits, such as
improving pain and symptom management and increasing advance care planning,16,22,24-26,29-32
but the timing of these consultations matters.33-37 Earlier care planning conversations are
associated with greater quality of life near EOL and may help patients receive care more
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consistent with preferences.18,21,38,39 Later GOC discussions are associated with greater risk of
aggressive care, hospital death, and odds of ICU admission.18 Specifically, PCC < 90 days before
death—timing that most typically occurs in hospital settings—is associated with higher rates of
inpatient, ICU, and emergency department care in the last month of life, and higher direct
inpatient costs in the last six months of life ($6,687 difference per person) compared to PCC
occurring more than 90 days before death.36 Higher EOL costs reflect greater use of acute and
intensive services, which are associated with worse quality of death.17 If care planning and EOL
discussions occur close to death, patients may make pressured decisions leading to care that is
not concordant with their preferences.15,40,41
In one study of advanced heart failure patients, PCC to discuss GOC during terminal
hospital admission was often either absent or very near death, with a median time of six days
between PCC and death and only 24 hours between orders for comfort care and death.42 The
timing is not much better among persons with other serious illnesses.12 Patients with cancer
experience the most timely consultations, a median of 16-33 days before death depending on
cancer type and other factors.15,43,44 Each additional day from hospital admission to care planning
conversation has been found to be associated with a 4% increased risk of aggressive
interventions and in-hospital death, and 19% greater odds of intensive care unit (ICU)
admission.18 Early discussion of prognosis and EOL care options facilitates earlier enrollment in
hospice and earlier use of palliative care services,45 which are associated with quality care.33,46
When care planning discussions occur close to death, or not at all, patients may not receive the
benefits of comfort care as early as they might have liked, possibly resulting in greater regret
about care decisions.6 Evidence suggests racial/ethnic minorities are less likely than Whites to
have these conversations with healthcare providers,47-52 but for minority patients who do have
these conversations, such as during PCC in which race may not be a factor,16 little is known
about their timing. Unfortunately, 84% of patients who receive PCC less than 90 days before
dying have their consultations inpatient while hospitalized,36 limiting the time palliative care teams
have to refer patients to services that enhance their quality of life.35 Despite the benefits of having
117

early PCC37,53,54 and GOC1,55 conversations, little is known about risk factor profiles associated
with the timing of these conversations in hospital settings where late conversations are more
likely to occur.
The main aim of this study is to identify risk factor profiles associated with patients
receiving palliative care consultations for GOC (hereafter called “PCC”) 0-14 days before death
(“PCC close to death”), 15-60 days before death (“moderately-timed PCC”), and more than 60
days before death (“early PCC”).
The timing categories are based on Medicare hospice data, which shows 41% of patients
on hospice received 0-14 days of care (28% received seven or fewer days of care, presumably in
the last week of life), 26% received 15-60 days of care, and 33% received more than 60 days of
hospice care.45 Hospice care is associated with family perceptions of excellent quality EOL care
and greater concordance between patient wishes and EOL care, with the highest quality EOL
outcomes associated with patients receiving hospice for more than 30 days.46 Evidence suggests
efforts to decrease ICU admissions near EOL, decrease hospital deaths, and increase earlier
hospice enrollment may improve the quality of EOL care.5 Earlier PCC also allows for more
opportunities to discuss treatment decisions and advance care planning,35 topics in PCC that are
associated with reduced hospitalizations near death and increased use of hospice.54 Better
understanding risk factors associated with PCC timing may help clinicians initiate these
discussions earlier with patients at risk for having late conversations and enable patients to make
decisions that result in high quality EOL care consistent with preferences.
To further understand associations between PCC timing and other outcomes, the
secondary aims of this study are to describe discharge to hospice from index admission,
presence of do-not-resuscitate (DNR) documentation during index admission, whether patients
changed their GOC during index admission, and median EOL acute care costs (defined as direct
acute care costs incurred in the health system during and following index hospital admission to

118

the point of death). Index admission is defined as the hospitalization in which PCC first occurred
during the study period (Appendix A).16

Methods
Study Design
This secondary analysis was designed to identify risk factor profiles associated with the
timing of PCC before death (0-14 days, 15-60 days, and greater than 60 days before death)
among patients who received inpatient PCC at an academic medical center. Supplementary data
from the medical center’s electronic record database (Medicaid status and days between PCC
and patient death) was matched to unique patient identifiers.
Dataset
Setting. Our analysis used data from a study conducted at a 776-bed, urban, academic
medical center in the Northeast region.16 The medical center serves a socioeconomically and
racially diverse area of patients, composed of African Americans (46%), Whites (36%), Asians
(9%), and Hispanics (6%).56 In addition, the medical center receives a significant number of
patients transferred from other hospitals in the region, including hospitals that serve
predominantly White patients from areas with higher median incomes and education levels. The
palliative care team at this medical center is well-established and predominantly operates as a
consultation service. The team includes physicians, advance practice nurses, registered nurses,
social workers, a pharmacist, and a chaplain.16 Two-thirds of the team’s consultations involve
GOC discussions.16
Data. The dataset includes demographic, clinical, and financial cost information tied to
each patient’s healthcare utilization in the medical center during the study period (July 1, 2014 to
October 31, 2016). The medical center’s palliative care registry was used to identify all patients
who received PCC specifically to discuss GOC during the study period. Consultations about pain
or symptom management, psychosocial or spiritual distress, or transition planning that did not
involve GOC discussion were excluded.
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Sample. Our study included patients 18 and over who were admitted to the medical
center between July 1, 2014 and October 31, 2016 (the study period), received PCC, and died
during the study period. Patients were included if they died in the hospital system while on
hospice or not on hospice, died outside the hospital system while on hospice, or died outside the
hospital system not on hospice but had been seen by a provider affiliated with the medical center
who updated the patient’s medical record to reflect their death. Patients who were admitted for
childbirth or rehabilitation were excluded, as were patients who died in community hospitals
whose deaths were not updated in the medical center’s records.
Data privacy and security. This study was approved by the University of Pennsylvania’s
Institutional Review Board, which granted the current study an exempt status (45 CFR 46.104,
category #4). The investigators followed University of Pennsylvania procedures for ensuring
patient data privacy and security. Prior to the transfer of data, all patient data was de-identified to
ensure privacy and compliancy with the Health Insurance Portability and Accountability Act
(HIPAA). Without sharing dates of initial PCC or dates of patients’ deaths, the health system’s
director of analytics provided the number of days between initial PCC and patient death, ensuring
patient privacy while allowing analysis to be unaffected by blinding. Age was provided in
categorical groups to further protect patient identity. De-identified data was transferred through
SecureShare, an internet-based application for securely exchanging files, and saved to a secure,
encrypted folder on the University of Pennsylvania School of Nursing’s firewall-protected network
drive. Accessing the folder and the network drive requires two-step authentication. The network
drive that contained the data is routinely monitored for system and security breaches. Only study
investigators and approved personnel, had access to the de-identified study data.
Measures
Timing of palliative care consultations for goals-of-care. The primary outcome of interest
is time between a patient’s first inpatient PCC during the study period and patient death,
categorized into three non-overlapping levels of data: PCC close to death, defined as 0-14 days
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before death; moderately-timed PCC, defined as 15-60 days before death; and early PCC defined
as more than 60 days before death. The date of first PCC during the study period was used to
calculate days between first PCC and patient death (Appendix A). Although the literature
suggests early palliative care referral may be defined as more than 90 days before death,36
consultations occurring in that timeframe predominantly occur in outpatient settings.36 Because
this study focuses on GOC conversations occurring during inpatient hospitalization, the time
parameters are shorter and were defined with other inpatient GOC studies in mind.15,57
Risk factors for profiles associated with the timing of PCC. Correlates included
sociodemographic data such as age, gender, self-reported race/ethnicity, and Medicaid status;
and clinical variables such as primary diagnosis at the time of index hospitalization discharge
based on diagnosis-related group (DRG), All-patient refined DRG (APR-DRG) severity of illness
(the extent of physiologic decomposition, determined at index hospitalization discharge), APRDRG risk of mortality (the likelihood a patient will die, determined at index hospitalization
discharge), whether a patient had any ICU care during the index admission, whether a patient
had ICU care for more than six days during the index admission (to indicate high acuity), whether
a patient was visited by an Oncology team during the index admission, source of referral to
palliative care (e.g., Oncology), and acute care utilization in the 30 days before index admission
(Table 4.1).
APR-DRG severity of illness and APR-DRG risk of mortality are assigned to a patient
based on the diagnoses and procedures coded for billing during the hospitalization, and have four
subcategories (minor, moderate, major, extreme) that are assigned by health system software
designed to assess patient risk and resource allocation.16,58,59 These measures take into account
a patient’s comorbidities and the stage and interaction of those diseases.59 High scores are
characterized by multiple serious illnesses and interaction among those illnesses, and are a
reliable proxy for comorbidities.60
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Descriptive variables associated with PCC timing. Discharge to hospice from index
admission, DNR documentation during index admission, whether patients changed GOC during
index admission, and EOL acute care costs (direct acute care costs incurred in the health system
during and following index hospital admission to the point of death) are described (Table 4.1).
Statistical Methods
Descriptive statistics and measures of central tendency were used to characterize the
variables and describe the sample based on timing of PCC before death (SAS v. 9.4, SAS
Institute Inc., Cary, NC) (Table 4.1). Chi-squared tests were performed to examine associations
between categorical variables. Kruskal-Wallis tests and analysis of variance (ANOVA) tests were
performed for the distributions of continuous measures by PCC timing, as appropriate. There
were minimal missing data in the dataset. Specialist referral data was missing for one patient.
This patient was included in the study. (In the parent study, 0.4% of patients were excluded due
to missing data.)
To inform development of the classification and regression tree (CART) model, an
adjusted multinomial logistic regression model was built using all available, clinically meaningful
independent variables (Stata v. 15, StataCorp, College Station, TX) (Table 4.2). Odds ratios were
calculated across variables using early PCC as the reference group. Classification and regression
tree modeling was then applied with SAS JMP software using all clinically meaningful variables,
regardless of significance demonstrated in the multinomial logistic regression model (Figure 4.1).
Risk of mortality is known to be a strong correlate of the PCC timing because it increases as a
patient nears death.61 To better understand the interaction of other variables, risk of mortality was
excluded from the model. The CART model shows how independent variables, or risk factors,
interact to create associations with the outcome of PCC timing.62
For CART modeling, the dataset was divided into training (N = 571), validation (N = 285),
and test (N = 285) sets. In training the decision tree, CART analysis software recursively divided
the training data one variable at a time to generate a series of splits that best identified the
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outcome of PCC timing.63 CART software chooses where to split variables based on where the
division most accurately homogenizes the outcome variable while minimizing the model’s
misclassification rate, a process that results in subgroups more homogenous in the outcome of
PCC timing than the original sample.62,64 Specifically, splitting occurred when the decrease in
entropy was less than 9.5. We then selected the tree with the most clinically meaningful patient
profiles. The test set was used to evaluate performance of the decision tree. Traditional statistical
power analyses do not apply to CART modeling,65,66 but our sample was sufficient for running
complex interactions because it was greater than the minimum 100 participants that is
recommended.66

Results
Timing of PCC. The sample included 1,141 patients who received inpatient PCC prior to
dying during the study period. Over half of patients received PCC 0-14 days before death (53.6%,
n = 612); 25.6% received PCC 15-60 days before death (n = 292); and 20.8% received PCC
more than 60 days before death (n = 237). Overall, patients had PCC a median of 13 days before
death. Patients in the early PCC group received PCC a median of 135 days before death,
patients who had PCC 15-60 days before death had it a median of 28 days before death, and
patients in the PCC group close to death received PCC a median of 5 days before death (P <
0.0001). Over half (54%) of patients in our sample received PCC within two weeks of dying, 26%
received PCC 15-60 days before death, and only 21% received PCC more than 60 days before
death.
Correlates of the timing of PCC before death. Table 4.1 presents the distribution of
potential risk factor variables based on the timing of PCC before death. Variance Inflation Factor
was less than three for all variables, indicating no evidence of multicollinearity among variables.
Results of the adjusted multinomial logistic regression (Table 4.2) were limited, suggesting other
variables not measured in this study may be associated with the timing of PCC before death.
Small sample sizes within groups may also have contributed to this finding. There were no
statistically significant differences among the three timing groups overall, but some differences
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were significant between groups. For example, compared to patients over age 75, patients aged
56-60 were found to be almost two times more likely to have consults close to death than early
(OR = 1.94, 95% Confidence Interval 1.09, 3.47; P = 0.03), with no significant difference for
moderately-timed PCC relative to early. Compared to patients with cancer, patients in “other”
diagnoses category were less likely to receive a moderately-timed consult than early consult (OR
= 0.47, 95% Confidence Interval 0.22, 0.10; P = 0.049) and, although not significant, less likely to
have PCC close to death (OR = 0.53, 95% Confidence Interval 0.28, 1.01; P = 0.052) compared
to early. Patients with “Other” category had primary diagnoses such as skin conditions and ulcers,
musculoskeletal conditions, psychiatric disorders, traumatic injuries, or postoperative or
procedure-related conditions. These conditions were combined into the “Other” category due to
smaller sample sizes. Finally, compared to referrals from Oncology specialists, patients referred
to PCC by General Medicine/Hospitalists were two times more likely to have consults close to
death (OR = 2.02, 95% Confidence Interval 1.16, 3.53; P = 0.01), with no significant difference for
moderately-timed PCC compared to early.
Decision tree model identifies profiles of patients associated with receiving PCC close to
death. As shown in Table 4.3, the CART model had 54.7% accuracy identifying the PCC timing
outcome (CI 48.8%, 60.6%), which was similar to the predictive error in the test data (53.7%).
The overall identification accuracy did not improve significantly, likely because the model was
only able to accurately identify patients who received PCC close to death (model sensitivity for
PCC close to death was 88.2%). The model’s specificity for PCC close to death was 32.6%,
which indicates the model less accurately identified patients who did not have PCC 0-14 days
before death. Although the model demonstrated poor ability to identify patients who had early
PCC or moderately-timed PCC (sensitivity 1.7% and 27.4%, respectively), the model effectively
identified which patients did not receive early or moderately-timed PCC (specificity 99.1% and
82.1%, respectively)—timing that is preferable to PCC close to death. In short, the model was not
effective at identifying which patients received moderately-timed (n = 147) or early PCC (n = 118),
but it was effective at identifying which patients received PCC close to death (n = 306) and which
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patients did not receive early or moderately-timed PCC. Smaller sample sizes, particularly for
early and moderately-timed PCC groups, may have contributed to these findings.
Risk factor profiles associated with patients likely to receive PCC close to death. Figure
4.1 illustrates the CART model’s identification of patients most likely to receive PCC 0-14 days
before death compared to moderately-timed and early PCC. In the model’s depiction of complex
interactions associated with PCC timing profiles, severity of illness was found to be the most
important variable, followed by ICU use, age, primary diagnosis, race/ethnicity, use of Oncology
services, and hospitalization 30 days prior to index admission. Severity of illness was highly
associated with PCC timing: 64% of patients with extreme illness received PCC close to death.
Only 13% of patients with extreme illness and 35% of patients with less than extreme severity of
illness received PCC more than 60 days before death, indicating opportunities to discuss GOC
earlier with patients. ICU use during index admission further increased probability of association
with PCC timing. ICU patients with extreme illness severity were more likely to receive PCC close
to death (64%). Although representing a lower probability, a staggering 50% of ICU patients with
less than extreme severity of illness also received PCC within 14 days of death. Patients with
extreme illness severity who were in the ICU and were Hispanic, “Other” racial/ethnic minority
(American Indian/Alaskan Native, Native Hawaiian/Pacific Islander, or “Other” race/ethnicity), or
did not disclose their race/ethnicity were more likely to receive PCC close to death (85%); age
under 46 or older than 75 further increased this probability (98%). Non-ICU patients with extreme
severity of illness, no hospital admission in the previous 30 days, and a primary diagnosis of
cancer, other cardiovascular disorders, endocrine disorders, GI disorders, gynecological or
urological disorders, blood disorders, infectious disease, sepsis, musculoskeletal disorders, or
neurologic disorders had a 58% probability of PCC close to death—a probability (96%) that
dramatically increased if the patient was also age < 40 or > 75.
On the other hand, patients with non-extreme illness severity who were not in the ICU
were less likely to receive PCC close to death (24%). Non-ICU patients with extreme illness
severity with conditions other than heart failure, respiratory disorder, or “Other” condition who did
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not receive Oncology care during index admission but had been admitted to the hospital 30 days
prior also demonstrated low probability for PCC close to death (19%). Finally, non-ICU patients
with extreme severity of illness who had heart failure, a respiratory disorder, or “Other” diagnosis
had the lowest probability of PCC close to death (17%) and high probability for early PCC (80%).
It is unknown if this is a case of reverse causation or if other factors are involved.
Findings of the secondary aims. During index admission, patients spent a median 11
days hospitalized (IQR 6-22 days, P < 0.0001), 3 days in the ICU (IQR 0-11 days, P < 0.0001),
and incurred median direct acute care costs of $26,005 (IQR $12,908-$59,889; P = 0.18; and
mean costs of $51,000, SD $93,302; P = 0.02). Index admission utilization and costs were
generally greatest among patients who received PCC 0-14 days before death. PCC groups
differed in age (P = 0.04), race/ethnicity (P = 0.02), primary diagnosis (P = 0.006), severity of
illness (P < 0.0001), risk of mortality (P < 0.0001), ICU care during index admission (P < 0.0001),
ICU care greater than 6 days during index admission (P < 0.0001), and whether they had been
visited by the Oncology team during their index admission (P = 0.03). About 80% of PCC patients
changed their GOC during PCC, with rates increasing the closer a patient was to death (P <
0.0001). Do-not-resuscitate (DNR) documentation also increased the closer a patient was to
death (early PCC 26%, PCC 15-60 days 59%, PCC close to death 86%, P < 0.0001), with 67% of
the total sample having resuscitation wishes documented during index admission. It is unknown if
DNR documentation occurred before or after PCC.

Discussion
The CART model effectively identified factors associated with PCC 0-14 days before
death, making it a useful tool for identifying vulnerable patients at risk of PCC close to death, and
provided insights into patient populations likely to receive PCC 15-60 and > 60 days before death.
In addition, the model effectively identified which patients did not receive early or moderatelytimed PCC, which enables clinicians to identify and target patients who are not getting more
optimally-timed, beneficial consultations, and develop interventions that better support such
patients’ needs. The model was not able to accurately identify which patients received early or
126

moderately-timed PCC, possibly because relatively few patients received early PCC and because
already small sample sizes for these groups diminished in the context of variable interactions. It is
also possible variables not included in our model may have improved the model’s ability to
identify patients likely to receive moderately-timed or early PCC. Given that more than half the
patients in the sample died within 14 days of receiving PCC and only one-fifth received PCC
more than 60 days before death, this study illuminates a critical need for clinicians to engage
patients with serious illness in PCC discussions about GOC earlier in the illness trajectory.
Patients in our study received PCC a median 13 days before death, which is less than the
national median length of hospice care (24 days)67 and cancer studies that show median times
ranging from 16-33 days between PCC and death.15,43,44
Among complex interactions identified by CART modeling, ICU utilization was found to
be the second greatest contributor to risk factor profiles associated with PCC timing. Intensive
care during index admission for patients with extreme severity of illness contributed to a 67%
probability of PCC close to death (and 50% probability of PCC close to death for all other ICU
patients), suggesting the importance of coordinating PCC for patients in the ICU regardless of
illness severity. This finding is consistent with evidence-based recommendations to involve PCC
when caring for patients in the ICU.28,68 One recent study found patients in the neuro-ICU who
received PCC were more likely to change GOC to less invasive care, receive fewer procedures in
the last 48 hours of life, and receive better symptom management.69 Another study found
involving PCC in the ICU increased advance care planning and decreased use of aggressive
interventions.70 Consulting palliative care earlier in the ICU stay gives patients and families more
time to benefit from GOC discussions and the improvements in symptom and care management
that follow. Because all ICU patients can benefit from PCC, research into systematic processes
for involving PCC early in the ICU admission, such as those developed using evidence-based
triggers and machine learning, are recommended.68,71,72 Early evidence suggest systematic
processes increase PCC in the ICU,71 possibly reducing disparities that result from referral-driven
care.
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A more systematic process for involving PCC in the care of patients with serious illness
may also help reduce racial/ethnic disparities in EOL care. It is unknown why ICU patients who
self-identified as Hispanic or other racial/ethnic minority demonstrated such a high probability for
receiving PCC close to death. Hispanics and other racial/ethnic minorities endure disparities in
access to care and experiences throughout the care continuum that may influence when they first
receive PCC.73-79 For example, providers are less likely to have EOL discussions55 and less likely
to discuss prognosis80 with Hispanics and other racial/ethnic minorities, possibly influencing their
health literacy and receptivity to PCC.76 Other factors such as religiosity, family dynamics, and
socio-cultural preferences may also contribute to PCC timing.76,79,81 More research is needed to
better understand barriers to earlier PCC with severely ill Hispanics and other racial/ethnic
minorities, and how clinicians can overcome such barriers to better support racial/ethnic
minorities with serious illness.73-75 Improved communication and earlier involvement with PCC
may help reduce the disparities in EOL care and costs documented among Hispanic patients and
other minorities.17,73,81-83
The model found only 17% probability that non-ICU patients with extreme severity of
illness who were admitted for heart failure, a respiratory condition, or a condition not otherwise
listed (e.g., pressure ulcers, musculoskeletal conditions) had PCC close to death. According to
CART, these patients had 80% probability of having early PCC. Patients with advanced heart
failure and respiratory disorders such as chronic obstructive pulmonary disease have different
illness trajectories than, for example, patients with cancer. The patterns of organ failure
associated with conditions like heart failure cause patients to be hospitalized during acute crises
from which they may recover. Patients who recover after receiving PCC during a disease
exacerbation may partially compose the early PCC group. Research is needed to better
understand which patients receive PCC early and why.
Over half the patients who had PCC more than 60 days before death changed their GOC
during PCC, suggesting the relevance and appropriateness of earlier conversations. The
proportion of patients who changed their GOC during PCC increased the closer a patient was to
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death, as did DNR documentation. Had patients engaged in these discussions earlier, they may
have chosen to change their care goals earlier and may have benefitted from greater time
receiving care consistent with their preferences. Health systems seeking to manage costs may
also benefit from offering patients earlier PCC. Despite having significantly more days to accrue
costs before death, as measured in our study, patients with earlier PCC had only $8,993 greater
median acute care EOL costs than patients who had PCC within 14 days of dying. Other
evidence suggests that early PCC appears to mediate the increase of inpatient costs toward EOL
observed among patients who receive late PCC,36 but more research is needed to understand the
monetary effect each day before death PCC has on EOL acute care costs.
This medical center treats a high number of severely ill patients transferred from other
hospitals within the region, which may have contributed to the majority of patients receiving PCC
close to death. Although timing improvements can be made in acute care settings using
systematic triggers for inpatient PCC among eligible patients,71,72,84-86 poor access to PCC in the
community likely contributes to late timing. Increased access to community-based palliative care
models would improve the time between PCC and death, enable patients to benefit from palliative
care longer,36,87 and help meet patient needs throughout the care experience and not just during
inpatient hospitalizations.88,89

Limitations
This study is limited in a few ways. First, given the secondary nature of the study, a
limited number of variables were available to assess. We were unable to assess other relevant
confounders such as socioeconomic variables (e.g., health literacy, income, or education level),
or religious and cultural beliefs. Due to the observational nature of the study, some unavailable
variables may be salient in risk factor profiles associated with the timing of PCC or be important
confounding factors, influencing results. Fortunately, the study was able to assess Medicaid use,
which can be considered a proxy for socioeconomic variables because its eligibility is based on
income. In addition, the index PCC may have occurred before some of the correlates, such as
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ICU admission or the assignment of severity of illness or risk of mortality, making conclusions
about chronology unfeasible but still resulting in relevant insights.
Second, our study does not include patients whose date of death is not recorded in the
health system database. Patients who received PCC but whose death information is not available
may have had shorter or longer durations between consultation and death. As such, the variables
we measured may be distributed differently across the three groups and may be associated with
timing differently. Given that 64% of the patients who received PCC in the parent study died
during the study period, and that not all patients are likely to have died during the study period,
our sample may include most patients who died during the study period. Unfortunately, we were
unable to differentiate between patients who died within the health system and those who died
outside the health system but whose death information was updated by providers affiliated with
the medical center (e.g., specialty physicians in an outpatient setting). We were unable to assess
any differences in demographic or clinical factors between patients whose deaths occurred insystem versus those whose deaths occurred outside the system. If there were differences in
these sub-populations, we were unable to account for them in our analysis.
Finally, our study examined a single academic medical center with high acuity and a wellestablished palliative care team located in an area with significant racial, ethnic, and
socioeconomic diversity. As such, the medical center may not represent all hospitals caring for
patients with serious illnesses, possibly limiting generalizability of results. Willingness to engage
in GOC/EOL conversations and referral patterns to PCC may differ in other systems. Despite
these limitations, our study results increase understanding of risk factor profiles associated with
the timing of inpatient PCC, including how race/ethnicity are associated with the timing of GOC
discussion.

Ethical Considerations
Given PCC’s association with less aggressive care and higher quality of life, and its role
in patient and family informed decision-making, identifying patients at risk for late consultation is
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an ethical priority. All patients should be given time to adequately understand prognosis and
consider care options, but our research shows the majority of patients receive consultation within
two weeks of dying and that disparities exist. The interaction of illness severity, ICU care, and
race/ethnicity suggests a need for more culturally effective care of seriously ill patients from
diverse backgrounds and a need for a more systematic process that integrates PCC across the
care continuum. Patients and families cannot reap the benefits of earlier palliative care if policies
and payment schemes do not support palliative care delivery in the community. New policies,
payment models, and innovative workforce models involving trained nurses and primary care
providers are needed to ethically and effectively deliver palliative care earlier to patients with
serious illness.

Conclusions
The majority of patients with serious illness who had PCC before dying did so within two
weeks of death, which may not be enough time to make decisions that result in the kind of death
and dying experience patients and families desire. A complex set of factors was associated with
PCC timing. Regardless of illness severity, ICU care is associated with patients receiving PCC
close to death, suggesting the need for systematic PCC across ICU patient populations.
Racial/ethnic disparities persist in the timing of PCC for extremely sick Hispanic and other
racial/ethnic minorities, making it an ethical priority to provide earlier, culturally-effective care and
communication to racial/ethnic minority patients. Timely communication of patient goals, values,
and EOL preferences should start in the community before inpatient hospitalization when late
PCC is likely to occur. Innovative care and payment models, policies, and workforce solutions are
needed to support earlier integration of palliative care in acute and community settings.
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Medicaid

Self-identified
Race/Ethnicity

Gender

Age (years)

18-39
40-45
46-50
51-55
56-60
61-65
66-70
71-75
>75
Male
Female
African American/Black
Asian
Hispanic
White
Other
Unknown/Chose not to disclose
Yes

Median number of days between PCC and death (IQR)

Table 4.1 Description of Study Population
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13.0
(4.0-46.0)
6.6%
3.7%
3.9%
9.1%
12.9%
13.6%
16.1%
13.1%
21.0%
46.6%
53.4%
25.0%
3.8%
2.2%
59.3%
3.2%
6.5%
10.3%

N = 1,141

Total

Tables

PCC 0-14
days before
death
N = 612
(53.6%)
5.0
(2.0-8.0)
6.4%
3.6%
3.4%
7.8%
13.2%
13.4%
15.0%
12.6%
24.5%
55.2%
44.8%
22.4%
3.3%
2.1%
60.0%
3.1%
9.2%
9.3%

PCC 15-60
days before
death
N = 292
(25.6%)
28.0
(20.0-39.5)
6.8%
4.4%
5.1%
9.6%
13.0%
14.4%
20.2%
14.7%
11.6%
51.0%
49.0%
28.4%
3.8%
2.1%
59.6%
2.7%
3.4%
10.3%

PCC > 60
days before
death
N = 237
(20.8%)
135.0
(89.0-281.0)
6.8%
3.0%
3.8%
11.8%
11.8%
13.1%
13.9%
12.2%
23.6%
51.5%
48.5%
27.4%
5.1%
2.5%
57.4%
4.2%
3.4%
13.1%

0.27

0.02

0.40

0.037

-

P
value

Acute care
hospitalization 30
days prior to
index
hospitalization

APR-DRG
Risk of Mortality

APR-DRG
Severity of Illness

Primary
Diagnosis
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77.0%
67.0%

No

Yes

77.6%

78.4%

21.6%

8.3%
7.0%
5.2%
1.1%
3.6%
18.6%
76.6%
1.8%
4.1%
22.7%
71.4%

6.9%
7.1%
6.6%
1.6%
5.5%
28.1%
64.8%
3.0%
8.8%
29.8%
58.5%
23.0%

15.4%

PCC 0-14
days before
death
N = 612
(53.6%)
90.7%
31.2%
22.9%
2.0%
5.2%
2.8%

14.0%

89.7%
33.2%
20.3%
1.9%
7.1%
2.8%

Yes

No
Cancer
Cardiovascular disorder / Heart failure
Endocrine disorder
GI disorder
Gynecologic
or urologic disorder
Infectious disease
and Sepsis
Neurologic disorder
Respiratory disorder
Other
Minor
Moderate
Major
Extreme
Minor
Moderate
Major
Extreme

N = 1,141

Total

55.1%

72.6%

27.4%

6.5%
6.5%
5.8%
1.7%
6.2%
34.6%
57.5%
4.5%
11.3%
34.2%
50.0%

11.6%

PCC 15-60
days before
death
N = 292
(25.6%)
89.7%
37.0%
16.8%
2.7%
9.2%
3.8%

54.4%

78.5%

21.5%

3.8%
8.0%
11.0%
2.5%
9.7%
44.7%
43.0%
4.2%
17.7%
42.6%
35.4%

13.5%

PCC > 60
days before
death
N = 237
(20.8%)
86.9%
33.8%
18.1%
0.8%
9.3%
1.7%

<0.0001

0.124

<0.0001

<0.0001

0.006

P
value

Median EOL direct acute care costs (index admission plus
future acute care costs in health system until death) (IQR)

Median direct acute care costs during index admission
(IQR)

$26,005
($12,908$59,889)
$31,082
($14,880$67,035)

$28,330
($13,635$58,476)
$28,333
($14,200$58,476)

5.0 (1-11)

3.0 (0-11)

72.7%
9.0 (5-17)

70%

No

27.3%

53.9%
10.5%
4.4%
13.6%
6.2%
34.0%
10.1%
19.1%
2.1%

46.1%

PCC 0-14
days before
death
N = 612
(53.6%)
22.4%

11.0 (6-22)

30.0%

59.7%
10.8%
3.9%
13.3%
7.3%
34.6%
9.8%
17.9%
2.4%

No
Cardiology
Gynecology/Oncology
General Medicine/Hospitalist
Neurology
Oncology
Pulmonary
Surgery
Other

Yes

40.3%

33.0%

N = 1,141

Total

Yes

No

Median days spent hospitalized during index admission
(IQR)
Median ICU days during index admission (IQR)

Visited by
Oncology during
index admission

ICU care during
index admission
ICU care > 6 days
during index
admission
Specialist who
referred patient to
Palliative Care for
PCC (one patient
had a missing
value)
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$27,542
($11,572$75,175)
$34,113
($14,484$77,510)

1.5 (0-13)

16.0 (7-27.5)

64%

36.0%

62.7%
13.1%
4.1%
14.8%
7.6%
31.3%
10.3%
16.8%
2.1%

37.3%

PCC 15-60
days before
death
N = 292
(25.6%)
44.9%

$21,397
($12,357$47,064)
$37,326
($18,461$89,057)

1.0 (0-7)

11.0 (7-24)

70.5%

29.5%

70.9%
8.9%
2.1%
11.0%
9.7%
40.5%
8.4%
16.0%
3.4%

29.1%

PCC > 60
days before
death
N = 237
(20.8%)
45.6%

0.0001

0.18

<0.0001

<0.0001

0.03

0.35

<0.0001

P
value

N = 1,141

Total

PCC 0-14
days before
death
N = 612
(53.6%)
93.0%

PCC 15-60
days before
death
N = 292
(25.6%)
75.7%

PCC > 60
days before
death
N = 237
(20.8%)
50.2%

P
value

Changed goals-of-care during PCC index admission (%
79.7%
<0.0001
yes)
DNR documented Yes
66.9%
86.3%
59.2%
26.2%
<0.0001
index admission
No
33.1%
13.7%
40.8%
73.8%
Discharged to
Yes
27.1%
31%
32.5%
10.1%
<0.0001
hospice1
No
72.9%
69%
67.5%
89.9%
1
From index admission including PCC. Chi-squared test of association was used to test differences among percentage variables. Kruskal-Wallis
tests and analysis of variance (ANOVA) were performed for the distributions of continuous measures by PCC timing as appropriate.
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Yes
Cardiovascular disorder/Heart
Failure
Endocrine disorder
GI disorder

Medicaid
(reference: No)

Primary Diagnosis
(reference: Cancer)

.1845
.3988
.1742

0.718 (0.44, 1.171)
1.763 (0.472, 6.581)
0.643 (0.34, 1.215)

.5728

.0747

2.022 (0.932, 4.386)
0.851 (0.485, 1.492)

.3903

.6545

.2754

P
value
.1184
.2801
.8832
.7498
.0245
.4179
.8237
.6291

0.785 (0.452, 1.364)

1.091 (0.744, 1.601)

African American/Black
Other (includes Asian,
Hispanic, American
Indian/Alaskan Native, Native
Hawaiian/Pacific Islander, and
“Other” race/ethnicity) *
Unknown/Chose not to
disclose

Gender
(reference: Male)

Self-Identified
Race/Ethnicity
(reference: White)

0.837 (0.609, 1.152)

Female

Age in years
(reference: >75)

Odds Ratio
(95% CI)
1.896 (0.849, 4.233)
1.711 (0.646, 4.532)
1.071 (0.427, 2.691)
1.106 (0.596, 2.050)
1.943 (1.089, 3.468)
1.25 (0.729, 2.142)
0.945 (0.577, 1.549)
1.142 (0.666, 1.96)

18-39
40-45
46-50
51-55
56-60
61-65
66-70
71-75

Variable

PCC 0-14 days vs.
> 60 days (ref)

1.061 (0.235, 4.788)
0.728 (0.365, 1.451)

0.752 (0.434, 1.303)

0.853 (0.459, 1.587)

1.838 (0.775, 4.359)

1.209 (0.666, 2.196)

1.186 (0.769, 1.831)

1.052 (0.733, 1.509)

Odds Ratio
(95% CI)
2.308 (0.952, 5.600)
2.152 (0.731, 6.335)
2.294 (0.883, 5.958)
1.380 (0.689, 2.766)
1.835 (0.945, 3.565)
1.31 (0.702, 2.442)
1.104 (0.623, 1.955)
1.262 (0.677, 2.353)

PCC 15-60 days vs.
> 60 days (ref)

Table 4.2 Adjusted Multinomial Logistic Regression Model Showing Variables Associated with PCC Timing before Death
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.9388
.3667

.3090

.6164

.1669

.5326

.4402

.7843

P
value
.0643
.1642
.0881
.3634
.0730
.3961
.7346
.4634

.4431

.8395

.3485

.2585

.5773

Overall
P
value

Specialist who referred
patient to Palliative

APR-DRG Severity of
Illness
(reference: Minor)
APR-DRG
Risk of Mortality
(reference: Minor)
Acute care
hospitalization 30 days
prior to index
hospitalization
(reference: No)
ICU care during index
admission (reference:
No)
ICU care > 6 days
during index admission
(reference: No)

Variable
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Odds Ratio
(95% CI)
0.728 (0.27, 1.964)
0.906 (0.542, 1.514)
0.955 (0.479, 1.903)
1.037 (0.535, 2.011)
0.534 (0.284, 1.006)
0.54 (0.115, 2.524)
0.762 (0.157, 3.69)
0.721 (0.143, 3.633)
0.586 (0.175, 1.965)
0.627 (0.181, 2.17)
1.084 (0.296, 3.974)
1.246 (0.841, 1.845)

1.122 (0.731, 1.723)
0.988 (0.663, 1.472)
1.014 (0.603, 1.706)
1.819 (0.703, 4.705)
2.023 (1.158, 3.533)

Gynecologic/Urologic
Infectious disease/Sepsis
Neurologic disorder
Respiratory disorder
Other
Moderate
Major
Extreme
Moderate
Major
Extreme
Yes

Yes
Yes
Cardiology
Gynecology/Oncology
General Medicine/Hospitalist

.9588
.2172
.0133

.9519

.5985

.2726

P
value
.5301
.7059
.8949
.9134
.0522
.4334
.7356
.6920
.3870
.4609
.9035

PCC 0-14 days vs.
> 60 days (ref)

0.865 (0.473, 1.58)
2.1 (0.756, 5.834)
1.776 (0.956, 3.3)

1.243 (0.777, 1.989)

0.703 (0.431, 1.146)

1.166 (0.753, 1.806)

Odds Ratio
(95% CI)
1.132 (0.4, 3.204)
0.594 (0.323, 1.093)
0.997 (0.46, 2.159)
0.608 (0.276, 1.339)
0.472 (0.224, 0.995)
0.619 (0.119, 3.228)
1.061 (0.197, 5.722
0.924 (0.163, 5.232)
0.486 (0.136, 1.736)
0.392 (0.105, 1.46)
0.487 (0.122, 1.945)

PCC 15-60 days vs.
> 60 days (ref)

.6369
.1548
.0692

.3643

.1577

.4908

P
value
.8152
.0940
.9932
.2170
.0485
.5694
.9448
.9290
.2669
.1626
.3083

.2785

.4782

.0741

.5474

.2186

.9116

Overall
P
value

Yes

Neurology
Pulmonary
Surgery
Other
1.234 (0.831, 1.831)

Odds Ratio
(95% CI)
0.684 (0.385, 1.214)
1.141 (0.652, 1.995)
1.41 (0.888, 2.239)
0.76 (0.296, 1.946)
.2968

P
value
.1943
.6439
.1456
.5669

PCC 0-14 days vs.
> 60 days (ref)

1.382 (0.892, 2.142)

Odds Ratio
(95% CI)
0.589 (0.298, 1.165)
1.096 (0.583, 2.063)
1.371 (0.817, 2.301)
0.521 (0.158, 1.721)

PCC 15-60 days vs.
> 60 days (ref)

.1474

P
value
.1282
.7753
.2326
.2852

0.3471

Overall
P
value

** Oncology service met with the patient as the patient’s 1st or 2nd service during index hospitalization.

* Asian and Hispanic patients are in the “Other” race/ethnicity category of this model because they were not evenly distributed across PCC timing
groups and their estimates could not be established when considered separately.

Visited by Oncology
service during index
admission**
(reference: No)

Care for PCC
(reference: Oncology)

Variable
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Table 4.3 Classification and Regression Tree (CART) model performance for identifying profiles
associated with the timing of palliative care consultation for goals-of-care before death
Sample

Statistic

Value

PCC patients who died
during the study period

Root node error

0.537

Accuracy (95% Confidence Interval)

0.547 (0.488, 0.606)

P-Value [Acc >NIR]

0.384

Sensitivity

0.882

Specificity

0.326

Positive predictive value

0.603

Negative predictive value

0.705

Sensitivity

0.274

Specificity

0.821

Positive predictive value

0.345

Negative predictive value

0.767

Sensitivity

0.017

Specificity

0.991

Positive predictive value

0.333

Negative predictive value

0.794

Patients with PCC
0-14 days before death

Patients with PCC
15-60 days before death

Patients with PCC
> 60 days before death

*The P-value represents the probability that model accuracy is higher than the no information rate
(NIR). Sensitivity represents the proportion of patients correctly identified in the model as having
had PCC in the associated timeframe. Specificity represents the proportion of patients that did not
have PCC in the associated timeframe and were correctly identified in the model. Positive
predictive value is the proportion of patients who actually received PCC in the associated
timeframe out of all patients identified in the model as having received PCC in that timeframe.
Negative predictive value is the proportion of patients who actually did not receive PCC in the
associated timeframe out of all those identified in the model as having not received PCC in that
timeframe.
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ILLUSTRATIONS

Figure 4.1 Classification and Regression Tree showing risk factor profiles for the timing of PCC before death
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*Unknown refers to
patients who did not
report their self-identified
race/ethnicity.
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CHAPTER FIVE: DISCUSSION AND CONCLUSIONS
Introduction
The United States spends more money on patients in the last year of life than any
country in the world.1 This high spending does not necessarily reflect higher quality EOL care
compared to other developed countries, but instead reflects greater use of intensive and acute
care at EOL.2-4 Aggressive EOL care is not only significantly more expensive than less
aggressive care,5 it is also associated with lower quality EOL care6-8 and higher decision regret
among families.9,10 Evidence suggests most patients do not prefer aggressive EOL care.11-15 This
incongruity between care preferences and EOL practices may be mitigated by EOL discussions
about care preferences led by trained professionals, including palliative care consultation (PCC)
teams.
Patient-provider discussions about end-of-life (EOL) and goals-of-care (GOC), including
those that occur during PCC, enable patients to ask important questions, express their
understanding of the terminal nature of their illness, and communicate what is important to them
as they near EOL. Understanding a patient’s values, goals, and care preferences enables
clinicians to provide care concordant with expressed desires,16-18 allowing vulnerable patients to
have more of the dying experience they want. These critical conversations are associated with
less aggressive, less intensive care near EOL,2,13,17,19-21 which in turn is associated with higher
quality EOL care6-8 and lower regret for EOL treatment decisions.9,10 End-of-life and GOC
discussions are also associated with lower acute care costs near death, with early evidence of
savings ranging from $6,000 to $9,500 per patient.2,21,22 Lower EOL costs are associated with
better quality of death,2 making the exploration of EOL costs and communication an ethical
necessity. End-of-life discussions and PCC mutually benefit patients and health systems: patients
who have these conversations appear to experience a higher quality dying experience more
consistent with values and preferences, and health systems incur lower costs as a result.2,23
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African Americans and other racial/ethnic minorities in the United States are less likely to
have important EOL care planning discussions with their healthcare providers24-30 and are more
likely to receive intensive, life-prolonging EOL care compared to Whites.24,31-36 They are also
reported to have higher EOL costs,31 which may contribute to a lower quality dying experience.2
In its groundbreaking report (2015), Dying in America, the National Academy of Medicine called
for more research into racial/ethnic disparities in EOL care,37 but costs studies have been limited
to date. In fact, evidence about EOL discussions, including those occurring during PCC, and
future healthcare utilization and costs has been especially limited in the context of race/ethnicity
and the timing of conversations.

Overall Goals
To fill gaps in the literature, this dissertation achieved the following goals: it explored
associations among EOL discussions, healthcare utilization, place of death, and costs in persons
with advanced cancer near EOL (Aim 1, Chapter 2); assessed future acute care costs and
healthcare utilization following palliative care consultation to discuss GOC or EOL (hereafter
called “PCC”) among Whites and African Americans with serious illness who either did or did not
have PCC (Aim 2a, Chapter 3); described acute care utilization, costs, and discharge to hospice
among racial groups who received PCC (Aim 2b, Chapter 3); examined risk factor profiles for
PCC 0-14 days before death (“PCC close to death”), 15-60 days before death (“moderately-timed
PCC”), and greater than 60 days before death (“early PCC”) among deceased persons with
serious illness who had PCC prior to dying (Aim 3a, Chapter 4); and described EOL acute care
costs, changes in GOC, DNR documentation, and discharge to hospice from a hospitalization
with PCC among deceased patients (Aim 3b, Chapter 4). These objectives were achieved
through a systematic review of the literature (Aim 1); a propensity-matched cohort study of
secondary data from a large, urban, academic medical center (Aim 2); and multinomial logistic
regression models and classification and regression tree analysis of decedents who received
PCC from the same dataset (Aim 3).
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The systematic review presented in Chapter 2 revealed significant variations in how
researchers and clinicians define advance care planning (ACP) and EOL discussions, and in how
they conceptualize and measure care outcomes. It also showed a gap in research exploring EOL
discussions and acute care costs, which this dissertation sought to help fill. Chapter 3 identified a
cost-savings of almost $9,000 per White patient associated with PCC and directional (yet not
statistically significant) savings among African Americans with PCC, suggesting PCC is a costeffective intervention, but that larger studies across multiple medical centers are needed to
understand why PCC is not significantly associated with reductions in future costs among African
Americans. Most notably, Chapter 3 also showed how PCC is associated with dramatic increases
in hospice use among both African Americans and Whites with PCC. Chapter 3 also provided
helpful cost and utilization data on underrepresented racial minority populations. Finally, Chapter
4 revealed risk factor profiles for PCC 0-14 days before death, 15-60 days before death, and
greater than 60 days before death. Together, these results point to some of the many benefits of
PCC, including opportunities to discuss and document care goals, enroll in hospice care or
choose less aggressive treatment, and conserve hospital resources in ways that align with patient
preferences. The results also suggest PCC may play different roles in acute care utilization
decision-making among different racial/ethnic groups and that other unmeasured factors may
contribute to PCC timing and effectiveness, highlighting the need for clinicians to adapt PCC to
patient and family needs, and for PCC to be integrated in care earlier in the illness experience.

Major Findings
Chapter Two: End-of-Life Discussions and Advance Care Planning are Associated with
Lower EOL Costs and Less Aggressive Healthcare in Persons with Cancer
High costs near the end-of-life (EOL) represent utilization of costly acute and lifeprolonging care near death5 and are associated with poor quality of death among patients.2 High
costs burden patients,38-42 families,43 and health systems responsible for providing cost-effective,
high-quality care.21 Importantly, costly aggressive care does not always align with patient goals
and preferences.10 As the second leading cause of death worldwide44,45 and one of the most
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expensive conditions to treat,46 cancer uniquely challenges clinicians to provide evidence-based
and cost-effective care aligned with patient preferences. Patient-provider discussions about care
goals and EOL preferences are associated with less aggressive care near death2,20,47,48 and lower
costs,49,50 making them a useful intervention for enabling health systems to improve concordance
between care preferences and actual care delivered51 and increasing quality of care48 while
managing resources.21
The systematic review found that among patients with advance-stage cancer,
discussions involving ACP, EOL or GOC were associated with lower acute healthcare costs in the
last 30 days of life (median $1,048 vs. $23,482; P < .001), but more cost research is needed. The
review also found these discussions are associated with less utilization of costly acute and
aggressive care near death and greater use of hospice care, which is associated with lower costs
and higher quality care. Specifically, the review found EOL and care planning discussions were
associated with lower likelihoods of acute care [Odds Ratios (OR) ranging 0.43 to 0.69], intensive
care (ORs ranging 0.26 to 0.68), emergency department use, and chemotherapy near death
(ORs 0.41, 0.57); shorter hospital length of stay; and greater use of hospice (ORs ranging 1.79 to
6.88) and odds for death outside the hospital. Furthermore, the review found that the timing of
these conversations was important. Perhaps because patients and families had more time to
understand prognosis and consider care options in light of patient values and goals, earlier
conversations (30 or more days before death) were found to be more strongly associated with
less aggressive care outcomes than later conversations.
Based on the review’s findings, clinicians can conclude that EOL and care planning
discussions are effective at helping patients achieve dying experiences that involve less
aggressive care, and that these conversations should occur earlier in the care continuum for all
cancer patients. Per this review, less aggressive care associated with EOL discussions also
appears to be associated with significant cost savings, which also benefit health systems.
However, cost data was very limited. More research is needed to understand the ways these
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discussions are associated with EOL costs and what influences the timing of when patients
receive these conversations.
Chapter Three: Palliative Care Consultation is Associated with Lower Costs for White
Patients and Greater Hospice Utilization for African Americans, Whites, and Other
Racial/Ethnic Minorities
Even though race does not predict EOL preferences,52,53 African Americans and other
racial/ethnic minorities are less likely than Whites to receive hospice care54,55 and more likely to
prefer and receive costly acute or aggressive care near death24,31-36,56,57 and die in hospitals.31
These differences in EOL acute care utilization result in significantly greater EOL costs for African
Americans and other racial/ethnic minorities compared to Whites,31 even after controlling for other
factors.58 Unfortunately, high EOL costs, which reflect greater utilization of acute and intensive
care services, are associated with poorer quality of death.2 Goals-of-care and EOL discussions
with healthcare providers, such as those that occur during PCC, are associated with less
aggressive EOL treatment2,10,20,21,59-65 that is perceived to be higher quality2,9,37,47 and significantly
lower acute care costs following discussion, including across hospitalizations.21,22 Unfortunately,
African Americans and other racial/ethnic minorities are less likely than Whites to have important
care planning and EOL discussions with their healthcare providers.24-29 Early evidence, however,
suggests race is not a factor in which patients receive PCC, making it a possible solution for
helping to overcome racial disparities in EOL care. However, studies assessing associations
between EOL or GOC discussion, or PCC, and costs have not analyzed cost outcomes by race.
In this study, the association between PCC and acute care costs across hospitalizations
following discharge from an admission involving PCC was examined (Aim 2a). This secondary
analysis of preexisting clinical and administrative data included 35,154 African American and
White patients with serious illness who were hospitalized at an urban academic medical center. A
portion of the patients received PCC (African Americans with PCC, N = 383; Whites with PCC, N
= 814). Variables of age, gender, Medicaid status, primary diagnosis, All-patient refined diagnosis
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related group (APR-DRG) Risk of Mortality, APR-DRG Severity of Illness, intensive care unit
(ICU) care during index admission, ICU care greater than six days during index admission,
Oncology services during index admission, acute care costs accumulated during the index
admission to represent acute care utilization, acute care hospitalization in 30 days prior to index
admission were used to match patients who received PCC and patients who didn’t receive PCC
for both racial groups, resulting in two separate race-based stratified propensity score models.
For each model, patient data from the two propensity groups most likely to have received PCC
were used to assess outcomes.
Stratified propensity score modeling for African American patients found African
Americans who received PCC were less likely to incur “any future acute care cost” compared to
African Americans who did not receive PCC (31.9% vs. 37.7%, P = 0.047), but differences in total
future acute care costs were not statistically significant ($11,651 vs. $15,050, P = 0.09). Of great
importance, African Americans with PCC were more likely to be discharged to hospice from index
admission (36.5% vs. 2.4%, P < 0.0001), suggesting PCC is effective at increasing quality
outcomes for African Americans near death. Significant differences in 30-day readmissions,
future hospital days, future ICU admission or number ICU days were not found.
Stratified propensity score modeling for White patients found Whites who received PCC
were less likely to incur “any future acute care cost” compared to Whites who did not receive PCC
(25.9% vs. 35.5%, P < 0.0001) with a significant difference in mean accumulated future acute
care costs ($8,095 vs. $16,799, P < 0.001), representing an average cost-savings of $8,704 per
patient. Whites with PCC were more likely to be discharged to hospice from index admission
(42.7% vs. 3.0%, P < 0.0001); had lower 30-day readmissions (10.2% vs. 16.7%, P < 0.0001);
and had fewer future days spent hospitalized (3.7 vs. 6.3 days, P < 0.0001).
In the secondary aim of this study (Aim 2b), which included an additional 2,946 patients
from the same parent dataset, Asians (PCC, N = 48; No-PCC, N = 913), Hispanics (PCC, N = 22;
No-PCC, N = 829), and patients who self-reported as other racial/ethnic minorities (including
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American Indians/Alaskan Natives, Native Hawaiians/Pacific Islanders, and “Other” race/ethnicity)
(PCC, N = 39; No-PCC, N = 1,095) were described in terms of index admission acute care and
intensive care utilization, discharge to hospice, DNR documentation, and future healthcare
utilization and costs following discharge from index admission. These patient groups were not
matched using propensity score modeling, so their results are not comparable to the outcomes of
the propensity-matched African American and White cohort. Descriptive statistics found that PCC
is associated with increased hospice use for Asians, Hispanics, and patients who self-report as
“Other” race/ethnicity (including Native Americans and Pacific Islanders). Finally, when patients
who had received PCC were compared by race/ethnicity, no significant racial/ethnic differences in
discharge to hospice were found, suggesting PCC is effective at supporting quality EOL care
across racial/ethnic groups.
Chapter Four: Palliative Care Consultation is Needed Earlier Across Patient Populations,
Especially ICU Patients and Hispanic and “Other” Racial/Ethnic Minority Patients
To understand prognosis and consider care options in light of personal values and
preferences, patients with serious illness need time to discuss their health and goals with
providers. If discussions about care planning or EOL occur too close to death, patients may make
pressured decisions, or fail to communicate desires or decisions, leading to care that does not
align with their preferences.20,66,67 Care planning and EOL discussions are associated with higher
quality EOL care,7,13 evidenced by associations with less aggressive treatment and lower use of
intensive care,2,13,17,19-21 lower hospitalization and 30-day readmission rates,2,19,21,62 greater use of
hospice and fewer in-hospital deaths.2,13,16,20,21,68 In addition, the timing of these conversations
matters: evidence suggests each additional day from hospital admission to discussion is
associated with increased risk of aggressive treatments and in-hospital death, and greater odds a
patient will receive ICU care.13 There are many benefits to early PCC69-71 and GOC48,72
conversations, yet patients often have these conversations close to death or not at all.18,73
Understanding which patients are at risk for late conversations may help clinicians initiate these
important discussions earlier, which may contribute to improved quality EOL care.48
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In this study, risk factor profiles were developed to better understand the interaction of
variables associated with the timing of palliative care consultations involving PCC 0-14 days
before death (“PCC close to death”), 15-60 days before death (“moderately-timed PCC”), and
greater than 60 days before death (“early PCC”) among patients who received PCC at an
academic medical center in the Northeast region. A sample of 1,141 patients who received PCC
prior to death were assessed in this secondary analysis of pre-existing clinical and administrative
data. De-identified patient data from a study about cost-savings associated with PCC across
hospital admissions21 was supplemented with new data that identified Medicaid status and the
number of days between first inpatient PCC and patient death. First, an adjusted multinomial
logistic regression model was created to identify variables associated with the timing of PCC
before death. These variables were intended to inform creation of a classification and regression
tree (CART) model. A CART analysis was applied to understand how independent variables
available in the dataset interacted to create patient profiles associated with the timing of PCC
before death.
Variance Inflation Factor was less than three for all variables in the study, indicating no
evidence of multicollinearity among variables. Adjusted multinomial logistic regression did not find
evidence of any significant associations among variables with PCC timing, suggesting other
unmeasured factors are associated with timing and that patients of all types are at risk for
consultations close to death. Small sample sizes within groups, which diminished in the context of
variable sub-categorization, may also have contributed to this finding. However, differences were
identified at the 0.05 significance level between moderately-timed PCC when compared to early
PCC, and between PCC close to death when compared to early PCC. Compared to referrals from
Oncology specialists, for example, patients referred to PCC by General Medicine/Hospitalists
were two times more likely to have consults close to death than early (OR = 2.02, 95%
Confidence Interval 1.16, 3.53; P = 0.01), with no significant difference for moderately-timed PCC
compared to early. Compared to patients over age 75, patients aged 56-60 were almost two
times more likely to have consults close to death than early (OR = 1.94, 95% Confidence Interval
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1.09, 3.47; P = 0.03), with no significant difference for moderately-timed PCC relative to early.
And compared to patients with cancer, patients in the “Other” diagnosis category (e.g., skin
conditions, psychiatric conditions, traumatic injuries, procedural complications) were less likely to
receive a moderately-timed consult than early consult (OR = 0.47, 95% Confidence Interval 0.22,
0.10; P = 0.049) and, although not significant, less likely to have PCC close to death (OR = 0.53,
95% Confidence Interval 0.28, 1.01; P = 0.052) compared to early. Conditions were included in
the “Other” category if they did not fit into one of the other larger diagnosis categories of the study
or had smaller sample sizes.
The CART model effectively identified which patients received PCC 0-14 days before
death (88.2% sensitivity), but not which patients received PCC 15-60 days before death (27.4%
sensitivity) or PCC greater than 60 days before death (1.7% sensitivity). The model showed high
specificity for early (99.1%) and moderately-timed (82.1%) PCC, suggesting the model was
effective at identifying which patients did not receive early or moderately-timed PCC. This finding
is significant because early and moderately-timed PCC are generally considered better for
patients and are associated with more optimal outcomes than PCC close to death. These results
suggest the model can be used to help clinicians identify which patients are not having early or
moderately-timed PCC, enabling clinicians to better target these patients and develop
interventions that provide more timely consultations.
The CART model showed 64% of patients with extreme severity of illness received PCC
close to death. ICU use during index admission was also associated with high probability of PCC
close to death. For example, ICU patients with extreme illness severity were more likely to
receive PCC close to death (67%). Half of ICU patients with less than extreme severity of illness
also received PCC within 14 days of death (50%), a probability that was lower than the overall
sample but still incredibly high. Patients with extreme illness severity who were in the ICU and
were Hispanic, “Other” racial/ethnic minority (American Indian/Alaskan Native, Native
Hawaiian/Pacific Islander, or “Other” race/ethnicity), or did not disclose their race/ethnicity were
even more likely to receive PCC close to death (85%). Being younger (age less than 46) or older
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than 75 further increased the probability among such patients (98%). Non-ICU patients with
extreme severity of illness and most conditions (excluding heart failure, respiratory disorders, or
“Other” disorders) who were not admitted to the hospital 30 days prior, age <40 and >75 also had
very high probability of PCC close to death (96%).
On the other hand, patients with non-extreme illness severity who were not in the ICU
were less likely to receive PCC close to death (24%). Patients with extreme severity of illness
who did not have ICU care but had heart failure, a respiratory disorder, or “Other” disorder had
only 17% probability of PCC close to death (and 80% probability of early PCC). Non-ICU patients
with extreme illness severity with conditions other than heart failure, respiratory disorder, or
“Other” condition who did not receive Oncology care during index admission but had been
admitted to the hospital 30 days prior also demonstrated low probability for PCC close to death
(19%). Finally, patients with extreme severity of illness who did not receive ICU care during index
admission demonstrated varying probability for PCC timing (48% for 0-14 days, 31% for 15-60
days, 21% for > 60 days). It is unknown if other factors contributed or if this is a case of reverse
causation.
The secondary, descriptive aim of this study revealed many findings. First, the data
showed that, despite having significantly more days to use acute care services and accrue costs
before death, patients with PCC more than 60 days before death had only $8,993 greater median
acute care EOL costs than patients who had PCC within 14 days of death. Research is needed to
understand the per day difference in costs associated with each additional day PCC occurred
before death. As patients neared death, they seemed to become more likely to change their care
goals during PCC (50% early PCC, 76% moderately-timed PCC, 93% PCC close to death; P
<0.0001). Similarly, the presence of a DNR increased the closer a patient was to death (26%
early PCC, 59% moderately-timed PCC, 86% PCC close to death; P < 0.0001). Finally, patients
were discharged to hospice from a hospitalization involving PCC when PCC occurred closer to
death (10% early PCC, 33% moderately-timed PCC, 31% PCC close to death; P < 0.0001),
suggesting patients farther from death may not be ready to immediately enroll in hospice. These
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figures do not describe hospice enrollment occurring after discharge from a PCC hospitalization.
Patients who receive PCC may choose to later enroll in hospice after considering their goals and
care options. Earlier PCC gives patients and families more time to consider hospice and, if
desired, benefit from its high-quality care longer.

Limitations
Systematic review (Chapter 2)
The systematic review presented in Chapter 2 had multiple limitations. First, only one
study tested causal relationships through a randomized controlled trial. This study was also the
only one to explore associations among EOL discussions for GOC and costs; the other two costrelated studies used advance directives as a comparator and insufficiently provided cost data.
Studies in the review did not uniformly define measured variables, uniformly collect measured
variables, or assess the same utilization variables, making synthesized comparisons difficult and
meta-analysis not possible. Studies that used medical records to identify EOL discussions could
not account for undocumented conversations and studies that used self-report to measure
discussions could not account for recall bias. In addition, studies featured patients with different
types of cancer in health systems that have varying levels of training, EOL intensive care
utilization, and resources. Although these differences may limit generalizability and the ability to
synthesize results, the review provided important clinical insights that may help improve EOL care
for persons with cancer while further justifying investment in interventions that improve EOL
communication.
Secondary analysis of patient data from a retrospective cohort study (Chapters 3 and 4)
The studies in Chapters 3 and 4 also featured limitations. The analyses included patient
data from a single, urban academic medical center served by a well-established palliative care
team. The medical center and its resources, clinicians, and patient population may not represent
all hospitals, limiting the generalizability of results. Furthermore, what was measured in each of
the studies was limited to variables available in the dataset and medical record system. We were
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unable to measure other variables of interest because they were either not available in the
medical record system or in the pre-existing dataset. In the propensity-score matching study
(Chapter 3) we were unable to control for unknown or unmeasured confounding variables such as
comorbidities, income, insurance status, education level, health literacy, religious beliefs, or
duration of survival. In the absence of diagnostic tests, we were also unable to understand how
closely propensity groups matched across each of the ten variables. This is a common limitation
in propensity score matching studies when groups, such as the race-based PCC groups, are
limited in size. However, as evidenced by the two highest propensity score tiers’ nearly identical
minimums and maximums and similar mean propensities, which were used in the analysis, the
per-race PCC and Non-PCC groups were matched well across variables such that they had
similar propensity for PCC. Similar propensity for PCC enabled meaningful comparison and
reliable analysis of results.
In the PCC timing study (Chapter 4), we were unable to test for interactions and
associations among timing and variables such as health literacy, education, religiosity, immigrant
status, language fluency, expected duration of survival, frailty, outpatient GOC discussions, family
dynamics, and more. Unmeasured variables may have been distributed differently in patients who
received PCC and those who did not (Chapter 3) and may have been more strongly associated
with PCC timing or contributed to risk factor profiles more strongly associated with PCC timing
(Chapter 4).
Next, the analyses could only measure variables tracked within the health system and
available in the dataset. The index PCC may have occurred before some of the correlates, such
as ICU admission, which makes conclusions about chronology or prediction unfeasible. In
addition, the analyses could not measure acute care utilization or costs incurred in community
hospitals outside the health system or care received in skilled nursing, outpatient settings, or in
the home. For hospice use, the analyses were unable to assess hospice use following discharge
from the index admission, which may have occurred. Chapter 4 was unable to include deceased
patients whose death information was not in the health system’s records. These patients may
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have differed from patients included in the analysis; measured variables may have been
distributed differently across the three groups, resulting in different associations with PCC timing.
Despite these limitations, study results are timely and useful. Results of Chapter 3 may
be used to show cost and utilization outcomes, including hospice use, associated with PCC
beyond the initial hospitalization among African Americans and among Whites in a sample
matched on known covariates within racial groups.21,61,63 Results of Chapter 4 may be used to
increase understanding of risk factor profiles associated with PCC close to death to support
clinicians in better providing more timely GOC and EOL discussions among seriously ill persons.

Directions for Future Work
The results of this dissertation research contribute to a growing body of literature that
identifies the cost-effectiveness and clinical-effectiveness of palliative care consultation and
supports its delivery across racial/ethnic patient populations early in the illness trajectory. The
results underscore a need for more cost research on PCC and EOL communication to enable
hospital administrators to support the development and expansion of palliative care programs. To
reduce prevalence of PCC close to death, as demonstrated in our study, PCC should be scaled in
primary, community settings where PCC can be integrated into care earlier. Furthermore, to avoid
racial/ethnic disparities in risk of receiving PCC close to death, PCC should be expanded in
settings with racially/ethnically diverse patient populations. Study results generate new questions
and underscore the need for research that explains findings and measures variables not available
in the parent study dataset.
An important area for future research involves racial/ethnic differences in EOL
communication and outcomes. Specifically, research is needed to understand why our study
found PCC was associated with an increase in hospice use but not a statistically significant
reduction in future acute care costs among African Americans. From a cost and utilization
perspective, research is needed to understand if there are (a) racial differences in readmission
rates or acute care use among PCC and Non-PCC hospice patients following discharge, (b) racial
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differences in non-hospice patient acute care utilization, specifically the types of care and
frequency of care, following discharge, and (c) profiles of patients who incur the greatest future
acute care costs and utilization. In terms of PCC delivery, research is needed to understand or
explain possible disparities in the effectiveness of PCC among racial groups. Specifically,
research is needed to identify factors not measured in this study that may contribute to PCC
differences among racial groups, such as patient-provider racial/ethnic concordance, patientprovider language concordance, education, income, religiosity and its role in decision-making,
health literacy and prognosis comprehension, documented or undocumented immigrant status,
family and cultural dynamics’ influence on decision-making, and the number of PCC visits over
time both inpatient and in the community.
In addition, research is needed to understand which aspects of communication or types
of PCC discussion content influenced patient decision-making, whether content differed by
race/ethnicity, and if differences in content were associated with utilization outcome differences.
For patient groups with historically lower rates of hospice use or higher rates of aggressive care
near EOL, such research may be useful. It would also be helpful to understand how patients who
intentionally choose aggressive EOL care differ from patients who receive aggressive care by
default or for other reasons, such as family dynamics or low health literacy.
Due to small sample sizes, the findings for Asians, Hispanics, and “Other” racial/ethnic
minorities in Chapter 3 are hypothesis-generating. Research with adequately large sample sizes
of racial/ethnic minorities, particularly Asians and Hispanics, is needed to better understand PCC
associations with outcomes in such understudied populations. It is especially important that future
research include measures of language, immigration status, education, and cultural values such
as the role of family in decision-making, as these variables were lacking in this dissertation study
and may have influenced preliminary results. In addition, specific questions emerged from the
study that are worth further exploration. For example, what factors explain why Asians with PCC
were found to have the lowest median index admission costs and the highest mean index
admission costs among PCC patients across racial groups? What makes utilization vary so
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dramatically in that population and can PCC interventions better address Asian patient and family
needs?
Finally, the results of these studies should be replicated in other populations and health
settings, including community settings where earlier PCC is more likely to occur when available.
The PCC timing study should be replicated in larger, more diverse samples with more relevant
variables to better identify risk factor profiles for patients not only likely to receive PCC close to
death, but also patients likely to receive moderately-timed and early PCC. In addition, primary
studies designed to account for all known confounders are needed. Understanding how patients
experience PCC earlier in the care continuum and how earlier community-based PCC is
associated with EOL care quality and cost outcomes would help clinicians and policy makers
better understand the utility of these discussions in community settings.

Research Implications
Palliative care consultation was found to be a powerful intervention for increasing hospice
use and decreasing the presence of “any” future acute care costs (representing any future acute
care utilization) among African Americans. Even stronger outcomes were found among Whites
who had PCC. As such, development in PCC should be supported in inpatient settings, as
studied in this dissertation, and in the community through primary palliative care, where PCC can
be initiated earlier in the care continuum. Innovative workforce solutions and interdisciplinary care
models featuring nurse leadership are needed to better provide PCC to patients with serious
illness in community settings. To enable interdisciplinary and nurse-led delivery of primary
palliative care, workforce training, novel payment methods, and supportive public policies are
needed. In addition, our results highlight a critical need for a systematic process to engage ICU
patients in PCC. Nurses can and should play an important role in the implementation of PCC
across settings.

Finally, the results of this research should encourage nurses and physicians across care
settings to initiate GOC conversations earlier with patients across racial/ethnic groups and take
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into account a patient’s language, cultural preferences, and health literacy. Awareness of risk
factor profiles associated with PCC close to death should prompt providers to target patients at
risk for late conversations. In addition, results from this dissertation can be used to help design
interventions that target patients at risk for not receiving early or moderately-timed PCC.

Ethical Considerations
Findings from this dissertation should be considered in light of clinical ethics and policies
that promote ethical care for patients with serious illness. All humans eventually die and yet the
modern American acute care health system is designed to maintain physical life and delay the
natural course of death, sometimes indefinitely, for people with serious illness who are at high risk
of dying.13 The quality of life that accompanies such life-extending care may not align with patient
goals, values, or wishes, which is why it is so important that healthcare providers have open,
ongoing discussions with patients and families starting early in the illness experience about what
quality of life and quality of death mean to the patient.74 While it is a clinician’s responsibility to
explain the implications and consequences of any given treatment or type of care, patients are
autonomous and must be free to make well-informed decisions that align with their own desires
and sense of well-being.75
Health literacy and other social determinants of health affect the choices people make
and the quality care they receive near death. Research is needed to not only understand
disparities in care stemming from social determinants of health, but also address and overcome
these differences and the systematic issues that may enable them. Further research is also
needed to design and implement innovative care models, workforce solutions, payment models,
and policies to deliver palliative care earlier and in community settings, and to better meet patient
needs across the care continuum. Better meeting patient and family needs across the illness
experience, and not primarily during inpatient hospitalization when payment schemes allow for
delivery of palliative care, is an ethical priority.
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Finally, although this dissertation found PCC was associated with cost reductions in
some populations, reducing costs should not be a major reason for engaging patients in PCC or
GOC discussions. Instead, clinicians and payers should focus on how PCC increases patient
autonomy, improves quality of care—and as this dissertation showed, increases hospice use
across all racial/ethnic patient populations—and saves resources.50 Better communication can
result in better quality EOL care, with lower costs naturally following, benefiting patients and
systems alike.19

Conclusion
This three-part dissertation increased knowledge of palliative care consultation
associations with acute care costs across hospitalizations and use of hospice services among
African American, White, and other patients with serious illness, explored risk factor profiles
associated with the timing of PCC before death, and described aspects of a hospitalization
involving PCC such as changes in goals-of-care plans and DNR documentation, and how these
elements differed based on PCC timing. The systematic review showed EOL discussions with
advanced cancer patients are associated with a median $22,434 reduction in costs in the last 30
days of life and lower odds of acute care at EOL, intensive care at EOL, chemotherapy near
death, emergency department use and shorter hospital length of stay, greater use of hospice, and
greater odds of patient death outside a hospital. The review found stronger results in discussions
occurring more than 30 days before death compared to later discussions. The review also
revealed a major need for more cost research related to EOL discussions and research about the
timing of such discussions.
The secondary analysis in Chapter 3 sought to help fill that research gap by comparing
cost-savings associated with PCC in a propensity score-matched study of African American and
White patients with serious illness with and without PCC. The study found PCC was associated
with an average reduction of $8,704 in future acute care costs among White patients, but cost
differences were not significant among African Americans. The presence of any future acute care
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cost, representing any acute care utilization following a hospitalization with PCC, was significantly
lower in African Americans and Whites with PCC. Most importantly, PCC was found to be
associated with significantly higher hospice use among Whites, African Americans, Hispanics,
Asians, and patients who self-identify as “Other” race/ethnicity. More research is needed to
understand why cost reductions were significant in White populations but not African Americans.
The secondary analysis in Chapter 4 further contributed to the growing field of palliative care and
EOL communications research by identifying risk factor profiles associated with the timing of PCC
before death. The model was most effective at identifying patients likely to receive PCC close to
death (0-14 days before death), making it a useful tool for clinicians seeking to provide timely
GOC discussions and PCC to patients at-risk for late consultation.
This dissertation research recognizes ethical issues related to assessing costs and EOL
patient care and supports each patient’s autonomy and right to make informed decisions about
care. The findings of this body of work can be used to improve patient-provider communication
about GOC and EOL, possibly improving the quality of EOL care patients receive or concordance
between patient wishes and actual care received. The results help justify investment in palliative
care in hospitals and in the community and can be used to enable the development of novel
models of palliative care delivery and payment schemes to better meet patient needs throughout
the illness experience.
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Variable Description
Eligible patients who had PCC to discuss goals-of-care (GOC) or end-oflife (EOL) during the study period, as documented in the palliative care
registry (yes, no). In the parent study dataset, all hospital admissions
during the study period were stratified according to a binary variable of
"PCC for GOC” and “No PCC for GOC” based on data available in the
palliative care registry 1. The first PCC for GOC/EOL during the study
period is defined as the patient’s index admission, referred to as index
admission or index hospitalization.
Inpatient PCC to discuss GOC/EOL occurring 0-14 days before patient
death, as recorded in health system electronic medical records and the
palliative care registry.
Inpatient PCC to discuss GOC/EOL occurring 15-60 days before patient
death, as recorded in health system electronic medical records and the
palliative care registry.
Inpatient PCC to discuss GOC/EOL occurring 61+ days before patient
death, as recorded in health system electronic medical records and the
palliative care registry.
“Future acute care costs” is calculated by adding together the direct costs
from all hospitalizations after the index hospitalization during the study
period. Cost incurred during the index hospitalization are excluded. Direct
costs represent the best estimate of the actual cost of providing hospital
services including nursing labor, other allied health professional labor,
pharmaceuticals, supplies, procedures, testing, and emergency
department (ED) visits that resulted in hospitalization. Indirect costs (i.e.,
overhead costs such as medical records, patient financial accounting,
depreciation of facilities, and the cost of utilities) are not included because

Variable name

Palliative care consultation
(PCC)

PCC 0-14 days before
death

PCC 15-60 days before
death

PCC > 60 days before death

Future acute care costs
(dollars) (direct costs)

APPENDIX A. DESCRIPTION OF VARIABLES

Continuous

Categorical

Dichotomous,

Categorical

Dichotomous,

Categorical

Dichotomous,

Categorical

Dichotomous,

Type of data
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Future number of days in
the hospital (after discharge
from index admission)

EOL acute care costs (direct
costs)

Future acute care – any
cost (yes, no)

Variable name

The number of days a patient was in the hospital following discharge from
the index admission during the study period; obtained from hospital
electronic medical records.

If a patient was billed for any acute care service, resulting in any acute
care billable charge according to McKesson Health Systems financial cost
accounting system following discharge from the index hospital admission,
as recorded in health system electronic records.
Total direct acute care costs from all hospitalizations after discharge from
the index hospitalization in which the initial PCC occurred during the study
period, to the point of patient death, as tracked by hospital cost accounting
software (McKesson Health Systems, King of Prussia, PA). Direct costs
provide the best indication of the actual cost of hospital services including
nursing labor, other allied health professional labor, pharmaceuticals,
supplies, procedures, and testing. Indirect costs (i.e., overhead costs such
as medical records, patient financial accounting, depreciation of facilities,
and the cost of utilities) are not included because they are fixed
independent of patient volume and cannot be reduced by avoiding
readmissions to the hospital.

This variable is also used to calculate EOL acute care costs following
PCC, as costs are tracked forward to the point of death.

they are fixed independent of patient volume and cannot be saved by
avoiding readmissions to the hospital. “Future acute care costs” were
obtained from McKesson Health Solutions (King of Prussia, PA), the
health system’s cost accounting system. This system tracks the charges
coded during each hospital encounter.

Variable Description

Continuous

Continuous

Dichotomous,
categorical

Type of data
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Variable Description
The number of days a patient was in the ICU following discharge from the
index admission during the study period; obtained from hospital medical
electronic records.
Readmission/hospitalization within 30 days of discharge from index
hospitalization (yes, no); obtained from hospital electronic medical records.
Patient was discharged to hospice at the end of the index admission (yes,
no); obtained from hospital electronic medical records.
Number of years a patient has lived at the time of index admission
discharge, categorized in five-year increments starting at age 40. Two
additional categories—“under age 40” and “over age 90” will be included.
Obtained from hospital electronic medical records.
Male or female gender; obtained from hospital electronic medical records.
Patient self-report of being Hispanic or non-Hispanic, white/Caucasian,
Black/African-American, Asian, or other ethnicity.
Patient self-report of being exclusively white or Caucasian, according to
medical records.
Patient self-report of being Black/African American, according to medical
records.
Patient self-report of being Black/African American, Hispanic, Asian,
American Indian/Alaskan Native, Native Hawaiian/Pacific Islander, Mixed
race/ethnicity, or other; obtained from hospital electronic medical records.

Variable name

Future number of days in
ICU (after discharge from
index admission)

30-day readmissions (after
discharge from index
admission)

Discharge to hospice (from
index admission)

Age

Gender

Race/ethnicity

Race/ethnicity: White

Race/ethnicity: African
American

Race/ethnicity: Nonwhite

Dichotomous,
categorical

Dichotomous,
categorical

Dichotomous,
categorical

Nominal, categorical

Dichotomous,
categorical

Ordinal, categorical

Dichotomous,
categorical

Dichotomous,
categorical

Continuous

Type of data
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Variable Description
Primary clinical diagnosis of illness based on the diagnosis related group
(DRG) coded at the time of discharge. Categories include: Cardiovascular
disorder, endocrine disorder, gynecologic/urologic disorder, solid tumor
cancer, hematologic malignancy, neurologic disorder, psychiatric disorder,
respiratory disorder, dementia, other. This data was obtained from hospital
medical records and is categorized based on ICD-9 and ICD-10 codes.
Provider or department who referred the patient to palliative care, as
recorded in hospital electronic medical records: emergency department,
ICU, specialty physician.
The extent of organ system derangement or physiologic decompensation
of a patient. Severity of Illness is measured in four subcategories: minor,
moderate, major, and extreme; and is assigned to the patient at the time of
discharge based on the patient’s diagnoses and procedures that were
coded for billing during the hospitalization. Severity of Illness is meant to
provide a basis for evaluating hospital resource use or to establish patient
care guidelines. There are five categories: minor, moderate, major,
extreme, unknown. This data was obtained from hospital medical records.
The likelihood of the patient dying. Risk of Mortality is assigned to the
patient at the time of discharge based on the patient’s diagnoses and
procedures that were coded for billing during the hospitalization. There are
five categories: minor, moderate, major, extreme, unknown. This data was
obtained from hospital medical records.
Any care in the intensive care unit (ICU) during the index hospital
admission (yes/no); obtained from hospital electronic medical records.

Variable name

Primary diagnosis

Source of referral to
palliative care

All Patient Refined
Diagnosis Related Group
(APR-DRG) Severity of
Illness (SOI)

All Patient Refined
Diagnosis Related Group
(APR-DRG) Risk of Mortality

ICU care during index
admission

Dichotomous,
categorical

Ordinal, categorical

Ordinal, categorical

Nominal, categorical

Nominal, categorical

Type of data
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Variable Description
Any care in the ICU for greater than six days during the index hospital
admission (yes/no); obtained from hospital electronic medical records.

Acute care costs accumulated during the index admission to represent
acute care utilization, defined as the impact of $1000 incurred.
Patient changed GOC during PCC (during hospital index hospital
admission), as recorded in the palliative care registry (yes, no). Patient
may have changed GOC from aggressive care to comfort care, or comfort
care to aggressive care.

Variable name

ICU care for more than six
days during index admission

Index admission direct costs

Patient changed goals-ofcare during PCC

Dichotomous,
categorical

Continuous

Dichotomous,
categorical

Type of data

